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Colorectal cancer (CRC) is one of the most frequent forms of neoplasia, being the 3rd 
most common cancer in men (663,000 cases per year, 10% of the total), and the 2nd in 
women (571 000 cases, 9.4% of the total). The global prevalence rate for CRC is 
11.5%, but the distribution of the CRC burden is quite heterogeneous, with more than 




 CRC is a late-onset disease, particularly prevalent in men (1.4:1 sex ratio), with and a 
median age at diagnosis of 72 years. Almost 90% of these cases will occur at ages of 50 
or over, and 70% of these will be over 652. This means that the development of CRC is 
a slow multistep process. A genetic model for CRC development, involving both 
somatic mutations and epigenetic changes, was first postulated by Fearon and 
Vogelstein in 19903. Although this chromosomal instability route has been observed to 
be the cause of up to 85% of CRC tumours4, it is not the only physiological mechanism 
that can give rise to CRC. It was later revealed that a considerable proportion of CRC 
(around 15%) arises through defects in the DNA mismatch repair system, leading to 
microsatellite instability5 (Figure 1).  
 
 
2. RISK FACTORS, DISEASE AETIOLOGY AND CRC GENETICS 
CRC is considered a complex disease. This means that it arises as a result of the 
interplay between many genetic variants and environmental factors6. Low-fiber diets, 
red meat consumption, obesity, alcohol intake or smoking habits have been related to 




Figure 1. Genetic model for CRC tumorigenesis. CRC development may principally arise by two 
different paths: chromosomal instability (CIN-blue) or microsatellite instability (MIN-green). The CIN 
sequence usually starts with mutations in the tumour suppressor gene APC (which may be enhanced by 
defects on MUTYH8). This leads to genomic hypomethylation, an increased replication rate and a higher 
incidence of aneuploidies during cell division, causing KRAS mutations. This further enables adenoma 
growth and clonal expansion of the cells, with additional mutations in DCC, SMAD4 and p53 
empowering the final transformation into a carcinoma3. Microsatellites are short DNA sequences highly 
prone to length variation due to their iterative nature. The accuracy in the replication of these DNA 
segments during cell division is ensured by the mismatch repair machinery (MMR), made up of the 
MLH1, MSH2, MSH6 and PMS2 proteins. Defects in these genes fuel replication errors in microsatellite 
locations throughout the genome, and many genes enriched for these sequences, such as TFGIIb, BAX or 
TCF49, are mutated. These ultimately enhance cell hyperproliferation and avoidance of apoptosis, 
subsequently initiating the CRC carcinogenetic sequence. Further alterations in other genes, such as Rb or 
c-myc have been proposed as the changes underlying the invasive potential of the tumour cells10. Adapted 
from Knudson et al.11. 
 
The three-way interaction: hereditary syndromes, familial and sporadic CRC 
Genetic susceptibility is thought to explain a significant proportion of the incidence of 
complex diseases. This genetic portion is usually represented by a small Mendelian 
component determined by rare high-penetrance mutations, a middle-sized familial 
factor driven by the interaction of several common variants, each conferring a modest 
effect on disease risk, and a large sporadic fraction, mostly induced by environmental 
variables. The importance of these common low-penetrance variants was stated in the 
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Common Disease-Common Variant (CDCV) hypothesis, which postulated that the 
genetic component of common complex diseases was mostly due to variants of 
low/moderate effect that appeared at an elevated frequency in the population12. 
For CRC, twin studies have estimated that inherited predisposition might account for up 
to 35% of the cases13. Highly penetrant mutations have been described to underlie the 
hereditary CRC syndromes, namely Familial Adenomatous Polyposis (a result of 
mutations in the APC gene), MUTYH-associated polyposis (MUTYH), Lynch (MLH1, 
MSH2, MSH6 and PMS2-MMR mutations) and Peutz-Jeghers syndromes 
(LKB1/STK11), Juvenile Polyposis (SMAD4 and BMPR1A)14 and the Hereditary Mixed 
Polyposis syndrome (BMPR1A) 15. The identification of the mutations leading to these 
syndromes has extensively relied on the use of linkage studies. With such penetrant 
effects, it is likely that the mutations causing these effects are very recent, and therefore, 
the chances of recombination in the corresponding haplotype will be very small, thus 
making it long. It is then appropriate to believe that markers flanking the mutations will 
co-segregate with the disease and so they could be used to identify these loci. Other 
potential loci connected to hereditary or familial phenotypes have been identified by 
linkage at 3q21-q24, 9q22.2-31.216, 7q3117, 11q13.3, 14q24.2 and 22q18, although the 
underlying genes responsible for the phenotype have not yet been found.  
 
Association: from candidate genes to genome-wide association studies 
Linkage analysis has achieved only limited success in the identification of CRC 
susceptibility loci. This makes sense, since highly penetrant mutations are only 
responsible for around 5% of the CRC cases19. For the familial and sporadic settings, 
which represent approximately 15% and 80% of the cases respectively, the genetic 
susceptibility is though to confer only low/moderate risk, and therefore linkage studies 
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show little power of detection. This is due to the fact that variants increasing CRC 
incidence in the expected range (1.5-2.0) will rarely cause multiple-case families and 
are therefore impossible to identify through linkage20. 
Association studies have been postulated as the most reasonable strategy in the 
identification of common modest-risk variants. The typical association designs are case-
control studies, in which the frequency of the potential susceptibility variant is 
compared between a group of affected and healthy individuals. The use of this approach 
was greatly encouraged by the completion of the Human Genome Project (HGP 
http://www.ornl.gov/sci/techresources/Human_Genome/home.shtml), and the discovery 
of a high genomic variation in the form of single nucleotide polymorphisms (SNPs). 
SNPs are the most abundant genetic markers in the genome (over 12 million), 
constituting a major source of inter-individual genetic and phenotypic variation. The 
construction of large SNP maps and databases after the completion of the HGP boosted 
the use of association studies in the discovery of new susceptibility variants for CRC 
and other diseases21. 
Initially, the strategy used to scan for new susceptibility variants was principally a 
direct candidate-gene approach, which relied on the evaluation of specific potentially 
relevant SNPs (mainly non-synonymous and regulatory changes) within selected genes 
that were thought to be important in the development of the disease. The main 
advantage this strategy confers is the easy biological interpretation of the associations, 
since changes in these genes can be easily linked to the neoplasic process. Soon whole 
genetic pathways, genes located in previously determined regions of linkage were 
extensively evaluated. For CRC, several approaches screening particular genes such as 
APC22, carcinogenesis-related pathways, like Wnt and DNA-repair ones23 or the mouse 
PTPRJ candidate 24 were thoroughly examined. 
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Nonetheless, no common variants contributing to colorectal cancer risk could be 
identified and consistently replicated, and the analysis through candidate-gene strategies 
proved largely insufficient to characterise the whole of the genetic variation underlying 
most diseases, with CRC being no exception. This was probably due to a number of 
reasons: firstly, candidate-gene studies were restricted to potentially relevant loci based 
on a priori estimates of the biological mechanisms. Secondly, most of these early 
designs were clearly underpowered to detect loci with the expected risk effect under the 
CDCV hypothesis. Moreover, liberal thresholds were used to call positive association 
findings and this usually resulted in the lack of replication for most of these hits25. 
Luckily, the completion of the HGP supplied with yet another important tool: the 
possibility to study the fine resolution of linkage disequilibrium (LD) in the genome. 
LD had been already described in the 60s as the non-random association of alleles at 
multiple loci in a proportion greater than the expected by Mendelian law26. The 
discovery of LD implicated that long DNA segments were transmitted together for 
generations, generating haplotype blocks in which the genotypes of the different SNPs 
are correlated with one another. The Haplotype Map (or HapMap) Project has been the 
key to the evaluation of these LD patterns in the genomic level21. The knowledge in the 
distribution of these blocks allows for the screening of the genetic variation in extensive 
regions by genotyping a relatively reduced set of informative markers, or tagSNPs. The 
implementation of this indirect approach (versus the direct approach usually undertaken 
by candidate-gene studies, in which the genotyped variant is thought to be the 
functional cause of the disease susceptibility), coupled to the progression of high-
throughput technologies and a reduction in genotyping costs, enabled association 
studies to be performed on a genome-wide basis, giving rise to the so-called Genome-
Wide Association Studies (GWAS). 
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GWAS represent a comprehensive yet unbiased option for association strategies, since 
they make no prior assumption on the location or functionality of the variants 
determining CRC risk. They represent an extremely good means of identifying common 
SNPs with modest effects on genotype. Since their implementation in late 2007, they 
have resulted in the discovery of several susceptibility loci in a variety of complex 
diseases and quantitative traits27. 
For CRC, GWAS have successfully identified 16 SNPs in 14 risk loci: rs6983267 at 
8q2428-31, rs4939827 at 18q21.132, rs4779584 at 15q13.333, rs3802842 at 11q23.131, 
rs16892766 at 8q23.3, rs10795668 at 10p1434, rs4444235 at 14q22.2, rs9929218 at 
16q22.1, rs10411210 at 19q13, rs961253 at 20p12.335, rs6691170 and rs6687758 at 
1q41, rs10936599 at 3q26.2, rs11169552 and rs7136702 at 12q13.13 and rs4925386 at 
20q13.3336. As expected by the complex disease model, these identified associations 
have all modest effects on disease risk, with odds ratios typically below 1.5.  
Even when GWAS have been quite successful for the discovery phase, we must bare in 
mind that the identified variants are most of the times not the functional ones. This 
means that the definition of the molecular mechanisms through which they influence 
disease risk and/or phenotype is yet to be assured for most of the cases. It is however 
quite outstanding, that some of these SNPs nearby genes seem to belong to the 
Transforming Growth Factor-beta (TGF-ß) signalling pathway, which has been 
extensively related to colorectal carcinogenesis37. On the other hand, these loci 
altogether explain only around 7% of the excess genetic susceptibility to CRC36. This 
highlights the need for further collaborative efforts involving larger sample sets and the 
combination of GWAS data that will hopefully lead to the identification of new variants 
that can explain the remaining proportion of expected genetic susceptibility. A summary 




Figure 2. The genetic risk factors in CRC. Overview of the loci related to CRC susceptibility and 
development. Frequent variants conferring high risk have not been found, since they are likely to affect 
the individual´s viability, whereas rare variants with low frequencies are difficult to detect. High-
penetrance rare mutations are typical of the hereditary syndromes, whereas more frequent moderately 
penetrant variants, discovered by association studies, are though to play an important role in the 
development of the disease. Adapted from A. Middeldorp; Genetics and tumor genomics in familial 
colorectal cancer 2010. 
 
Copy-number variation 
 The spectrum of human genetic variation ranges from single base pair changes to large 
chromosomal rearrangements. For much of the last decade, aims at explaining the 
genetic susceptibility underlying common diseases were focused on the inspection of 
SNPs. However, several independent reports confirmed in the last few years that there 
is indeed another form of variation that may involve an equally great proportion of the 




CNVs are events that range from 1kb to the microscopic detectable limit (!3Mb), and 
include duplications, deletions and inversions of DNA segments. Approximately 80% 
of these CNVs segregate at allele frequencies of 5% or greater in the population, 
making them a common source of genetic variation. Although the incidence of CNVs is 
considerably smaller than that of SNPs, they can affect large stretches of DNA, adding 
up to an estimated 12% of the genome40. Several CNV maps have been performed so 
far to establish the distribution of these events in the genome41-43. Most of the 
information gathered so far on CNVs is available at the Database of Genomic Variants 
(http://projects.tcag.ca/variation/) and the UCSC browser (http://genome.ucsc.edu/cgi-
bin/hgGateway). 
It has been observed that the incidence of CNVs appears to be greater in regions with 
segmental duplications (SD)41. SDs are segments of DNA over 1kb in size that have 
90% sequence homology with other locations elsewhere in the genome. The presence of 
these duplications could lead to non-allelic homologous recombination (NAHR) events 
between copies and the eventual creation of CNVs. NAHR was the first mechanism 
proposed for CNV creation, but processes such as double-strand break repair, B-DNA 
structures or transposition of mobile elements have also been seen to contribute to CNV 
formation44. On the contrary to what might have been expected, CNVs do not seem to 
be biased against genic regions, and around 40% of CNV events have been seen to 
overlap both RefSeq and OMIM genes45. Amongst these, there is a noticeable 
enrichment for genes with roles in adaptability and fitness, particularly olfactory 
receptors and genes implicated in xenobiotic metabolism. This could implicate 
structural variation in the dynamics of response to external stimuli and thus gene and 
organismal adaptation and evolution46. 
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It has also been postulated that CNVs may play an important role in the genetics of 
complex diseases42. Although most of these variants are presumed to be benign, they 
can have subtle influences on phenotypes and disease development, as has been 
described for HIV-1 infection47 and glomerulonephritis48. It is thus of great importance 
to test the possibility that CNVs may confer susceptibility to other diseases, such as 
CRC. It has been suggested that most common CNVs (around 77%) are in linkage 
disequilibrium with SNPs45,49,50. Hence, the implications of most of these in disease 
aetiology could be effectively evaluated indirectly through SNP analysis. However, 
there are two main reasons to justify the use of CNV-specific genotyping procedures. 
Firstly, CNVs appear to be present at low-coverage regions in both the reference human 
genome sequence and HapMap, probably because of the problematics in the sequencing 
of these regions. This implies that the coverage of the available SNP genotyping arrays 
is actually biased against CNV locations. Secondly, the presence of CNV events may 
generate inconsistencies that would make them unlikely to be accurately assessed in 
SNP-based studies. For instance, it has been described that deletions are prone to 
creating Mendelian errors, whereas duplications tend to leave high residual missing 
genotype rates and fail Hardy-Weinberg equilibrium (HWE)43. Fortunately, the new 
generations of arrays have accounted for these problems, and there are now a variety of 
CNV (Agilent Technologies) and dual SNP-CNV chips (Affymetrix 6.0, Illumina 1M) 
that specifically target the CNV component independently. A variety of algorithms have 
been proposed to infer copy-number status from the probe intensities obtained in these 
arrays (QuantiSNP51, Birdsuite52, PennCNV53), in order to enable later association 
measurements.  
The need to explore the genome for other sources of variability that could explain the 
remaining of the genetic component of common disorders has been increasingly urgent 
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in the past years. The first GWAS studies seemed to point that CNV contribution to 
common disease had been overestimated, for most of the genetic risk conferred by these 
variants had already been accounted for in SNP studies45,50. Nevertheless, there have 
also been some encouraging findings, particularly in the field of neuropsychiatric 
disorders that have shown that CNVs can still explain part of the remaining unexplained 
genetic variation in common diseases54.  
 
 
3. CRC MANAGEMENT AND TREATMENT 
The degree of CRC development and thus the therapeutic strategy to follow is 
determined by tumour staging. Historically, Duke´s staging system has been used for 
CRC diagnosis, although in the last few years there has been a trend towards an 
integration with the Tumour-Node-Metastasis (TNM) classification for solid tumours55. 
Although surgery is the most common choice of action for all-stage CRC patients, the 
use of chemotherapy is commonly indicated as well. 
Additionally, there is significant divergence in treatment strategies depending on the 
location of the tumour. This is principally due to the anatomical differences between 
colon and rectum, and the consequent implications these have over surgical resection of 
the tumour and its aftermath. It is for this reason that colon and rectal cancer strategies 
will be discussed separately. 
 
Colon cancer 
As has been stated in the former paragraph, surgery is the cornerstone treatment for 
colon cancer, particularly when it is localised (stages I, II and III). Moreover, the use of 
adjuvant (postoperative) treatments is also common for node-positive (stage III) disease 
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patients, for whom recurrence is a serious problem56. Adjuvancy has also been tested 
for stage II patients in clinical trials, although its use remains controversial, for the 
shown improvements in overall survival rates have been outweighed by the treatment 
toxicities and comorbidities57. The usual drug choices for these stages are typically 5-
fluorouracil (5-FU) and leucovorin (LV) in monotherapy, or in combination with 
oxaliplatin (FOLFOX). The mechanisms of action of these agents will be explained in 
the coming sections (See Pharmacogenetics: Five-fluorouracil and Oxaliplatin). On the 
other hand, chemotherapy is also extensively used as a palliative measure for metastatic 
colon cancer (stage IV). Treatment at this stage includes administration of 5-FU/LV in 
combination with oxaliplatin (FOLFOX) or irinotecan (FOLFIRI)58 (see 
Pharmacogenetics section). The use of monoclonal antibodies targeting the vascular 
endothelial growth factor (VEGF) and the epidermal growth factor receptor (EGFR) is 
also common at this stage. VEGF inhibitors, such as bevacizumab, are used to prevent 
the formation of new blood vessels, which would enable tumour growth and spreading, 
whereas two humanised monoclonal antibodies are used for the inhibition of EGFR-
mediated signalling: cetuximab and panitumumab59. 
 
Rectal cancer 
The management of rectal cancer varies somewhat from that of the colon. Radical 
surgery is also the main treatment of choice, but is limited by the frequent impossibility 
of achieving wide margins due to the presence of the bony pelvis. Therefore, the risk of 
local recurrence is much higher than in colon cancers60. Neoadjuvant (preoperative) 5-
FU/LV chemotherapy along with radiotherapy (chemoradiation), followed by adjuvant 
chemotherapy with 5-FU/LV or FOLFOX is considered as the standard protocol for 
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rectal cancer stages II and III58. For rectal stage IV cancer patients, same protocol as for 




It has been long known that there is a high inter-individual diversity in the outcome of 
drug administration. These differences may be due to multiple factors, such as health 
state of the patient, sex, age or co-administration with other drugs. However, the 
observation during the 1940s that some of these unusual drug responses presented 
familial clustering resulted in the realisation that at least part of this variation may also 
be due to genetic factors61. This led to the birth of pharmacogenetics, as the scientific 
field that aims to understand the genetic basis of this observed variability in therapeutic 
outcome in order to individualise treatments for improved response and reduced 
toxicity. Ever since this discovery, many studies have aimed at unravelling the genetic 
contributions to drug therapy outcome. 
 
Why these variations? Pharmacokinetics and pharmacodynamics 
The genetics underlying drug efficacy and toxicity may implicate variants in many 
genes. Then it is feasible to assume that many of the genes that encode for proteins 
involved in drug availability or enabling of drug function may influence therapeutic 
results. 
Pharmacokinetics has been used in relation to the differences in the delivery of a drug 
or metabolite to its target molecules. These discrepancies may arise in processes such as 
drug absorption, distribution, metabolism or elimination62. Several variants have already 
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been described that contribute to variability in pathways of drug disposition. The human 
cytochrome P450 (CYP) gene family members may be a good example of this63. 
Likewise, the term pharmacodynamics describes the relationship between drug 
concentration and its effect. The appearance of pharmacodynamic variation may arise 
directly from variability within the drug target or from the genetic variation in other 
molecules with which the drug or the target interact62.  
 
The candidate-gene approach in pharmacogenetics 
Early pharmacogenetic studies greatly focused on variants with Mendelian effects on 
response. By these means, a handful of mutations have been discovered that account for 
a large proportion of the population effects64. Nevertheless, given the normal 
distributions observed in the phenotypes of drug administration, both for efficacy of 
response and the development of toxicities, it is quite rare that single polymorphisms 
will explain the whole variety of outcomes observed. There is also the fact that most of 
these high-risk genetic variants are uncommon, and therefore may only explain a small 
proportion of the population variances. Thus, it is widely believed that most drug effects 
may be, same as for complex diseases, polygenic in nature65. 
As in disease association studies, the classical approach to identifying new 
susceptibility loci has been the analysis of single-gene variants. In this sense, 
pharmacokinetic-related genes, such as drug metabolisers and drug transporters, and 
pharmacodynamic effectors, such as drug targets, have been screened for evidences of 
association66,67. Extensive studies have also been performed to screen the genetic 
variation in entire biological and pharmacological pathways, such as the DNA-repair 




Pharmacogenetics in cancer 
The matching of patients to the protocol most likely to be effective and less harmful is 
of essential importance in cancer chemotherapy, since many anticancer drugs have 
narrow therapeutic indexes and the threshold delimiting the therapeutic range and the 
toxic response is diffuse. It is for this reason that there have been extensive studies on 
the pharmacogenetics of anticancer drugs. A brief description of each of the most 
common CRC chemotherapy drugs and the associations found will be thus presented. 
 
Five-fluorouracil (5-FU) 
Five-fluorouracil was introduced about 50 years ago as the first systemic chemotherapy 
agent for CRC treatment70. Since then, it has formed the backbone of treatment for both 
adjuvant and advanced settings in CRC chemotherapy, particularly in combination with 
its cofactor leucovorin (LV). Capecitabine is an oral pro-drug of 5-FU. This molecule is 
a frequent alternative to 5-FU administration, since it effectively increases the 
concentration of 5-FU in the neoplasic cells71. The mechanism of action of these 
fluoropyrimidine compounds relies on the inhibition of thymidylate synthase (TYMS), 
the rate-limiting enzyme in pyrimidine nucleotide synthesis72 (Figure 3). 
The administration of 5-FU-LV/capecitabine has however some potentially serious side 
effects. Gastrointestinal and haematological adverse drug reactions (ADRs), and hand-
foot syndrome are frequently observed73. It has been estimated that 26-65% of these 
variations in susceptibility to 5-FU-induced toxicity are due to genetic components. 
Several variants have been described as associated with this inherited predisposition, 





Figure 3. Fluoropyrimidine mechanism 
of action. Fluoropyrimidines (5-FU and 
capecitabine) are primarily converted to 
fluorodeoxyuridine diphosphate (FdUDP). 
FdUDP can either be phosphorylated or 
dephosphorylated to generate the active 
metabolites fluorodeoxyuridine 
triphosphate (FdUTP) and 
fluorodeoxyuridine monophosphate 
(FdUMP), respectively. FdUMP inhibits 
TYMS, whereas FdUTP is directly 
incorporated into growing DNA chains, 
resulting in impaired strand elongation and 
an increase in DNA fragmentation. The 
collateral formation of fluorouridine 
triphosphate (FUTP) also contributes to the toxic effects of 5-FU by disruption of mRNA function93. The 
detoxification of the fluoropyrimidines occurs almost exclusively by the action of the dihydropyrimidine 
dehydrogenase (DPYD) enzyme in the liver94. Adapted from Klein et al. 200195 (The Pharmacogenomics 
Journal); copyright of PharmGKB. 
 
Figure 4: Mechanism of action of 
platinum anticancer drugs. 
Platinum compounds are able to 
destroy cancerous cells by interfering 
with DNA, via inter- and intra-strand 
crosslinks, and DNA-protein binding, 
thereby preventing cell division and 
growth. The formation of these DNA 
adducts may be overcome by several 
cellular mechanisms: the cell´s 
system repair genes (both the 
mismatch and the excision repair), 
the translesional replication 
machinery (POL and REV3L 
proteins) or the damage recognition 
system (HMGB1). Detoxification of 
platinum may also occur through 
glutathione-S-transferases (GSTs); members of this gene family have been implicated in both 
detoxification events and carcinogenesis98. Adapted from Marsh et al. 2009 Pharmacogenetics Genomics; 














































Oxaliplatin is a third-generation platinum compound that induces the formation of DNA 
adducts, inducing an apoptotic response in the tumour cell78 (Figure 4). It has modest 
activity against colorectal cancer by itself, but is shown to produce clinical benefits in 
response rates and overall survival in addition to the classic 5-FU-LV (a combination 
typically known as FOLFOX)79. Because of this, the use of FOLFOX has been widely 
implemented for adjuvant and palliative cancer therapies. 
As happens with other chemotherapeutical agents, administration of 
oxaliplatin/FOLFOX has considerable side effects. A severe cumulative sensory 
neuropathy that may endure even after treatment ending has been the most substantial 
of these80. Diarrhoea, neutropenia and nausea/vomiting may also appear with high 
prevalences81. This heterogeneity in treatment outcome has also been targeted by 
pharmacogenetic studies. The most remarkable associations are shown on Table 1. 
 
Table 1: Description of the variants associated with drug outcome in CRC treatments. 




DPYD 5-FU detoxification 
IVS14+1 
(rs3918290) 




TYMS Pyrimidine synthesis 





Lower toxicity 83  
3´UTR 6bp indel 
(rs34489327) 
G>C transversion at 
the 2nd repeat of 3R 
(no rs found) 
 MTHFR Folate metabolism c.C677T (rs1801133) T allele 
Better response; 
higher toxicities 84 










Impairs union of TFIID 




(rs4148323) Slower degradation rate 
Neutropenia in 
Asian populations 87 









*Denotes both dbSNP and common literature codings for this variant. 
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Other treatments: irinotecan and targeted therapies 
Irinotecan is a topoisomerase 1 inhibitor used in solid tumour chemotherapy. This 
impairs DNA replication, resulting in cell death. As with oxaliplatin, this drug is 
typically administered in combination with 5-FU-LV (commonly referred to as 
FOLFIRI)89. Around 30% of patients administered with irinotecan develop severe 
neutropenia or diarrhoea during the treatment. A polymorphism in the UGT1A1 gene, 
responsible for irinotecan detoxification through glucuronidation has been linked to 
these adverse effects86 (Table 1). 
Treatment with cetuximab, a monoclonal antibody directed against EGFR, improves 
overall and progression-free survival in patients with colorectal cancer that have not 
responded to chemotherapy. However, the effectiveness of cetuximab administration 
depends heavily on the mutational status of the KRAS gene. Is has been observed that 
KRAS mutated tumours do not benefit from cetuximab administrations88. 
 
Pharmacogenomics 
Although candidate-gene approaches have had reasonable success in identifying genetic 
variants that are important in specific phenotypes, the evaluation of a gene in isolation 
will most likely never provide the sensitivity and specificity that is needed for tailored 
treatment decisions. This evidences an urgent need to detect some new polymorphisms 
that are able to predict a bigger portion of the expected heritability. 
Along these lines, pharmacogenetics may as well follow the path of disease genetics, 
and take advantage of the knowledge acquired on the genome over the last two decades 
and the developments on genotyping technologies. The term pharmacogenomics has 
been described as the wide-range genomic application of pharmacogenetics, although 
several definitions with different connotations are available90. Pharmacogenomics could 
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mean a new chapter for variant discovery, and an opportunity to find new understanding 
on the molecular basis of drug disposition and drug action without the constraints of 
predetermined candidate genes.  
Since 2007, several GWAS have appeared on the pharmacogenetic field, analysing drug 
outcomes in different diseases, such as asthma, psychiatric disorders or cardiovascular 
disease91. Less than half of these GWAS published on response have however yielded 
significant results. Positive findings in this field include the identification of the genes 
responsible to variation in response to coumarin anticoagulants. This effect has been 
mainly linked to variation in only three principal genes: CYP2C9, VKORC1 and 
CYP4F2 explaining almost 64% of the total attributable genetic variation92. Fewer 
GWAS have been published on ADRs (around 30% of the total GWAS), and only two 
of them have successfully reported significant findings: fluoxacin-induced liver injury 
linked to HLA-B*570193 and simvastatin-induced myopathy, determined by variants in 
the SLCO1B1 gene94. 
Nevertheless, the number of GWAS in pharmacogenetics is increasing rapidly. 
Although most of these studies have failed in identifying any new variants, they have 
pointed out at some new loci that could be very interesting for follow-up. Further 
GWAS studies in larger cohorts could verify the importance of these associations and 
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Heritability in colorectal cancer (CRC) predisposition has been estimated to be around 
35% by twin studies. Although ! 5% of this proportion may be explained by high-
penetrance mutations, and an additional 7% is thought to be due to the presence of a 
combination of some of the already-described 16 susceptibility SNPs, there is still a 
significant fraction of CRC susceptibility that remains unexplained. 
On the other hand, there is also considerable variation in the way CRC patients respond 
to chemotherapy. Besides, the fact that most drugs used in CRC treatment have narrow 
therapeutic ranges results in the frequent development of adverse drug reactions 
(ADRs). Hence, the identification of the genetic variation modulating this outcome 
would be most helpful in both the individualisation of the treatment and the reduction of 
health costs. 
 
1. The first aim of this study has thus been the screening for new susceptibility genetic 
variants in CRC. This objective is divided into two categories: 
 
 A. The study of SNP variability. Both candidate-gene approaches and genome- 
 wide association studies (GWAS) were used for this purpose. 
 
 B. An evaluation on the possibility that copy-number variants (CNVs) may also 
 be influencing CRC susceptibility. 
 
2. The second aim of the study has been the analysis of the genetic variation underlying 
the differences on toxicity responses in chemotherapy-treated CRC patients. 
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For the first aim, we have intended to search for new variants that could explain at least 
a part of the missing heritability in CRC. For this purpose, we have chosen to 
investigate the most common sources of variability in the genome: SNPs and CNVs. 
In the SNP part of the study, we have followed two different approaches: a candidate-
gene strategy evaluating the polymorphic variation in genes with a potential functional 
implication in CRC carcinogenesis and a genome-wide association study. For the 
former, we have assayed in separate studies the genes present in the human syntenic 
regions of the 15 Scc (susceptibility to colorectal cancer) mouse loci (chapter 1), and 
those belonging to two pathways that have been consistently linked to CRC 
development: Wnt and BMP (chapter 2). For the latter, we have carried out a GWAS in 
a Spanish cohort (chapter 3). The advantage of this strategy against the candidate-gene 
one is that there is no a priori hypothesis on where the susceptibility loci may be 
located. 
Regarding the CNV study, we have also performed a GWAS scan of the genomic 
structural variation and its potential implication in CRC neoplasia (chapter 4), using 
two different copy-number calling algorithms: Birdsuite´s Birdseye and QuantiSNP v2. 
 
In the second part of this study, our purpose was to analyse the relationship between 
common genetic variation and the development of ADRs after chemotherapy. For this, 
we evaluated the correlation between two of the most common administered drugs in 
CRC treatment: 5-fluorouracil and oxaliplatin (FOLFOX) and the presence of ADRs by 
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Null Results in Brief
Colorectal Cancer Susceptibility Quantitative Trait Loci in
Mice as a Novel Approach to Detect Low-Penetrance
Variants in Humans: A Two-Stage Case-Control Study
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Abstract
Thirty-five percent of colorectal cancer (CRC) susceptibility is thought to be attributable to genetics, but only
a small proportion of the cases (<6%) can be explained by highly penetrant mutations. The rest of the suscep-
tibility could be explained by a number of low-penetrance variants following a polygenic model of inheritance.
Genetic modeling in rodents has been a successful tool for the unraveling of the genetic basis of diseases.
The investigation of mouse quantitative trait loci led to the discovery of 15 “susceptibility to colorectal cancer”
(Scc) loci. Thus, we aimed to analyze the human-mouse syntenic regions defined by these Scc loci and select
human candidate genes within. Twenty-one genes were chosen and their single-nucleotide polymorphisms
were tested as possible low-penetrance variants predisposing to CRC risk. Our most strongly associated
single-nucleotide polymorphism, rs954353, seems to be in the 5′ region of the CYR61 gene, which could
implicate it in terms of the cis-regulation of the gene. CYR61 has been proposed as a connection point among
signaling pathways and a probable marker for early CRC detection. However, we could not replicate the as-
sociation. Despite our negative results, we believe that our candidate gene selection strategy could be quite
useful in the future determination of variants predisposing to disease. Cancer Epidemiol Biomarkers Prev; 19(2);
619–23. ©2010 AACR.
Introduction
Colorectal cancer (CRC) is the second most frequent
neoplasm and one of themost important morbidity causes
in the developed world (1). Despite the fact that 35% of
CRC susceptibility could be attributable to genetics, only
a small proportion of the cases (<6%) can be explained by
highly penetrant mutations, suggesting that the rest of the
susceptibility should exist in the form of low-penetrance
variants following a polygenic model of inheritance (2).
Genetic modeling in rodents has been proved to be an
important tool in the unraveling of the genetic basis of
diseases. The investigation of mouse quantitative trait loci
(QTL) to identify chromosomal regions harboring genetic
variants that affect susceptibility successfully led to the
discovery of 15 “susceptibility to colorectal cancer” (Scc)
loci (3, 4). Because there is increasing evidence that causal
genes underlying disease QTLs are conserved between ro-
dents and humans (5), a sensible approach to identify
these genes would be to map them in mice and, subse-
quently, investigate the role of their human homologues.
Hence, our aim is to analyze the human-mouse syntenic
regions defined by these Scc loci and select human candi-
date genes to screen their single-nucleotide polymor-
phisms (SNP) and test them as possible low-penetrance




Subjects on stage I were 515 CRC cases and 515
controls from EPICOLON I, a prospective, multicenter,
population-based epidemiology study (6). Subjects
on stage II (933 cases and 955 controls) belonged to
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Scc4 17 PRKD3 2p22-p21 Protein kinase D3 Receptor of phorbol







MSH2 2p21 MutS homolog 2 DNA mismatch repair rs13019654; rs17036614;
rs458314; rs7607076
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EPICOLON II, an extension of EPICOLON I. Cases and
controls were matched for sex and age. All samples were
obtained with informed consent reviewed by the ethical
board of the corresponding hospital.
Candidate Gene Selection
QTLs were defined by their flanking markers by revi-
sion of the author's data and the MGI (7). Genes within
each human-mouse syntenic region showing enriched








Gene description Gene ontology SNPs analyzed
Scc9 10 MDM2 12q14.3-q15 Transformed 3T3
cell double minute 2






























at MYCL1 is a marker for
poor prognosis in CRC
rs3117088; rs3134614;
rs3134615
Scc12 7 DMBT1 10q25.3-26 Deleted in malignant
brain tumors 1
Role in the interaction

















VIP 6q25 Vasoactive intestinal
peptide
Proangiogenic factor rs12212849; rs3823082;
rs637572; rs671330;
rs680314; rs688136
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NOTE: For some of the Scc loci, more than one gene was selected because of their possible functional implications.
Mouse Susceptibility QTLs and CRC Risk in Humans




expression in primary affected tissues in mice were se-
lected with ExQuest (8). Finally, 21 human genes were
chosen from the 15 Scc (Table 1; ref. 9).
SNP Selection and Genotyping
One hundred forty-seven SNPs were selected from the
21 genes with PupaSuite (10), FESD (11), dbSNP (12), and
HapMap Phase II (genome build 36; ref. 13). SNPs with
unadjusted P values <0.01 were replicated in an indepen-
dent case-control series. Genotyping was done in the
SNPlex (Applied Biosystems), MassARRAY (Sequenom,
Inc.), and TaqMan (Applied Biosystems) platforms at
the Santiago de Compostela node of the Spanish Geno-
typing Center.
Statistical Analyses
Quality control was assessed with the Genotyping
Data Filter (14) and Structure v2.2 (15). Genotypic distri-
butions in controls followed Hardy-Weinberg equilibri-
um, and there was no sign of underlying population
stratification. Association was evaluated for every single
SNP and all possible haplotypes in each gene with Hap-
loview v4.0 (16) and Unphased (17). Permutation tests
and Bonferroni were used for multiple-testing correc-
tions. Odds ratio (OR) and 95% confidence intervals were
calculated with PLINK v1.03 (18). Descriptive informa-
tion and association data for all the SNPs that passed
quality control are shown in Supplementary Table S1.
Results
Allelic association tests revealed only one significant
SNP after multiple-testing correction: rs12086058, lying
in an intergenic region 6.4 kb upstream the CYR61 gene
(1p31-p22). The OR value for this SNP showed a protec-
tive effect of the minor allele (Table 2). Haplotype analy-
sis and comparisons between sporadic and familial
groups did not yield any significant associations (data
not shown).
Linkage disequilibrium analysis in the CYR61 region
showed rs12086058 to be in high correlation with
rs954353 (r2 = 1). This SNP was located 1.8 kb upstream
CYR61, which suggested a possible implication in the
cis-regulation of the gene. Genotyping of rs954353 yielded
a better association value than rs12086058 (2 × 10−4). OR
also showed a protective effect of theminor allele (Table 2).
To verify the results, SNPs with nominal P < 0.01
(rs12086058, rs954353, and rs10077888) were further rep-
licated on an independent sample. Nevertheless, none of
the associations could be replicated (Table 2).
Discussion
Our study combines the advances in CRC genetics in
animal models with the investigation of the variation un-
derlying the disease in humans. We selected 21 genes
identified from syntenic regions defined by mouse QTLs
to screen their SNP variability in a two-stage case-control
association study. However, we did not find any replica-
ble association. Our study had enough power to detect
OR ≥1.3, assuming allelic association and α = 0.05 (19).
Results in stage I were therefore simply due to chance or
to type I error.
Nevertheless, our most strongly associated SNP,
rs954353, seems to be in the 5′ region of the CYR61 gene,
which could still implicate it in terms of cis-regulation.
We analyzed the region harboring rs954353 and found
it to be lying very close to two transcription factor bind-
ing site sequences. The direct sequencing of these failed
to find any common variants within the consensus target
that could explain the association signal found in stage I.
However, we did find a 6-bp insertion polymorphism
38 bp upstream the first transcription factor binding site.
This variant showed significant differences in frequencies
between cases and controls (P = 0.0236), although no fur-
ther implications could be stated about its relationship
with CRC susceptibility (data not shown).
CYR61 has been proposed as a connection point among
signaling pathways and a probable marker for early CRC
detection (20). Besides, it has been extensively implicated
in carcinogenesis-related events such as angiogenesis
(21), tissue invasion (22), cell migration, and metastasis
(23), although no association studies have been published
thus far that analyze its relationship with CRC.
Despite our negative results, we believe that our candi-
date gene selection, through the identification of genes or
regions conferring susceptibility to other species, could be
quite useful in the future determination of variants pre-
disposing to disease. Our QTLs analyses proved to be
very helpful as a starting point in the search for candidate
genes affecting CRC susceptibility because all the genes
identified were somehow related to carcinogenetic events.
Table 2. Association analyses for the three SNPs selected for replication on stage II
SNP_ID Gene Relevance Alleles Observed
MAF






rs12086058 CYR61 5′UTR A/G 0.428 0.71 (0.59-0.86) 0.0005 0.0326 0.0405 0.4099
rs954353 CYR61 5′UTR A/G 0.434 0.70 (0.59-0.84) 0.0002 0.0246 0.027 0.3917
rs10077888 TNFAIP8 Intronic C/G 0.302 0.75 (0.61-0.92) 0.0019 0.2058 0.2565 0.8188
Abbreviations: MAF, minor allele frequency; 95% CI, 95% confidence interval; UTR, untranslated region.
Fernández-Rozadilla et al.




In fact, although this approach has not been successful
thus far for CRC, it positively identified a haplotype
in PTPRJ as a breast cancer genetic susceptibility low-
penetrance allele (24). Hence, we encourage future efforts
in this field and believe that the relationship between
CYR61 and CRC should be studied in other populations
to fully discard a putative genetic association.
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Abstract
Background: Colorectal cancer (CRC) is considered a complex disease, and thus the majority of the genetic susceptibility is
thought to lie in the form of low-penetrance variants following a polygenic model of inheritance. Candidate-gene studies
have so far been one of the basic approaches taken to identify these susceptibility variants. The consistent involvement of
some signaling routes in carcinogenesis provided support for pathway-based studies as a natural strategy to select genes
that could potentially harbour new susceptibility loci.
Methodology/Principal Findings: We selected two main carcinogenesis-related pathways: Wnt and BMP, in order to screen
the implicated genes for new risk variants. We then conducted a case-control association study in 933 CRC cases and 969
controls based on coding and regulatory SNPs. We also included rs4444235 and rs9929218, which did not fulfill our
selection criteria but belonged to two genes in the BMP pathway and had consistently been linked to CRC in previous
studies. Neither allelic, nor genotypic or haplotypic analyses showed any signs of association between the 37 screened
variants and CRC risk. Adjustments for sex and age, and stratified analysis between sporadic and control groups did not
yield any positive results either.
Conclusions/Significance: Despite the relevance of both pathways in the pathogenesis of the disease, and the fact that this
is indeed the first study that considers these pathways as a candidate-gene selection approach, our study does not present
any evidence of the presence of low-penetrance variants for the selected markers in any of the considered genes in our
cohort.
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Introduction
Colorectal cancer (CRC) is one of the main forms of cancer,
being the second most frequent neoplasm in both sexes and one of
the most important morbidity causes in the western world [1]. The
genetic contribution to CRC has been estimated to be around
35% by extensive twin studies [2]. However, highly penetrant
variants, that cause mendelian predisposition syndromes, account
only for, at most, 5% of the disease cases [3]. The remaining
genetic susceptibility is thought to follow a polygenic model, with
an interplay of multiple low-penetrance allelic variants appearing
in high frequency in the general population, and each conferring a
modest effect on disease risk [4,5].
Candidate-gene studies have been one of the most commonly
used tools in the screening for new variants affecting CRC risk.
Gene selection in these studies is mainly based on the functional
implications of a possible association, and thus genes selected have
either been chosen because of the previous presence of other high/
low risk alleles [6], or their participation in a pathway implicated
in the pathogenesis of the disease [7]. Candidate-gene studies can
be performed by either direct approaches, where the variants
genotyped are presumed to be the underlying cause of the disease




because of their location (variants in exonic or regulatory regions),
or by indirect approaches, where tag SNPs take advantage of the
linkage disequilibrium properties of the human genome to try and
screen the most of the variability in a given gene.
This latter approach has also allowed, together with the
development of high-throughput technologies, the implementation
of new hypothesis-free approaches (in opposition with hypothesis-
based candidate-gene approaches), covering the majority of the
genome (genome-wide association studies or GWAS). This imple-
mentation has successfully led to the identification of some new
susceptibility loci [8–14], including rs4444235 and rs9929218, that
fall within reach of two genes belonging to the BMP pathway.
Nevertheless, these have been found to predict only a small
proportion of the disease susceptibility, with the remaining yet to
be discovered [15].
We hence aimed to find such susceptibility variants through a
candidate-gene approach screening a selected number of variants
within two cellular pathways that have consistently been linked to
CRC tumorogenesis: the Wnt and the BMP signaling pathways
[16,17].
The Wnt pathway contains genes that have for long been known
to be responsible of some hereditary CRC syndromes, such as APC
and familial adenomatous polyposis [18]. Moreover, somatic
alterations in APC are found in almost 80% of the sporadic colorectal
cancers, and Wnt signaling activation is involved in the best part of
sporadic colorectal carcinomas [19]. On the other hand, the BMP
pathway acts as positive regulator of some of the Wnt proteins [17],
and the tumor suppressive role of this signaling pathway in the
pathogenesis of CRC and other cancers is well established [20,21].
Besides, mutations in two of its genes, SMAD4 and BMPR1A, are
responsible for juvenile polyposis syndrome, another hereditary
CRC condition [22]. Considering all this information, we thought it
would be interesting to screen some of the genetic variability within
these pathways for any evidence of new CRC related variants that
could explain at least part of the missing heritability. Our approach
was mainly functional, for only SNPs within exonic or cis-regulatory
sequences (59 and 39 unstranslated regions) were selected to analyse
their relationship with CRC susceptibility.
Results and Discussion
Following our pathway-based candidate-gene selection method,
we performed our study in a total of 45 SNPs that were in either
exonic or regulatory regions, in an overall of 21 genes from both
the Wnt and BMP pathways. Details of SNP features and
association values for the 37 SNPs that successfully passed quality
control criteria are shown on Table 1. None of the screened SNPs
were significantly associated with an altered risk of CRC,
considering odds-ratios and related p values for allelic and
genotypic tests (trend, dominant and recessive). Logistic regression
for age and sex adjustment was performed, although it did not
improve p value results. Haplotype analysis results were consistent
in both Unphased and Haploview, and did not show any signs of
positive associations either for any of the 8 genes for which this
analysis was performed (AXIN1, HDAC9, BMP4, DACT1, CDH3,
CDH1, BTRC, and APC), (Figure S1). Stratification analysis
comparing sporadic and familial cases was also implemented,
but it did not provide any evidence of differences in susceptibilities
between the groups that could be a sign of any specific associations
within either of the groups (Table 2).
Thus, our strategy has not managed to detect any new
susceptibility loci for CRC risk.
Pathway-based expectations have proved to be quite discour-
aging in the literature as well, for strong candidate pathways, such
as DNA-repair ones, surprisingly failed too in identifying any new
risk variants [7,23–24]. In addition to this, most of the genetic
variants that have been found to be associated with disease are
located in intergenic regions, with potential functions that are yet
unknown.
Still, in light of the recent discoveries that followed up the
analysis of genome-wide data, both Wnt and BMP have earned a
renewed fame. The susceptibility locus found on 8q24 (rs6983267)
has been linked to an enhanced Wnt signaling through its
interaction with TCF4 [25,26], and a meta-analysis conducted on
a series of GWAS data succeeded in associating two variants in the
BMP4 and CDH1 gene regions with the disease (rs4444235 and
rs9929218, respectively)[8].
Even though this is actually the first association study that
considers the pathways as a whole for gene selection, some of the
genes included in our analysis (i.e APC, CCND1, CDH1 and TCF7)
had already been screened for risk alleles [6,27–30]. It is quite
remarkable that there has been a growing debate over some of
these loci, specially the p.V1822D variant in APC (rs459552). This
missense change is widely documented in the literature, with some
studies defending it as neutral (this study and others)[31], and
some conferring its minor allele a protective effect [6,28]. Lack of
appropriate study power, resultant from insufficient number of
samples has been a major problem in many of these studies
and thus most of them have not provided very convincing results
[32].
Although our study had over 80% power to detect OR as low
as 1.21 with minor allele frequencies of 0.30 (57% of our SNPs),
and 1.24 for MAFs down to 0.2 (78% of the SNPs), assuming a
log-additive model and a=0.05, we were unable to detect any
positive associations suggesting the presence of any new CRC
susceptibility variants. Nevertheless, it is quite remarkable that,
albeit our failure to replicate the associations for the BMP4 and
CDH1 SNPs, this is the first study that investigates any of the so-
called 10 new GWAS-discovered susceptibility loci in a Southern-
European population.
Despite our negative results, we must consider that we did not
whatsoever comprehensively cover all possible low-penetrance
variants within the selected genes. This is mainly due to the fact
that our strategy was purely functional, selecting the variants that
were a priori good candidates to be directly associated with the
disease. This indeed may constitute a limitation in the study, for
most of the genetic variation within the loci was not investigated.
Thus, we believe further efforts should be made to screen a wider
variety of loci within these pathways, specially considering the
previous positive associations described so far for both Wnt and
BMP-related genes.
Pondering the potential odds ratios of the variants des-
cribed so far (1.11, CI 1.08–1.15 and 0.91, CI 0.89–0.94 for
rs4444235 and rs9929218, respectively), we assume larger
cohorts may be required to detect such subtle effects. On the
other hand, when considering candidate-gene approaches, it
would also be useful to meta-analyse previous studies and pull
the information across of them altogether in the search of




Subjects were 933 CRC patients and 969 controls that belonged
to the EPICOLON project, a prospective, multicentre, popula-
tion-based epidemiology survey studying the incidence and
features of familial and sporadic CRC in the Spanish population
Wnt-BMP Pathways in CRC Risk




[33]. Cases were selected across 11 hospitals in Spain as all
patients with a de-novo histologically confirmed diagnosis of
colorectal adenocarcinoma and who attended 11 community
hospitals across Spain between November 2006 and December
2007. Patients in whom CRC developed in the context of familial
adenomatous polyposis or inflammatory bowel disease, and cases
where patients or family refused to participate in the study were
excluded. Demographic, clinical and tumour-related characteris-
tics of probands, as well as a detailed family history were obtained
using a pre-established questionnaire, and registered in a single
database. Of these, 592 (63%) were male and 341 (37%) female.
Median age for cases was 73 (range 26–95), whereas mean was
71(SD610.7). Hospital-based controls were recruited together
with cases and were confirmed to have no cancer or prior history
of neoplasm, and no family history of CRC. All controls were
randomly selected and matched with cases for sex and age (65
years) in a 1:1 ratio. Both cases and controls were of European
ancestry and from Spain.
Table 1. Description of the 37 SNPs that passed quality control criteria and their associated p values.










controls p-value OR (95% CI)
ADAR rs2229857 Missense K384R A/G 0.3306 0.3201 99/360/385 88/347/382 0.512 1.05 (0.91–1.22)
APC rs2229992 Synonymous Y486Y C/T 0.3981 0.4125 145/382/317 141/392/284 0.3728 0.94 (0.82–1.08)
APC rs351771 Synonymous A545A C/T 0.3817 0.375 124/397/324 125/416/347 0.7978 1.02 (0.89–1.18)
APC rs41115 Synonymous T1493T C/T 0.3796 0.3761 126/385/328 127/414/347 0.8595 1.00 (0.88–1.16)
APC rs42427 Synonymous G1678G A/G 0.3741 0.3713 124/382/336 116/365/323 0.9252 1.01 (0.88–1.17)
APC rs459552 Missense V1822D A/T 0.2302 0.2134 48/293/504 41/297/550 0.2197 1.11 (0.94–1.30)
APC rs465899 Synonymous P1960P C/T 0.3828 0.3743 126/395/324 125/414/348 0.7107 1.03 (0.90–1.19)
APC rs866006 Synonymous S1756S A/C 0.3775 0.3756 123/370/323 124/401/339 0.925 1.00 (0.87–1.19)
AXIN1 rs1805105 Synonymous D254D C/T 0.3918 0.4096 136/387/318 164/397/324 0.2692 0.93 (0.81–1.07)
AXIN1 rs214250 Synonymous S428S C/T 0.2206 0.2028 32/307/502 34/265/522 0.2138 1.12 (0.94–1.32)
AXIN1 rs214252 Synonymous A609A A/G 0.2207 0.2005 32/305/499 34/258/521 0.1403 1.13 (0.96–1.34)
AXIN1 rs400037 Missense R388Q C/T 0.1826 0.1829 27/244/545 39/234/580 0.8972 1.04 (0.87–1.24)
AXIN2 rs2240308 Missense P50S A/G 0.4502 0.4219 168/423/252 152/442/290 0.1031 1.11 (0.97–1.27)
BMP4 rs17563 Missense V152A C/T 0.4946 0.4855 211/407/220 208/420/233 0.5498 1.07 (0.93–1.23)
BMP4 rs4444235 – – C/T 0.4563 0.4557 168/436/242 196/411/274 0.9343 0.99 (0.86–1.14)*
BTRC rs17767748 Synonymous I229I C/T 0.05516 0.056 3/86/745 4/91/789 0.9324 1.00 (0.74–1.36)
BTRC rs4151060 Missense A543S G/T 0.04793 0.04904 4/73/768 2/83/802 0.6997 0.96 (0.70–1.32)
CCND1 rs603965 Synonymous P241P A/G 0.4969 0.4822 204/406/209 206/430/237 0.4164 1.06 (0.93–1.22)
CDH1 rs1801552 Synonymous A692A C/T 0.3547 0.3781 105/371/343 126/365/325 0.1834 0.92 (0.81–1.07)
CDH1 rs9929218 Intronic – A/G 0.2811 0.2873 65/345/435 83/342/459 0.5486 0.97 (0.83–1.13)*
CDH3 rs1126933 Missense Q563H C/G 0.3828 0.3802 129/382/325 129/361/324 0.8369 1.02 (0.88–1.17)
CDH3 rs17715450 Synonymous R747R A/C 0.3783 0.3959 116/390/316 147/402/330 0.2792 0.93 (0.80–1.07)
CDH3 rs2274239 Synonymous K652K C/T 0.3599 0.3771 108/390/344 126/368/328 0.2863 0.93 (0.81–1.07)
CDH3 rs2296408 Synonymous T271T G/T 0.3698 0.3724 107/394/321 130/388/352 0.8768 1.00 (0.87–1.15)
CDH3 rs2296409 Synonymous T240T C/T 0.3585 0.3643 106/391/344 130/387/371 0.7962 0.98 (0.85–1.13)
CDH3 rs8049247 Synonymous I204I A/C 0.1665 0.1682 21/238/582 22/249/600 0.8683 0.97 (0.81–1.17)
DACT1 rs17832998 Missense A464V C/T 0.3468 0.3448 111/362/369 116/381/392 0.9293 1.01 (0.88–1.17)
DACT1 rs863091 Synonymous V378V C/T 0.2047 0.2033 30/283/525 41/249/524 0.932 1.01 (0.85–1.19)
HDAC9 rs1178127 Missense P621P A/G 0.21 0.2203 37/273/516 41/300/526 0.4737 0.94 (0.80–1.12)
HDAC9 rs34096894 Synonymous L152L C/T 0.01953 0.01351 0/33/812 1/22/865 0.2075 1.33 (0.78–2.27)
NLK rs3182380 Synonymous I498I C/T 0.05142 0.05535 2/83/761 3/85/734 0.4686 0.92 (0.68–1.24)
PPARD rs2076167 Synonymous N163N A/G 0.2956 0.294 72/355/417 78/328/417 0.9891 1.00 (0.86–1.16)
SMURF1 rs219797 Synonymous S166S C/G 0.4452 0.4712 160/428/252 210/415/261 0.1591 0.90 (0.78–1.03)
TCF7 rs30489 Missense G256R C/T 0.07683 0.07937 6/118/722 6/128/748 0.7655 0.97 (0.75–1.25)
TLE1 rs2228173 Synonymous E118E A/G 0.1183 0.1172 11/178/656 6/196/685 0.992 1.02 (0.82–1.26)
WIF1 rs7301320 Synonymous A73A C/T 0.2237 0.2219 48/265/494 47/281/517 0.9768 1.00 (0.84–1.18)
WNT2B rs910697 Synonymous Q390Q A/G 0.4218 0.4301 154/404/286 172/419/296 0.5463 0.95 (0.83–1.09)
Minor allele is depicted in bold.
MAF. Minor Allele Frequency; OR 95% CI. Odds Ratio and 95% Confidence Interval. GT counts. Genotype counts.
*Described OR (95%CI) for rs4444235 and rs9929218 were 1.11 (1.08–1.15) and 0.91 (0.89–0.94), respectively, as taken from Houlston et al.. Nat Genet 2008.
doi:10.1371/journal.pone.0012673.t001
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The study was approved by the ‘‘Comité Ético de Investigación
Clı́nica de Galicia’’, and each of the institutional review boards of
the hospitals where samples were collected (‘‘Ethics Committee of
the Hospital Clı́nic-Barcelona’’, ‘‘Ethics Committee of the
Hospital del Mar-Barcelona’’, ‘‘Ethics Committee of the Hospital
German Trias i Pujol-Barcelona’’, ‘‘Ethics Committee of the
Hospital Sant Pau-Barcelona,’’ ‘‘Ethics Committee of the Hospital
Universitari Arnau de Vilanova-Lleida’’, ‘‘Ethics Committee of
the Hospital General-Alicante’’, ‘‘Ethics Committee of the
Hospital de Donosti’’, ‘‘Ethics Committee of the Hospital General
de Asturias-Oviedo’’, ‘‘Ethics Committee of the Hospital Clinico-
Zaragoza’’, ‘‘Ethics Committee of the Hospital de Calahorra-La
Rioja’’, ‘‘Ethics Committee of the Hospital Meixoeiro-Vigo’’). All
samples were obtained with written informed consent reviewed by
the ethical board of the corresponding hospital.
DNA extraction
DNA was obtained from frozen peripheral blood; extraction
was performed in a CHEMAGEN robot (Chemagen Biopolymer-
Table 2. Association values for stratified analysis in familial and sporadic CRC groups.
Familial vs control Sporadic vs control Familial vs sporadic
ADAR rs2229857 0.08586 1.28 (0.97–1.68) 0.8662 1.01 (0.87–1.18) 0.1011 1.26 (0.95–1.67)
APC rs2229992 0.6564 1.06 (0.81–1.39) 0.2732 0.92 (0.80–1.07) 0.3214 1.15 (0.87–1.51)
APC rs351771 0.3266 1.15 (0.87–1.50) 0.8956 1.01 (0.87–1.17) 0.3659 1.14 (0.86–1.49)
APC rs41115 0.4254 1.12 (0.85–1.47) 0.9802 1.00 (0.86–1.15) 0.4306 1.12 (0.85–1.47)
APC rs42427 0.3978 1.13 (0.86–1.48) 0.9322 0.99 (0.86–1.15) 0.3825 1.13 (0.86–1.49)
APC rs459552 0.05147 1.35 (1.00–1.83) 0.4821 1.06 (0.90–1.26) 0.1313 1.27 (0.93–1.72)
APC rs465899 0.3161 1.15 (0.88–1.51) 0.8003 1.02 (0.88–1.18) 0.3885 1.13 (0.86–1.49)
APC rs866006 0.3634 1.14 (0.86–1.49) 0.8589 0.99 (0.85–1.14) 0.3256 1.15 (0.87–1.52)
AXIN1 rs1805105 0.0674 0.77 (0.58–1.02) 0.5492 0.96 (0.83–1.10) 0.1524 0.81 (0.61–1.08)
AXIN1 rs214250 0.5041 1.12 (0.81–1.55) 0.2312 1.11 (0.93–1.32) 0.9975 1.00 (0.72–1.39)
AXIN1 rs214252 0.4511 1.13 (0.82–1.57) 0.1736 1.13 (0.95–1.34) 0.9984 1.00 (0.72–1.39)
AXIN1 rs400037 0.1971 1.25 (0.89–1.74) 0.6545 0.96 (0.80–1.15) 0.1447 1.29 (0.92–1.81)
AXIN2 rs2240308 0.7901 1.04 (0.78–1.36) 0.0733 1.14 (0.99–1.31) 0.5069 0.91 (0.69–1.20)
BMP4 rs17563 0.1037 1.25(0.95–1.64) 0.9434 1.01 (0.87–1.16) 0.1119 1.25 (0.95–1.64)
BMP4 rs4444235 0.2311 0.85 (0.65–1.11) 0.6689 1.03 (0.90–1.19) 0.1486 0.82 (0.62–1.08)
BTRC rs17767748 0.7285 1.10 (0.63–1.93) 0.813 0.96 (0.71–1.31) 0.6361 1.15 (0.65–2.03)
BTRC rs4151060 0.1176 1.52 (0.90–2.57) 0.4741 0.89 (0.64–1.24) 0.04729 1.72 (1.00–2.96)
CCND1 rs603965 0.335 0.87 (0.66–1.15) 0.2045 1.10 (0.95–1.26) 0.1203 0.80 (0.61–1.06)
CDH1 rs1801552 0.6563 1.07 (0.80–1.41) 0.08919 0.88 (0.76–1.02) 0.1812 1.21 (0.91–1.61)
CDH1 rs9929218 0.8686 0.98 (0.73–1.31) 0.6861 0.97 (0.83–1.13) 0.926 1.01 (0.75–1.37)
CDH3 rs1126933 0.1283 1.23 (0.94–1.62) 0.7438 0.98 (0.84–1.13) 0.09059 1.27 (0.96–1.67
CDH3 rs17715450 0.2767 0.86 (0.65–1.13) 0.4126 0.94 (0.82–1.09) 0.5064 0.91 (0.68–1.21)
CDH3 rs2274239 0.1972 0.83 (0.63–1.10) 0.4589 0.95 (0.82–1.10) 0.3649 0.88 (0.66–1.17)
CDH3 rs2296408 0.4447 0.90 (0.68–1.19) 0.9386 1.01 (0.87–1.16) 0.4216 0.89 (0.67–1.18)
CDH3 rs2296409 0.1256 0.80 (0.60–1.07) 0.9158 1.01 (0.87–1.17) 0.1138 0.79 (0.59–1.06)
CDH3 rs8049247 0.9636 1.01 (0.71–1.44) 0.867 0.98 (0.82–1.19) 0.9021 1.02 (0.71–1.47)
DACT1 rs17832998 0.9185 0.99 (0.74–1.31) 0.8619 1.01 (0.88–1.17) 0.8392 0.97 (0.73–1.29)
DACT1 rs863091 0.5683 0.90 (0.64–1.28) 0.7737 1.03 (0.86–1.22) 0.4595 0.88 (0.62–1.24)
Gene SNP ID p-value OR (CI 95%) p-value OR (CI 95%) p-value OR (CI 95%)
HDAC9 rs1178127 0.8693 1.03 (0.74–1.42) 0.3847 0.93 (0.78–1.10) 0.5511 1.11 (0.80–1.54)
HDAC9 rs34096894 0.8555 0.89 (0.27–2.99) 0.1093 1.55 (0.90–2.67) 0.3638 0.58 (0.18–1.91)
NLK rs3182380 0.4747 0.79 (0.42–1.50) 0.7387 0.95 (0.69–1.30) 0.5917 0.84 (0.44–1.60
PPARD rs2076167 0.1051 0.77 (0.57–1.06) 0.5291 1.05 (0.90–1.23) 0.06342 0.74 (0.55–1.02)
SMURF1 rs219797 0.9123 0.99 (0.75–1.29) 0.09224 0.89 (0.77–1.02) 0.4764 1.10 (0.84–1.45)
TCF7 rs30489 0.1722 1.36 (0.87–2.11) 0.4351 0.90 (0.69–1.17) 0.07095 1.51 (0.96–2.38)
TLE rs2228173 0.4715 1.16 (0.78–1.71) 0.8995 0.99 (0.79–1.23) 0.4626 1.16 (0.78–1.73)
WIF1 rs7301320 0.2681 1.20 (0.87–1.64) 0.8226 0.98 (0.83–1.16) 0.2418 1.21 (0.88–1.67)
WNT2B rs910697 0.4228 0.90 (0.68–1.17) 0.7713 0.98 (0.85–1.13) 0.5418 0.92 (0.70–1.21)
MAF. Minor Allele Frequency; OR 95% CI. Odds Ratio and 95% Confidence Interval.
doi:10.1371/journal.pone.0012673.t002
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Table 3. Description of all genes selected from both pathways and SNPs screened within each of them.
Gene Name Function
pathway/genes modulated
by BMP signalling SNPs selected
ADAR, Adenosine deaminase,
RNA- specific
Converts multiple adenosines to inosines
and creates I/U mismatched base pairs in
double-helical RNA
Wnt signalling36 rs2229857
APC, Adenomatous Polyposis Coli B-catenin degradation Wnt signalling36 rs2229992,rs351771,rs4115,
rs42427rs459552,rs465899,rs86006




B-catenin ubiquitination Wnt signalling36 rs17767748,rs415060
CCND1, Cyclin D1 Cell cycle control Wnt signalling36 rs603965
CSNK1A1, Casein kinase 1, alpha 1 B-catenin fosforilation Wnt signalling36 NA
CSNK2A1, Casein kinase 2, alpha 1 B-catenin fosforilation Wnt signalling36 NA





Cell adhesion and signal transduction Wnt signalling36 NA
EIF4E, Eukaryotic translation initiation
factor 4E
Translation initiation factor Wnt signalling36 NA
ELAC1, ElaC homolog 1 (E. coli) Zinc phosphodiesterase Wnt signalling36 NA
FRAT1, Frequently rearranged in advanced
T-cell lymphomas
B-catenin stabilization Wnt signalling36 NA
FZD1, Frizzled homolog 1 (Drosophila) Receptor for Wnt proteins Wnt signalling36 NA
GSK3B, Glycogen synthase kinase 3
beta
B-catenin fosforilation Wnt signalling36 rs34002644
HDAC9, Histone deacetylase 9 Transcriptional regulation, cell cycle Wnt signalling36 rs1178127,rs34096894





MAP3K7, Mitogen-activated protein kinase
kinase kinase 7
Signaling transduction induced by BMP Wnt signalling36 NA
MYC, v-myc myelocytomatosis viral
oncogene homolog (avian)
Regulation of gene transcription Wnt signalling36 NA
NLK, Nemo-like kinase Negatively regulation wnt pathway Wnt signalling36 rs3182380
PPARD, Peroxisome proliferator-
activated receptor delta
Ligand-activated transcription factor. Wnt signalling36 rs2076167
PPP2R4, Protein phosphatase 2A activator,
regulatory subunit 4
Folding of proteins Wnt signalling36 NA
TLE1, Transducin-like enhancer of
split 1 (E(sp1) homolog, Drosophila)
Transcriptional corepressor Wnt signalling36 rs2228173,rs8782
WIF1, Wnt inhibitory factor 1 Inhibition of the WNT activities Wnt signalling36 rs1026024,rs7301320
WNT1, Wingless-type MMTV integration
site family, member 1
Ligand for members of the frizzled family Wnt signalling36 NA
BMP4, Bone morphogenetic protein 4 Induces cartilage and bone formation. BMP signalling17 rs17563
BMPR1B, Bone morphogenetic protein
receptor, type IB
Transmembrane serine/threonine BMP signalling17 NA
SMAD1, SMAD family member 1 Signal transduction BMP signalling17 NA
SMAD4, SMAD family member 4 Signal transduction BMP signalling17 rs75667697
SMAD5, SMAD family member 5 Signal transduction BMP signalling17 NA
SMURF1, SMAD specific E3 ubiquitin
protein ligase 1
Ubiquitination and degradation of SMAD
proteins
BMP signalling17 rs219797
AXIN2, Axin 2 B-catenin regulation Wnt signalling, BMP induced
genes34
rs2240308
CDH1, Cadherin 1, type 1, E-cadherin B-catenin regulation Wnt signalling, BMP induced
genes34
rs1801552
CDH3, Cadherin 3, type 1, P-cadherin
(placental)




DAB2, Disabled homolog 2,
mitogen-responsive phosphoprotein
B-catenin regulation Wnt signalling, BMP induced
genes34
NA
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Technologie AG, Baesweiler, Germany) in accordance with the
manufacturer’s instructions, at the Galician Public Fundation of
Genomic Medicine in Santiago de Compostela. Cases and
controls were extracted in mixed batches to avoid any kind of
bias.
Candidate-gene selection
Both Wnt and BMP pathways were initially selected after the
findings of Nishanian et al. [34], who demonstrated the interaction
between these two pathways. Both pathways were thoroughly
investigated through the Cancer Genome Anatomy Project site
[35], but we failed to find any information regarding the BMP
pathway in either this or other web browsers. For that reason, Wnt
genes were selected by browsing the pathway through Biocarta
[36], whereas BMP genes had to be strictly selected from previous
literature [17,34]. Forty-one genes were finally selected to be
included in the analysis.
SNP selection and genotyping
SNP selection criteria only considered functional markers
with minor allele frequencies above 0.05 and at least two
independent validation criteria as established in dbSNP [37].
This included all exonic variants selected with Pupasuite [38]
and gene-regulatory regions in cis (59or 39 UTR ends), as
defined by the FESD web browser [39]. 59UTR variants were
only included when they complied to the abovementioned
criteria and were presumed to be in the potential binding site of
a known transctiptional binding factor. 39 UTR variants were
included because of their potential relationship with miRNA
binding regions [40]. Because some of the selected genes had no
SNPs of such these kinds in any of the three browsers at the time
of SNP selection, they ultimately had to be dropped out of the
study. Finally, 43 SNPs were chosen within 21 genes to be
screened as potential direct modifiers of CRC susceptibility
(Table 3).
rs4444235 and rs9929218 are two variants lying in the near-by
and intronic regions of BMP4 and CDH1, respectively, that have
been recently reported to be associated with the disease [8].
Considering that the SNPs that we had chosen within these two
genes were not good taggers for these two variants (r-squared
values were 0.6 for the SNPs in BMP4, and 0.02 for those in
CHD1) (Figure 1), we decided to include them in our study as well,
although they did not fulfill our selection criteria, making the total
number of interrogated SNPs rise to 45.
Genotyping was performed with the MassARRAY (Sequenom
Inc., San Diego, USA) technology at the Santiago de Compostela
node of the Spanish Genotyping Center. Calling of genotypes was
done with Sequenom Typer v4.0 software using all the data from
the study simultaneously.
Statistical analyses
Quality control was performed, first by excluding both SNPs
and samples with genotype success rates below 95%, with the
help of the Genotyping Data Filter (GDF) [41]. Genotypic
distributions for all SNPs in controls were consistent with Hardy-
Weinberg equilibrium as assessed using a X2 test (1df). All p-
values obtained were $0.05, thereby excluding the possibility of
genotyping artifacts (data not shown). Population stratification
was assessed with Structure v2.2 [42]. Briefly, the posibility of
different scenarios was tested assuming a different number of
underlying populations (k ranging from 1 to 4), allowing for a
large number of iterations (25 K in the burn-in period followed
by 500 K repetitions). The mean log likelihood was estimated for
the data for a given k (referred to as L(K)) in each run. We as well
performed multiple runs for each value of k computing the
overall mean L(K) and its standard deviation. All results seemed
to be concordant with the original assumption of a single existing
population. Moreover, additional procedures for better con-
founding variable visualization were undertaken by means of a
Principal Component Analysis (PCA) using the EIGENSOFT
tool smartpca [43], although number of markers was very low. No
differences were found of population stratification between cases
and controls for either STRUCTURE or the first 10 components
of the PCA analysis (Figure S2). After quality control 1746




by BMP signalling SNPs selected
DACT1, Dapper antagonist of beta-catenin,
homolog 1 (Xenopus laevis)
Disheveled inhibitor Wnt signalling, BMP induced
genes34
rs17832998,rs698025,rs863091
KIFAP3, Kinesin-associated protein 3 Interacts with apc Wnt signalling, BMP induced
genes34
NA
LEF1, Lymphoid enhancer-binding factor 1 Transcriptional activator of Wnt signaling Wnt signalling, BMP induced
genes34
NA
TCF7, Transcription factor 7
(T-cell specific, HMG-box)
transcriptional repressor of CTNNB1 Wnt signalling, BMP induced
genes34
rs30489
WNT2B, Wingless-type MMTV integration
site family, member 2B
Wnt ligand Wnt signalling, BMP induced
genes34
rs910697
WNT5A, Wingless-type MMTV integration
site family, member 5A
Wnt ligand Wnt signalling, BMP induced
genes34
NA
WNT5B, Wingless-type MMTV integration
site family, member 5B
Wnt ligand Wnt signalling, BMP induced
genes34
NA
Genes finally screened are depicted in bold.
NA denotes not available SNPs for a given gene considering our selection criteria. rs4444235 and rs9929218 are not shown, for they were included because of their
previous associations and not because they fulfilled our functional criteria.
doi:10.1371/journal.pone.0012673.t003
Table 3. Cont.
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Association tests were performed by chi-squared tests for every
single SNP and haplotypes where possible with both Haploview
v4.0 [44] and Unphased [45]. In short, LD patterns across genes for
which more than one SNP was genotyped were checked in
Haploview and tested for association using Unphased (to check in
any of the haplotypes was associated) and Haploview (to see which
of the haplotypes was associated). Genotypic association tests,
logistic regression analysis for sex and age adjustment, and stratified
analysis between sporadic and familial groups were estimated with
PLINK v1.03 [46]. OR and 95% confidence intervals were
calculated for each statistic, and to address the issue of multiple-
testing, permutation tests and the Bonferroni correction were used.
Study power was estimated with CATS software [47].
Supporting Information
Figure S1 Haplotype structure and analysis for the 8 genes for
which more than one SNP was genotyped. The table shows
association values for each SNP generated by Haploview.
Found at: doi:10.1371/journal.pone.0012673.s001 (3.40 MB TIF)
Figure S2 Principal component analysis plot for the first vs.
second component, comparing our case and control populations.
Found at: doi:10.1371/journal.pone.0012673.s002 (0.96 MB TIF)
Note S1
Found at: doi:10.1371/journal.pone.0012673.s003 (0.03 MB
DOC)
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Colorectal cancer is a known to be a complex disease, with much of the expected 
inherited risk being due to several common low risk variants. Genome-Wide 
Association Studies (GWAS) have conveniently identified 14 loci harbouring some 
of the susceptibility variants that influence the risk of developing CRC. 
Nevertheless, these have only been able to explain part of the missing heritability, 
with the remaining yet to be discovered. We followed a GWAS approach and 
performed a genome-wide association study in a Spanish cohort of 881 cases and 
667 controls. After association analyses, 64 variants on 24 genomic loci were found 
to be associated with CRC with p-values in the order of 10-5. No evidences of 
association in the nearby regions of any of these variants in the CORGI British 
cohort were found. However, there were evidences for 8 of these loci that minor 
allele frequencies (MAFs) between Northern and Southern-European populations 
may be different. Based on this, we evaluated the association signals of these eight 
loci in a Spanish replication cohort of 1481 cases and 1850 controls. One of these 
SNPs, rs11987193 at 8p12 was positively replicated (pooled p=2.061x10-5). The T 
allele of this SNP shows a protective effect on CRC risk and may be related to 
DUSP4 function. 
 




Even though genetic susceptibility is 
thought to be responsible for almost 35% of 
al CRC cases1, high penetrance mutations 
in Mendelian predisposition genes, such as 
APC, the mismatch repair (MMR) genes, or 
MUTYH have only been able to explain 
<5% of CRC cases2. The recent advances in 
the field of genetic epidemiology have 
validated the hypothesis that at least part of 
that remaining missing susceptibility lies in 
the form of multiple common low-risk 
variants, each conferring a modest effect on 
disease risk.  
GWAS are one of the most widespread 
methodologies for the detection of such 
susceptibility loci. The procedure (in 
opposition to gene-candidate association 
studies) offers an unbiased strategy for the 
detection of new low-penetrance variants, 
for it does not assume any a priori 
hypothesis on the location of these loci. 
This advantage has been proved important, 
since so far this kind of surveys have 
successfully identified variants at 8q24.21 
(rs6983267)3, 8q23.3 (rs16892766), 10p14 
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(rs10795668)4, 11q23 (rs3802842)5, 15q13 
(rs4779584)6, 18q21.1 (rs4939827)7, 
14q22.2 (rs4444235), 16q22.1 
(rs99292218), 19q13.1 (rs10411210), 
20q13.3 (rs961253)8, 1q41 (rs6691170 and 
rs6687758), 3q26.2 (rs10936599), 12q13.1 
(rs11169552 and rs7136702) and 20q13.33 
(rs4925386)9. The combined effect of the 
variants at these 14 loci altogether is 
thought to explain !7% of the familial 
cancer risk9. Still, there is a high proportion 
of the CRC cases for which no genetic 
cause has been identified.  
 
In this study we have attempted a new 
screening for CRC susceptibility variants 
by undertaking a GWAS approach on our 
cohort of 881 CRC cases and 667 controls 
from the Spanish population. The use of a 
Southern-European dataset is also a 
novelty; since all of the populations were 
GWAS analyses have been conducted so 
far have been of Northern-European origin. 
This would provide additional confirmation 
of the relationship of the 14 described loci. 
We must however also consider the 
possibility that there may be differences, at 
these or other particular loci in the genome, 
between these sets of populations, which 
could effectively lead to discrepancies in 
the tagging of the real causative variants 
behind the association signals. 
 
Materials and Methods 
Study populations. Subjects on Phase I were 
881 cases and 473 controls ascertained through 
the EPICOLON II Project and 194 additional 
controls from the Spanish National DNA bank. 
The EPICOLON Consortium comprises a 
prospective, multicentre and population-based 
epidemiology survey of the incidence and 
features of CRC in the Spanish population10,11. 
Cases were selected as patients with de novo 
histologically confirmed diagnosis of colorectal 
adenocarcinoma. Patients with Familial 
Adenomatous Polyposis, Lynch Syndrome or 
Inflammatory Bowel Disease-related CRC, and 
cases where patients or family refused to 
participate in the study were excluded. 
Median age for cases on stage I was 73 (range 
26-95), whereas mean was 71.2 years. Hospital-
based controls were recruited together with 
cases for the EPICOLON initiative. All of these 
were confirmed to have no cancer or prior 
history of neoplasm and no family history of 
CRC. Controls were randomly selected and 
matched with cases for hospital, sex and age (± 
5 years). Controls from the National DNA bank 
were also genotyped, to lessen the deficit in 
controls. They were matched for sex, age (± 10 
years) and geographical origin of the sample 
with the remaining cases. Both cases and 
controls were of European ancestry and from 
Spain (stated, where possible, as all four 
grandparents being Spanish). Gender and 
hospital distribution of samples for case and 
control groups is shown on Supplementary 
Table 1. 
Samples on Phase II consisted of: 1436 CRC 
patients and 1780 controls. Of these, 821 CRC 
patients were recruited in 4 different Spanish 
centers: Hospital Sant Pau, Hospital Gregorio 
Marañón, Catalan Institute of Onconlogy (ICO) 
and the CHUS hospital in Santiago de 
Compostela, 105 CRC cases and 1330 controls 
came from the Spanish National DNA bank, and 
510 CRC cases and 450 DNA controls belonged 
to the EPICOLON I Project. Of these, 60.4% 
were male and 39.6% female; age median was 
69.61 (69.02-70.20) for cases and 52.00 (51.42-
52.58) for controls. 
DNA was obtained from frozen peripheral 
blood by standard extraction procedures for all 
samples. Cases and controls were extracted in 
mixed batches to avoid bias. 
 
Ethics statement. The study was approved by 
the “Comité Ético de Investigación Clínica de 
Galicia”, and each of the institutional review 
boards of the hospitals where samples were 
collected. All samples were obtained with 
written informed consent reviewed by the 
ethical board of the corresponding hospital, in 
accordance with the tenets of the Declaration of 
Helsinki. 
 
SNP genotyping and QC. Affymetrix chip 6.0 
(Ayymetrix. CA USA) was chosen to obtain 
genome-wide coverage for our SNP 
susceptibility scan in phase I genotyping. The 
chip includes probes for almost 1M SNP 
markers. Genotyping in phase 2 was conducted 
by Sequenom MassARRAY technology 
(Sequenom Inc.. San Diego. CA. USA). 
Genotyping for both stages was performed at 
the Santiago de Compostela node of the Spanish 
Genotyping Center. Genotype calling for the 
Affymetrix 6.0 array intensities was performed 
with the Birdseed algorithm, included within 
Birdsuite v1.412. Samples were organised in 23 
batches of 16<n<99 according to hospital of 
origin for computational purposes. We obtained 
valid genotypes for 909.622 SNPs by these 
means. Conversion of genotype data into 
PLINK v1.07 format13 was performed using in-
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house scripts. Quality control of the data 
included the removal of both loci and samples 
with genotyping success rates <99% and 
concordance check of genders between clinical 
recorded data and Affymetrix asigned sex. 
Hardy-Weinberg equilibrium (HWE) was 
evaluated with a 1 degree of freedom (df) "2 
test, or Fisher´s exact when genotype counts<5; 
markers <1x10-4 threshold on the unaffected 
group of samples were removed from further 
analyses. SNPs with MAFs below 0.05 were 
also eliminated due to power-related reasons 
and to avoid unnecessary noise signals. 
Differential missingness between cases and 
controls was also accounted for by excluding 
markers with p-values below 1x10-4. A total of 
674.718 SNPs remained after this filtering.  
To address the possibility of underlying 
population stratification, Principal Component 
Analysis (PCA) on a set of 98,986 independent 
SNPs (maximum pairwise r-squared value of 
0.1) was also performed on the cohort with the 
help of the EIGENSOFT smartpca tool14. Long-
range LD regions, as described by Price et al.15, 
were also removed from this analysis. Results 
for this PCA are depicted on Figure 1A. Outliers 
(taken as samples with >5% distance from the 
cluster centroid), as well as samples spread on 
principal components 1 and 2 (Eigenvector 1 <-
0.01 and Eigenvector 2 >0.05) were removed 
from subsequent analyses, since they deviated 
from the main cloud. No evidences were found 
of population stratification between cases and 
controls for the first 10 components of the PCA 
analysis (Figure 1B). Other potentially 
confounding variables, such as Nsp-vs-Sty-
genotyped markers, hospital of collection, 
genotyping plate, or geographical origin of the 
samples were also checked for as sources for 
stratification (data not shown). All results 
seemed to be concordant with the original 
assumption of a single existing population 
except for hospital of origin. When considered 
as a confounding variable, the EPICOLON 
cohort clustered into three separate subgroups: 
samples from the Donostia hospital (VAS 
dataset), the only collection centre for the 
Basque Country regions (North of Spain), 
samples from the Meixoeiro hospital (GAL 
dataset), the single collection point in Galicia 
(NW Spain), and all others (REST dataset) 
(Figure 1C). An additional PCA with the 
EPICOLON II cohort and the HapMap3 
populations was also performed to illustrate the 
clustering of the EPICOLON II cohort with the 
HapMap3 populations16 (Figure 1D). The 
plotting was then restricted to those with 
Caucasian origin (CEU and TSI) or those with a 
potential Spanish contribution (MEX) (Figure 
1E). Samples that clustered away from the 
European end of the plot (showing evidences of 
non-European ancestry) were also excluded 
from further analyses. 
The final dataset was comprised of 1477 
samples (848 cases and 629 controls). The total 
count per subgroup was 167 for VAS, 366 for 
GAL and 944 for REST. 
A second stage of quality control was 
undertaken after the association analyses by 
means of the Evoker software17. Associated 
SNPs at a selected threshold were plotted to 
compare the efficiency of the calling procedure 
by comparing the intensity clusters derived from 
the genotyping array against the genotype 
clusters assigned by the calling algorithm. 
 
Statistical analysis. Association analysis was 
assessed as a 1 df "2 allelic test for each of the 
three subgroups independently for phase one, 
and for second stage replication, with the help 
of PLINK13. The adequacy of the distribution of 
p-values was evaluated using quantile-quantile 
(Q-Q) plots of test statistics and lambda 
genomic inflation factors. Meta-analysis was 
conducted using the R package META18 and 
PLINK. Both methods are based on a Mantel-
Haenszel approach for data pooling. Cochran´s 
Q statistic19 and the I2 heterogeneity index20 
were also estimated to account for inter-
population heterogeneity. Risks associated with 
each marker were estimated by odds ratios (OR) 
and their 95% confidence intervals (CIs), 
assuming both fixed and random-effect models. 
Imputation of the linkage disequilibrium (LD) 
blocks around each of the 24 loci that showed 
evidences of association was accomplished with 
Impute v221 using two reference panels: 1000 
Genomes Project (b36) for wide coverage22, and 
HapMap3 (r2 b36) for deep coverage16. 
Imputation results were filtered by minor allele 
frequency (MAF) of the markers, since the 
procedure generates genotypes for a high 
number of rare variants that could give spurious 
association results (thus SNPs with MAFs<5% 
were excluded), missing data proportion (set to 
a 5% max), and the frequentist-add-proper-info 
column of the output. This latter proportion is 
indeed the ratio of the empirically observed 
variance of the allele dosage to the expected 
binomial variance p(1-p) at HWE, where p is 
the observed allele frequency from HapMap23. 
Optimal values should be within the (0.4-1) 
range and provide a measure for quality and 
accuracy of the imputation. Since the proportion 
of cases and controls deviates significantly from 
the standard 1:1, we also considered the 
possibility that the genotype probabilities for 







Figure 1. PCA analysis on the EPICOLON cohort. A. Raw data; B: filtered data by case/control; C: 
filtered data by hospital of origin; D: EPICOLON and HapMap3 populations; E: EPICOLON. CEU. TSI 
and MEX. Significant differences may be seen in section C. with Meixoeiro and Donosti hospitals 
















Figure 2: PCA analysis on the WTCCC (Affymetrix 6.0 data), HapMap3 CEU and TSI and 
EPICOLON populations. A set of 15,000 independent markers was used to perform the analysis. The 
first eigenvector seems to separate the Northern and Southern European populations. 
Thus we filtered out SNPs for which the 
probability of two out of the three genotypes 
was #25% in at least 5% of the cases or the 
controls. Pooled analysis was performed by 
logistic regression with stage and subgroup as 
covariates. Additional statistical calculations, 
such as Pearson´s product-moment correlation 
values, were calculated using R. Imputation 




We observed during our quality control 
check-up procedure, that there was an 
important batch effect due to differences by 
hospital of collection of the sample, 
dividing the EPICOLON cohort into three 
separate subgroups. Pondering this, we 
considered it appropriate to proceed on 
forward with the association analyses by 
contemplating each cluster as a separate 
population (the GAL, VAS and REST 
groups), in order to avoid any bias leading 
to an increased false positive association 
rate. 
Association results were thus obtained for 
each of the GAL, VAS and REST 
subpopulations separately. Q-Q plots for 
the subgroups showed some signs of 
inflation in the distribution of the 
association p-values for the GAL and REST 
groups (Supplementary Figures 1A and 1B. 
respectively). The VAS group however, 
showed better fitting but no deviations 
indicative of association hits, probably due 
to its smaller sample size (Supplementary 
Figure 1C). Lambda genomic factor 
calculations (1.04192, 1.02323 and 1.02292 
for the GAL, VAS and REST populations, 
respectively) were however consistent with 
no evidences of an increased false 
discovery rate. 
 
Meta-analysis from the association results 
in the three separate populations was 
carried out with the R META package as 
well as PLINK. Q-Q plot distribution of 
these results is depicted on Supplementary 
Figure 1D. Ninety-seven percent of the 
SNPs showed consistency in p-value 
calculations (differences <0.1 between both 
approaches); 0.43% showed differences 
between 0.1-0.15, and 2.11% of the 
markers showed a discrepancy of 0.15 or 
greater in the p-values obtained by either 
method (Supplementary Figure 2). 
Sensitivies for both methods were similar 
with only a 13% increased loci detection for 
META at a p-value threshold of 1x10-4. 
However, Heterogeneity between the GAL, 
VAS and REST groups was defined as 
I2>75%. For markers above this threshold, a 
random-effects model was considered, 



























With these criteria, we found 93 SNPs 
associated at a level of 1x10-4 or below. 
Evoker intensity plots were created to allow 
for a visualisation of the intensity clusters 
in comparison with the genotypes assigned 
by the calling algorithm in order to detect 
potential calling artefacts (Supplementary 
Figure 3). Sixty-four final SNPs located on 
24 different genomic loci remained after 
this checking. 
 
The locations of these 64 SNPs were fine-
mapped by imputing the LD blocks around 
these regions, in order to refine the 
association signals. Table 1 provides with a 
summary of the loci and extent of the 
imputed regions. We approached this 
analysis in two different ways: a) 
imputation of the LD blocks in all samples 
altogether, then splitting of the dataset into 
the three subgroups, performance of the 
association analyses and meta-analysis of 
these; b) imputation of each chromosomal 
region separately in every subgroup, 
running of the association tests and meta-
analysis. Results for both were however 
similar, as ascertained by correlation 
analysis of the p-values at every segment 
(correlation coefficients 0.876-0.998). An 
example of the correlation plots for one of 
the regions may found on Supplementary 
Figure 4. This analysis improved the 
association at loci 1p33 (best SNP 
rs12060081), 14q31.3 (rs2057115), 15q21.3 
(rs7176932) and 22q12.3 (rs17725348) 
(Supplementary Figure 5). 
Evidences of association (taken as the 
presence of markers with p-values below 
1x10-4) were screened for in the ±1Mb 
region surrounding every SNP in the 
CORGI GWAS3. Only 5 of these locations 
showed to have some CORGI associated 
SNP at the established threshold, but r-
squared pairwise measures of LD evidenced 
them all to be independent signals (r2<0.8 
for all-data not shown). 
 
MAFs in controls for all 64 associated 
SNPs were then checked in the HapMap3 
CEU and TSI populations, as well as the 
Wellcome Trust Case Control Consortium 
(WTCCC2) control cohorts25. Ten SNPs in 
8 loci showed significant and consistent 
deviations in TSI and EPICOLON MAFs 
compared to the Northern-European  
Table 1: Associated loci and imputation 
regions. Location of the 24 associated loci and 
description of the regions that were imputed for 
finer mapping. 
 
CHR LOCUS IMPUTATION REGION 
1 1p33 47,985,000-48,255,000 
2 2p25.2 5,518,000-5,623,000 
2 2p24.1 22,284,000-22,608,000 
3 3p21.31 46,887,500-47,562,000 
3 3q12-q13 120,991,750-121,488,000 
5 5q35.1 172,706,000-172,719,000 
6 6q16.1 99,253,000-99,325,000 
6 6q23.1-q23.2 131,177,000-131,499,500 
8 8p12 29,383,500-29,403,500 
8 8q13.3 72,696,800-72,704,400 
8 8q22.1 96,663,000-96,777,000 
10 10p15.1 5,619,000-5,736,000 
10 10q23.31 92,677,000-92,789,200 
12 12q24.31 119,533,000-119,597,000 
13 13q32.3 99,584,500-99,846,500 
14 14q31.3 85,090,000-85,120,800 
14 14q32.12 92,202,500-92,271,850 
15 15q21.3 52,143,300-52,192,400 
15 15q25.3 86,171,000-86,253,700 
17 17p13.2 13,145,300-13,256,000 
17 17p12 5,201,500-5,322,700 
18 18p11.22 8,552,000-8,595,800 
18 18q21.2 50,980,500-51,327,000 
22 22q12.3 34,479,200-34,790,200 
 
populations (CEU and WTCCC2) (Table 
2). PCA analysis on the four populations 
and 15,000 independent SNPs effectively  
separated the Northern and Southern-
European populations (Figure 2). Given this 
evidence, we decided to replicate the best-
associated markers at these loci (taken as 
either directly genotyped or imputed best 
score SNP) in an independent  
Spanish cohort. rs7087402 at 10q23.31 
could not be included for genotyping design 
reasons.  
 
One of these SNPs, rs11987193 was 
successfully replicated in the second stage 
(p=0.039, OR=0.847 (0.725-0.991); Table 
3). Although the association signal was 
modest, pooled analysis of the data from 
both stages was consistent with the 
presence of a CRC susceptibility variant in 
this location (p=2.061x10-5; OR=0.788 
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Table 2. MAF comparison for the associated SNPs. Frequencies for all 64 SNPs at 24 associated loci 
for the EPICOLON, WTCCC2 control cohorts, CEU and TSI HapMap3 populations. Loci with consistent 
deviations in frequencies between Northern and Southern European populations are highlighted in bold. 
 







1p33 rs12080929 48,208,735 0.265 0.248 0.312 0.324 
2p25.2 rs4669394 5,541,078 0.084 0.073 0.08 0.103 
2p24.1 rs1554266 22,284,300 0.425 0.454 0.373 0.426 
2p24.1 rs1554267 22,284,451 0.42 0.454 0.371 0.415 
2p24.1 rs1554269 22,284,627 0.42 0.454 0.372 0.421 
2p24.1 rs4557006 22,297,345 0.425 0.455 0.373 0.436 
2p24.1 rs6759922 22,303,754 0.42 0.450 0.370 0.436 
2p24.1 rs4416248 22,309,026 0.42 0.451 0.370 0.436 
3p21.31 rs10461018 46,970,246 0.469 0.419 0.454 0.426 
3p21.31 rs2061197 46,976,354 0.465 0.419 0.454 0.426 
3p21.31 rs749511 47,010,739 0.447 0.407 0.436 0.422 
3p21.31 rs2305634 47,018,542 0.46 0.422 0.472 0.429 
3p21.31 rs2278963 47,029,873 0.447 0.406 0.436 0.422 
3p21.31 rs7610636 47,039,440 0.465 0.425 0.468 0.441 
3p21.31 rs11917361 47,045,501 0.447 0.405 0.435 0.422 
3p21.31 rs6442055 47,085,726 0.447 0.406 0.436 0.422 
3p21.31 rs6767907 47,137,665 0.447 0.406 0.436 0.422 
3p21.31 rs9837343 47,152,392 0.447 0.406 0.435 0.422 
3p21.31 rs295442 47,310,885 0.434 0.403 0.457 0.436 
3p21.31 rs17410853 47,338,975 0.398 0.364 0.401 0.377 
3p21.31 rs8180040 47,363,951 0.434 0.402 0.454 0.431 
3p21.31 rs4858888 47,380,309 0.434 0.403 0.454 0.431 
3p21.31 rs2062278 47,391,765 0.429 0.396 0.455 0.431 
3p21.31 rs12636851 47,438,571 0.429 0.395 0.446 0.426 
3p21.31 rs6800271 47,445,791 0.429 0.3970 0.451 0.431 
3p21.31 rs3816779 47,518,393 0.429 0.399 0.453 0.436 
3p21.31 rs7628631 47,535,867 0.429 0.396 0.445 0.436 
3p21.31 rs11130137 47,553,842 0.429 0.398 0.449 0.436 
3q12-q13 rs2472680 121,010,466 0.031 0.049 0.072 0.034 
3q12-q13 rs6438550 121,019,507 0.031 0.050 0.072 0.025 
5q35.1 rs11745626 172,706,309 0.181 0.156 0.186 0.113 
5q35.1 rs11740081 172,707,280 0.183 0.157 0.188 0.113 
5q35.1 rs17733311 172,712,710 0.181 0.163 0.193 0.108 
6q16.1 rs12213685 99,288,865 0.146 NA 0.107 NA 
6q16.1 rs4262197 99,299,694 0.128 0.149 0.105 0.127 
6q16.1 rs6941632 99,302,147 0.155 0.172 0.119 0.152 
6q16.1 rs6936798 99,305,520 0.155 0.172 0.119 0.152 
6q16.1 rs7750336 99,322,459 0.155 0.172 0.121 0.152 
6q16.1 rs9398904 99,323,739 0.119 0.145 0.103 0.118 
6q16.1 rs7740725 99,324,762 0.119 0.144 0.104 0.118 
6q23.1-q23.2 rs12199765 131,192,418 0.288 0.257 0.202 0.275 
8p12 rs11996339 29,386,099 0.385 0.385 0.448 0.515 
8p12 rs11987193 29,391,927 0.283 0.267 0.309 0.309 
8p12 rs12548021 29,400,381 0.35 0.392 0.289 0.328 
8q13.3 rs17788534 72,697,475 0.115 0.139 0.141 NA 
8q22.1 rs3104964 96,664,912 0.415 0.400 0.367 0.497 
* Only control samples from our EPICOLON population were considered for MAF calculations. 
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Table 2. (Continuation). 
 







10p15.1 rs7074607 5,623,371 0.155 0.147 0.102 0.132 
10q23.31 rs7087402 92,760,125 0.492 0.495 0.444 NA 
12q24.31 rs568489 119,578,624 0.434 0.393 0.397 0.48 
12q24.31 rs2686555 119,579,555 0.434 0.392 0.404 0.48 
13q32.3 rs17196583 99,624,356 0.17 0.176 0.145 0.206 
14q31.3 rs7148493 85,094,169 0.378 0.380 0.363 0.391 
14q32.12 rs8177528 92,247,404 0.364 0.362 0.335 0.343 
15q21.3 rs1897019 52,163,314 0.362 0.397 0.313 0.422 
15q21.3 rs4644815 52,163,793 0.362 0.397 0.313 0.422 
15q21.3 rs4644804 52,164,106 0.369 0.398 0.316 0.422 
15q21.3 rs12913167 63,265,330 0.365 0.397 0.315 0.426 
15q25.3 rs16941001 86,249,170 0.067 0.081 0.059 0.074 
17p13.2 rs12603094 5,288,680 0.137 0.139 0.103 0.172 
17p13.2 rs16954697 5,297,637 0.124 0.132 0.098 0.191 
17p12 rs9898623 13,255,126 0.08 0.076 0.085 0.074 
18p11.22 rs10502376 8,579,765 0.388 0.478 0.496 NA 
18q21.2 rs2958182 51,300,019 0.319 0.337 0.261 0.284 
22q12.3 rs956119 34,582,213 0.062 0.073 0.104 0.083 
* Only control samples from our EPICOLON population were considered for MAF calculations. 
 
 
Table 3. Association results for stage II. P-values and ORs for the replication stages. 
 
LOCUS SNP P-VALUE PHASE I P-VALUE PHASE II OR PHASE II 
1p33 rs12080061*  1.620E-05  0.083 0.869 (0.7414-1.019) 
8p12 rs11996339 9.697E-08 0.690 0.971 (0.842-1.12) 
8p12 rs11987193  9.750E-06  0.039 0.847 (0.724-0.992) 
8p12 rs12548021 1.071E-06 0.234  1.095 (0.9431-1.271) 
10p15.1 rs7074607 8.751E-05  0.174 0.867 (0.705-1.065) 
10q23.31 rs7087402 5.180E-06 NA NA 
14q32.12 rs8177528  5.471E-05  0.423  1.056 (0.910-1.225) 
18p11.22 rs10502376 9.819E-05 0.986 0.973 (0.842-1.125) 
18q21.2 rs2958182  5,657E-05  0.714  1.001 (0.861-1.164) 
22q12.3 rs17725348* 4.011E-05 0.273 0.875 (0.690-1.110) 
* Denotes imputed SNPs; NA: not available 
 
 
Table 4. Replication results for the already-described loci. Half of the loci showed direct evidences of 
association 
LOCUS REPORTED SNP ASSOCIATED SNP IN EPICOLON R
2 P-VALUE OR (95% CI) 
8q24 rs6983267 rs6983267 - 0.065 0.871 (0.751-1.009) 
10p14 rs10795668 rs10905436 0.929 0.066 0.623 (0.737-1.010) 
11q23 rs3802842 rs3802840 1 0.037 1.190 (1.010-1.402) 
12q13 rs11169552 rs11169567 0.166 9.502E-04 1.282 (1.106-1.486) 
15q13 rs4779584 rs4779584 - 8.772E-04 1.389-1.144-1.686) 





(0.706-0.879)). The other two SNPs at this 
locus, rs11996339 and rs12548021 did not 
appear as significant in this second stage, 
although this was pretty much expected, 
since the signals were independent. 
Aside from the search of new susceptibility 
variants, we also investigated the association 
signals for the 14 known CRC susceptibility loci. 
Direct evidence of replication (taken as the 
presence of an associated SNP with p-value <0.1 
near the described location) was found for 6 of 
the sites (see Table 4). Imputation of the LD 
regions around these associated loci was 
conducted to search for an enhancing of the 
signals. No significant improvements were 
found, except for locus 15q13 (data not shown). 
Association results and MAF measures for all 16 
SNPs at the 14 loci (considered as the result 
obtained for the best matching proxy) are 
visualised on Table 5 and compared to the 
described literature. 
Discussion 
Genome-wide association studies have so far 
successfully identified 14 susceptibility-to-
colorectal-cancer loci8,9. Although this has been a 
significant improvement in the unravelling of the 
genetic basis of the disease, these variants alone 
do not completely explain all the inherited 
variation that has been attributed to CRC. 
 
Following the lead of the previous studies, 
we addressed the issue of trying to detect 
new colorectal cancer susceptibility 
variants through the performance of a 
GWAS in a Spanish cohort. This was the 
first attempt to perform a CRC GWAS in a 
Southern European population. By these 
means, we were able to positively identify a 
new susceptibility variant, rs11987193, at 
8p12. 
 
During the analysis, we were faced with the 
fact that, although there were no differences 
in case and control populations, there was a 
significant stratification issue determined 
by the hospital of origin of the samples. 
Because of this, the analyses had to be 
modified to match our case scenario 
without losing significant power. The 
subdivision of the population had also great 
implications on the imputation procedure, 
although in this case both of the approaches 
taken seemed to give concordant results (as 
seen from the correlation analysis of the p 
values). This is most likely a result from the 
three subgroups having different sizes, with 
the largest being the determinant in the 
outcome of the analysis. 
 
Nevertheless, the substructure in our cohort 
did not seem to greatly affect outcome 
quality. The evaluation on the already-
described signals achieved direct 
replication for 6 of the loci (8q24, 10p14, 
11q23, 12q13, 15q13 and 18q21), although 
the best-associated markers for these 
regions did not always match with the best 
proxy for the already described SNPs. This 
would make sense if we consider that any 
given GWAS relies on an indirect 
approach, and we would expect the 
associated SNPs to only be taggers of the 
real causative variant. Results for allele 
frequencies and ORs seem consistent with 
the bibliography8,9. 
 
In a similar way, we carried out additional 
quality control procedures during our study. 
We tested the performance of two different 
software at the meta-analysis step: the R 
package META and PLINK´s own 
implementation. The former showed higher 
sensitivity rates but the computational 
intensity of the method does not favour its 
use in meta-analysis studies. Evoker plots 
were also examined, and a considerable 
proportion of the association signals (31%) 
was by these means identified as artefacts 
generated during the batch calling 
procedure. This was particularly true for 
SNPs with lower allele frequencies, for the 
proportion of homozygous individuals for 
the minor allele would be low enough in 
batches with lower sample sizes for these 
individuals to be wrongly called as 
heterozygous. Hence, we encourage for this 
additional controls to be performed in order 
to reduce false positive findings. 
 
The association analysis in itself provided 
with positive results in 64 SNPs on 24 
different genomic loci at a p-value <0.0001. 
A first attempt at replication was aimed by 
inspection of these association signals on 
the CORGI cohort3. However, none of the 
signals seemed to be shared between 
datasets. This lack of replication could be  
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Table 5. Data for the 14 reported loci. Comparison between bibliography data and EPICOLON 
association results for the 16 SNPs at the 14 susceptibility loci. 
 

















rs66877589 1q41 G 0.2 1.09 (1.06-1.12) rs6691195 1 T 0.19 
1.104  
(0.919-1.325) 0.291 
rs66911709 1q41 T 0.34 1.06 (1.03-1.09) rs11579490 0.902 T 0.37 
1.003  
(0.862-1.166) 0.974 
rs109365999 3q26 T 0.24 0.93 (0.91-0.96) rs7621631 1 A 0.21 
0.997  
(0.8334-1.191) 0.97 
rs168927668 8q23 C 0.07 1.32 (1.21-1.44) rs2437844 0.925 A 0.08 
1.128  
(0.8711-1.461) 0.36 
rs69832678 8q24 T 0.48 0.83 (0.79-0.87) rs6983267 - T 0.45 
0.871  
(0.751-1.009) 0.065 
rs107956688 10p14 A 0.33 0.91 (0.86-0.96) rs706771 0.965 A 0.33 
0.891  
(0.762-1.043) 0.15 
rs38028428 11q23 C 0.29 1.21 (1.15-1.27) rs3802840 1 T 0.26 
1.190  
(1.010-1.402) 0.037 
rs111695529 12q13 T 0.26 0.92 (0.90-0.95) rs11169544 1 C 0.23 
0.988  
(0.831-1.175) 0.891 
rs71367029 12q13 T 0.35 1.06 (1.03-1.09) rs7136702 - A 0.37 
1.143  
(0.984-1.328) 0.0806 
rs44442358 14q22 C 0.46 1.12 (1.07-1.18) rs11623717 0.902 G 0.45 
1.013  
(0.875-1.173) 0.859 
rs47795848 15q13 T 0.19 1.19 (1.12-1.26) rs4779584 - T 0.15 
1.389  
(1.144-1.686) 8.722E-04 
rs99292188 16q22 A 0.29 0.88 (0.83-0.92) rs9925923 1 T 0.29 
0.940  
(0.800-1.104) 0.451 
rs49398278 18q21 C 0.47 0.85 (0.81-0.89) rs7226855 1 G 0.45 
0.820  
(0.707-0.950) 8.204E-03 
rs104112108 19q13 T 0.10 0.79 (0.72-0.86) rs7252505 0.831 A 0.13 
0.902  
(0.722-1.127) 0.363 
rs9612538 20p12 A 0.36 1.13 (1.08-1.19) rs5005940 1 T 0.34 
0.1078  
(0.923-1.255) 0.349 
rs49253869 20q13 T 0.32 0.93 (0.91-0.95) rs4925386 - T 0.31 
0.960  
(0.820-1.124) 0.61 
REF: reference article from which association data was taken to perform the comparison; REP: reported; CTRLS: controls; AFFY: 
Affymetrix 
 
due to both false positive findings and 
artefacts from the calling algorithm26, or to 
real differences between both populations 
leading to dissimilar abilities to tag the real 
causative variant. A PCA analysis on the 
EPICOLON samples compared to the 
WTCCC control cohorts and the data from 
the HapMap3 CEU and TSI populations 
showed clear differentiation between the 
Northern and Southern European 
populations. Although not significant, SNP 
loadings also evidenced principal 
component 3 to be exclusively driven by a 
region of chromosome 8 (7.2-12Mb) where 
a common inversion is known to occur27,28, 
whereas Eigenvectors 4-7 were driven by 
HLA-A locus in the 6q21.2-21.3 region of 
chromosome 6, which has been also 
described as highly variable between 
populations29. Given this evidence, we 
compared the MAFs in the 64 EPICOLON 
SNPs with those in the WTCCC cohorts 
and HapMap3 populations and detected 
discrepancies in the frequencies of 10 of 
these markers at 8 genomic loci. Therefore, 
we proceeded on to replicate these SNPs in 
an independent Spanish cohort. 
 
One of the SNPs, rs11987193, was 
favourably replicated in both this second 
stage and the pooled analysis. The T allele 
of this marker appears to have a protective 
effect over CRC risk. The rs11987193 SNP 
is located in the 8p12 locus, 128kb 
downstream DUSP4. This gene is a 
member of the dual kinase phosphatase 
family, which are well-known tumour 
supressors30. They act through the 
downregulation of MAP kinases, thus 
preventing cellular proliferation and 
differentiation. Deletions in this gene have 
already been described to happen in other 
types of cancers, such as those of the 
breast31 and lung32. In the case of CRC, 
DUSP4 expression appears to be modulated 
by KRAS mutations33. 
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The fact that this SNP was not replicated 
during the initial assessment of the 
association signals in the CORGI cohort, 
together with the evident MAF 
discrepancies, could be a sign of differences 
in the tagging of the real causative variant 
amongst populations. Even when 
Europeans are presumed to be genetically 
homogeneous, it is not unrealistic to believe 
that punctual LD variations may be actually 
happening within populations, and that 
these may constitute a certain impediment 
in our ability to replicate association 
signals. Further evaluation of this marker in 
other Southern European populations with 
similar MAFs is encouraged before 
analysing the relationship between this 
variant and CRC risk susceptibility in 
Northern cohorts. 
 
Our GWAS study has succeeded in the 
replication of 6 of the 14 already-described 
loci. Given the population-specific 
differences seen so far, we consider this an 
important achievement, since most of these 
association signals had not been previously 
evaluated in Southern European cohorts. 
Outstandingly, we have accomplished the 
identification of a new CRC risk variant at 
8p12, determined by rs11987193. The 
peculiarities of this locus may have 
important repercussions on subsequent 
analysis. For this reason, the eventual 
identification of the real variant is of 
uttermost importance. Finer mapping of the 
locus, coupled with additional replication 
efforts in larger cohorts will be needed to 
fully ascertain the relationship between this 
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Supplementary Table 1: Phase I and Phase II cohorts. Main features and sample distribution of the 
stages. Gender count, hospital of collection and age statistics for cases and controls are shown for each 
phase. 
 




HOSPITAL OF COLLECTION/COHORT 
(number of samples) 
PHASE I: 881 CASES 550/332  71.2 (70.5-71.9)  
Hospital Universitari Trias i Pujol (35) 
Hospital del Mar (123) 
Hospital Clinic (91) 
Hospital General Universitario de alicante (46) 
Hospital Donostia (97) 
Hospital Universitari Arnau de Vilanova (44) 
Hospital Sant Pau (157) 
Hospital do Meixoeiro (214) 
Hospital de Calahorra (15) 
Hospital Royo Villanova (22) 
Hospital Universitario Central de Asturias (37) 
Spanish National DNA bank (0) 
PHASE I: 667 CONTROLS 392/275 65.7 (64.7-66.7) 
Hospital Universitari Trias i Pujol (20) 
Hospital del Mar (73) 
Hospital Clinic (0) 
Hospital General Universitario de alicante (12) 
Hospital Donostia (70) 
Hospital Universitari Arnau de Vilanova (33) 
Hospital Sant Pau (89) 
Hospital do Meixoeiro (175) 
Hospital de Calahorra (1) 
Hospital Royo Villanova (0) 
Hospital Universitario Central de Asturias (0) 
Spanish National DNA bank (194) 
PHASE II: 1436 CASES 875/561  69.6 (69.0-72.2) 
Hospital Gregorio Marañón (104) 
Hospital Sant Pau (125) 
Catalan Institute of Oncology (439) 
Complexo Hospitalario Universitario de Santiago 
(153) 
EPICOLON I (510) 
Spanish National DNA bank (105) 
 PHASE II: 1780 CONTROLS  1068/712  52 (51.4-52.7)  
EPICOLON I (450) 

























Supplementary Figure 2. P-value comparison of R META vs PLINK meta-analyses. Black: 














Supplementary Figure 3. Evoker plots. Left: successful calling; genotype clusters match intensity ones; 










Supplementary Figure 4. Correlation plot for p-values in the two imputation strategies. An example 









































































































































































































































































Supplementary Figure 5. Imputation plots for the 24 loci associated with CRC in EPICOLON. P-
value plots for the imputed markers in the associated regions. Diamonds represent typed SNPs, squares 
depict imputed markers; the biggest diamond is the best-associated SNP in the region, irrespective of 
typed/imputed status; red grading represents LD relationships. X axis: Chromosome location; Y axis: 
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Colorectal cancer (CRC) is a complex disease, and therefore its development is 
determined by the combination of both environmental factors and genetic variants. 
Although genome-wide association studies (GWAS) of SNP variation have conveniently 
identified 14 susceptibility loci, a significant proportion of the observed heritability is yet 
to be explained. Common copy-number variants (CNVs) are one the most important 
genomic sources of variability, and hence a potential source of variation to explain part of 
this missing genetic fraction. We have performed a GWAS on CNVs in 881 cases and 667 
controls from a Spanish cohort, to explore the relationship between common structural 
variation and CRC development. Eleven of the common CNVs analysed in our study 
showed considerable potential to represent susceptibility variants. Nevertheless, we 
recommend additional characterisation of these CNVs by independent methods, as well as 
replication in larger cohorts in order to unequivocally ascertain the relationship between 
these variants and CRC. 
 




Colorectal cancer (CRC) is one of the most 
important forms of malignancy in the 
world, accounting for almost 50,000 deaths 
every year1. According to the Common 
Disease-Common Variant hypothesis, the 
architecture of CRC inherited 
predisposition is thought to be mainly 
explained by a combination of 
moderate/low-penetrance variants that 
interact amongst themselves to determine 
which individuals finally develop the 
disease2. Genome-wide association studies 
(GWAS) on SNPs have succeeded in the 
identification of 14 loci that influence the 
risk of CRC development at 8q24, 18q21.1, 
15q13.3, 11q23.1, 8q23.3, 10p14, 14q22.2, 
16q22.1, 19q13, 20p12.33, 1q41, 3q26.2, 
12q13.13 and 20q13.334. However, these 
altogether can only explain around 7% of 
the excess heritability observed, and hence, 
it is believed that many other variants are 
yet to be discovered that could account for 
the missing heritability proportion. 
Although GWAS have been a decisive tool 
for the discovery of new risk variants for 
common diseases, they have mainly relied 
on the evaluation of genomic variability in 
the form of SNPs. Even when these 
markers are by far the most abundant forms 
of polymorphisms in the genome5, other 
forms of genetic variation such as CNVs, 
also account for a high proportion of human 
polymorphic sequences6. Several studies 
have already highlighted the importance of 
CNVs and their potential implication in the 
genetic susceptibility to common 
diseases7,8. 
It is commonly believed that most high-
frequency CNVs are well tagged by 
common SNPs9,10. Nonetheless, the 
presence of CNVs in a given region often 
triggers experimental difficulties in the 
determination of SNP genotypes. For 
instance, it has been described that 
sequence deletions usually result in 
Mendelian errors, and duplications may 
result in both deviations from Hardy-
Weinberg equilibrium or increases in 
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missing genotype rates11. Hence, such 
locations have purposefully been excluded 
from the design of SNP genotyping arrays, 
resulting in an underrepresentation of CNV 
regions. Surveys on the distribution and 
features of CNVs throughout the genome 
have thus been consistently biased, and 
wider, more comprehensive scans may be 
important in the examination of the 
relationship between CNV changes and 
susceptibility to common diseases. 
Fortunately, the latest generation of 
genotyping assays has specifically 
accounted for this problem, and specific 
CNV probes are now implemented to attain 
a wider coverage in their genomic 
distribution. 
Consequently, we decided to explore the 
possibility of CNV variation playing a part 
in CRC susceptibility by carrying out a 
GWA study in a Spanish cohort. For this, 
we used an array (Affymetrix 6.0) that 
allows for specific both SNP genotyping as 
well as the simultaneous targeting of copy-
number (CN) variable regions across the 
genome12. Given the lack of consensus on a 
standard analysis procedure, we have 
chosen to use two different CNV calling 
algorithms, Birdsuite´s Birdseye12 and 
QuantiSNP13, to reduce the chances of false 
positive findings. 
 
Materials and Methods 
Study populations. Total number of individuals 
was 881 for CRC cases and 677 for controls. All 
cases and 473 controls belonged to the 
EPICOLON II Project. Details on the project 
and samples have been described elsewhere14,15. 
An additional 194 controls were obtained from 
the Spanish National DNA bank 
(www.bancoadn.org). DNA was extracted from 
frozen peripheral blood by standard procedures 
in mixed case-control batches. All samples were 
obtained with written informed consent, and 
reviewed by the ethical board of the 
corresponding hospital, in accordance with the 
tenets of the Declaration of Helsinki. 
 
CNV genotyping, calling and QC. Samples 
were genotyped with the Affymetrix 6.0 array, 
which offers coverage for around 1 million CN 
variable regions. CNV calling was performed 
with two different algorithms: Birdseye (the 
CNV-discovery component of Birdsuite12 and 
QuantiSNP v213. Population stratification issues 
were addressed by performing Principal 
Component Analysis with the EIGENSOFT tool 
smartpca16 on a set of 100,000 neutral 
independent SNPs (maximum pairwise r-
squared=0.1). Outliers (taken as samples with 
>5x deviations from the cluster centroid) were 
removed from subsequent analyses. There were 
no evidences of case-control differences 
denoting cohort substructure for any of the first 
10 components. Other potentially confounding 
variables were also checked for as sources for 
stratification (Fernández-Rozadilla et al., 
manuscript in preparation). The final sample set 
consisted of 1477 samples (848 cases and 629 
controls). 
Further QC procedures were performed to 
ensure the reliability of the measures: 
restrictions by chromosome (only autosomes 
were used throughout the study), filtering by 
each algorithm´s quality scores (LOD !10 in 
Birdseye and a Bayes Factor (BF) !30 for 
QuantiSNP) and checking of B allele frequency 
(BAF) and log-R ratio (LRR) plots. Creation of 
additional plots comparing several variables 
(MAF, scores, CNV size, copy-number state) 
was made in R to test the performance of both 
algorithms separately. It also aided in the 
identification of outlier CN events, with variants 
over 2Mb in size or a probe count>10,000 being 
removed from subsequent analyses. 
 
Statistical analysis. A statistical tool, 
CNVAssoc, was developed to perform the 
association tests between case and control 
groups after copy-number had been stated at 
each location with the two different algorithms. 
The software compares the frequencies of CNV 
events amongst cases and controls by 
considering several copy-number states to be 
possible at each location: homozygous deletions 
(0), single deletions (1), three, four and five-
copy status (3,4,5). Then, it counts the incidence 
of every one of these states against the absence 
of the same, creating two-by-two contingency 
tables that can be used to calculate Fisher´s 
exact test for association. It also implements a 
copy-number polymorphism test approach, in 
which each CNV is considered to behave as a 
common variant. By these means, the 
inheritance of such variation should follow a 3-
state Mendelian pattern and the 3 alleles should 




The use of both Birdseye and QuantiSNP as 
calling algorithms allowed for the 
successful identification of a total of 
619,199 and 453,443 copy-number 
changes, respectively. These were 
distributed in 11,331 and 5,984 CN variable 
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regions, or CNVRs11. CNVRs are described 
as segments defined by the overlap of 
CNVs detected across samples. Of these all, 
1,744 and 1,243 were polymorphic at a 
frequency of >5% in the control population 
(CNVR polymorphisms, or CNPs). Counts 
by algorithm and CN status are shown on 
Table 1. 
A number of plots were created to compare 
the performance of both algorithms. A 
correlation was observed in either of the 
cases between CNV size and frequency 
(Supplementary Figure 1). As expected, 
larger structural rearrangements over 3Mb 
were rare events present in only a couple of 
samples, whereas CNPs tended to 
encompass smaller regions. The size of the 
detected changes and quality measures (Lod 
Scores and Bayes Factors) seemed also to 
be consistent across CN states 
(Supplementary Figures 2 and 3). Larger 
CN changes seemed to appear at higher 
frequencies in CN events involving gain 
and loss of a single copy (CNs 1 and 3). 
This would make sense in a biological 
context, where larger DNA segments would 
have higher chances of affecting a region of 
the genome where loss of both alleles is 
unviable and a double gain compromises 
dosage-dependent processes. Moreover, 
quality score values seemed to be 
dependent on the number of probes and not 
to the size of the detected CNV 
(Supplementary Figures 4 and 5). This 
positive correlation could be explained by 
the incidence of a CN change over several 
consecutive probes diminishing the 
probabilities of the detection being due to 
signal noise. 
A marked hospital batch effect was 
observed during the quality control 
procedure that split the population in three 
separate clouds: samples from the Donostia 
hospital (VAS dataset; 97 cases and 70 
controls), samples from the Meixoeiro 
hospital (GAL dataset; 194 cases and 172 
controls) and all other samples (REST 
dataset; 557 cases and 387 controls) (Figure 
1). The existence of this population 
substructure and the unavailability of 
association methods that allowed for the 
correction of this phenomenon entailed the 
division of the cohort into three separate 
subgroups from this moment of the analysis 
on. 
Before performing the association, we 
considered the evaluation of the amount of 
existing overlap between algorithms. For 
this purpose, we plotted the relationship 
between chromosomal location and CNV 
frequency in the control population for the 
largest of the subgroups (the REST dataset) 
(Supplementary Figure 6). Since we aimed 
to assess the relationship between common 
CNV variation and CRC susceptibility, we 
generated a list of all CNPs detected by 
either algorithm. A considerable amount of 
overlap was seen between methods, with 
fifty-six shared locations (Supplementary 
Table 1). 
The relationship of these CNPs with CRC 
susceptibility was evaluated by running 
CNVAssoc in the REST population (Table 
2). Eleven CNPs in ten loci were associated 
(minimum p-value in any of the segments 
<0.05) in the analysis of both Birdseye and 
QuantiSNP calls in either the same copy 
number or one in the same direction (loss or 
gain). Association in these 11 was also 
checked for concordance of signals in the 
GAL and VAS populations (Table 3). 
The potential tagging of these CNPs 
through SNP markers, as described by 
previous studies on genomic CN variation is 
on Table 4. 
 
Table 1. CNV counts by calling algorithm. Total counts of detected CNVs for Birdseye and 
QuantiSNP.  
 



















CNVR 11,331 1,114 5,723 4,555 2,398 5,984 973 3,036 3,035 1,176 
CNP 1,774 325 1,065 610 496 1,243 222 433 723 232 
CNVR: copy-number variable region, defined by the overlap of CNVs across samples; CNP: polymorphic CNVR, as CNP: with 




Figure 1. PCA on hospital effect based on 100.000 independent SNPs. There is a marked effect that 
divides the cohort into 3 main clouds: those determined by the Meixoeiro and Donosti hospitals. 
 
Table 2. Features for the 11 associated CNPs in the REST population for both Birdseye and 
QuantiSNP. Association values for each algorithm are shown, as well as a description taken from the 
UCSC browser.  
 
CHR LOCATION BS FREQ CTRLS BS P 
QS FREQ 
CTRLS QS P CN UCSC browser  
2p22.3 34,552,818 34,590,667 0.15-0.5 1.2E-05 0.10-0.17 9.1E-11 1 
Serum leptin concentration QTL2; 
Osteoarthritis QTL2 
4p16.1 9,823,257 9,844,366 0.17-0.34 0.012 0.05-0.28 4.4E-07 0,1 SLC2A9 glucose transporter; DGV indel 
4p16.1 10,001,452 10,009,766 0.05-0.26 0.01 0.05 0.008 0,1 SLC2A9 glucose transporter; DGV indel 
6q14.1 77,496,586 77,509,523 0.08-0.34 0.05 0.09 0.038 0 Osteoarthritis QTLs 16 and 22 
11q11 55,130,595 55,210,152 0.08-0.41 0.0026 0.05 0.043 1 
Olfactory receptor OR4A15; DGV 




20,089,383 0.0621762 3.2E-06 0.05-0.28 0.0017 3 Centromeric 
15q13.3 32,487,975 32,618,236 0.06-0.15 0.049 0.11 0.0047 0,1 
Cholinergic receptor CHRNA7 
(susceptibility locus for juvenile 
myoclonic epilepsy); DKFZp434L187; 




34,614,572 0.13-0.20 0.013 0.07-0.16 0.044 3 
UBE2MP1; Segmental Duplications; 
DGV indel; Rheumatoid arthritis QTL25; 
Blood pressure QTL27 
17q12 36,671,885 36,684,057 0.14 2.5E-07 0.05-0.29 0.017 0,1 
ARHGAP23 and KIAA1501; DGV indel; 
Segmental Duplications; Blood Pressure 
QTLs 16 and 34, COPD QTLs 12 and 22; 
Rheumatoid arthritis QTL28 
17q21.31 41,521,621 42,120,174 0.05-0.3 0.0029 0.074 0.044 3,4 
Several genes; Related to Sclerosterosis, 
Van Buchem disease and N-
acetylglutamate synthase deficiency. 
Downstream BRCA1 
18q12.2 36,514,418 36,519,387 0.09-0.17 0.048 0.079 0.0023 1 COPD QTL28; Body weight QTL67 
BS FREQ CTRLS: CNV frequency in controls for Birdseye analysis; QS FREQ CTRLS: CNV frequency in controls for QuantiSNP 
analysis;BS P: Birdseye p-value; QS P: QuantiSNP p-value; CN: copy-number; DGV: Database of Genomic Variants; COPD: 







































Table 3. Features for the 11 associated CNPs in the GAL and VAS populations for both Birdseye 
and QuantiSNP. The best p-values of association are shown for each algorithm and subpopulation.  
 















2p22.3 6.2E-05 0.28 NS 0.06-0.17 0.021 0.21 NS 0.05-0.15 
4p16.1 0.029 0.31-0.47 0.00024 0.07-0.28 0.016 0.20-0.59 0.025 0.07-0.18 
4p16.1 NS 0.05-0.22 NA NA NS 0.08-0.21 NA NA 
6q14.1 NS 0.09 NA NA NA NA NA NA 
11q11 NS 0.11-0.31 NA NA NS 0.17-0.37 NA NA 
15p11.1-
q11.1 6.4E-10 0.11-0.15 1.1E-09 0.06-0.30 NA NA NS 0.07-0.24 
15q13.3 0.0025 0.08-0.18 0.0094 0.09-0.13 NS 0.11-0.20 NS 0.05-0.1 
16p11.2-
p11.1 NS 0.10-0.14 0.039 0.05-0.13 NS 0.07-0.10 NS 0.05 
17q12 NA NA NS 0.20 NS 0.13-0.42 0.0091 0.05-0.13 
17q21.31 0.00039 0.05-0.20 0.024 0.10-0.15 0.0087 0.05-0.33 NS 0.07-0.1 
18q12.2 0.031 0.16 NA NA NS 0.21 NS 0.05 





Table 4. CNP tagging of the eleven CNPs by SNPs. The best tag-SNPs by platform and also in 
HapMap are depicted, as well as their pairwise properties with the corresponding CNP. Data was 
obtained through the data made available by the Wellcome-Trust Case-Control Consortium (WTCCC)10. 
 










2p22.3 34,548,934-34,590,089 0.372 rs12104507 0.534 rs10179790 0.989 rs10495822 0.926 
4p16.1 9,820,419-9,843,644 NA rs6826450 0.954 rs9990501 0.943 rs231 0.955 
4p16.1 10,001,049-10,012,579 0.253 rs4302457 0.994 rs4302456 0.994 rs4302456 0.995 
6q14.1 77,495,977-77,517,068 0.269 rs9447790 0.592 rs9447791 0.961 rs9447791 0.973 
11q11 55,202,577-55,214,079 0.26 rs654189 1 rs11230088 1 rs1944862 1 
15p11.1-
q11.1 18,689,010-18,894,182 0.007 rs12594870 0.022 rs12593328 0.080 rs17134298 0.071 
  19,044,664-19,093,683 NA rs6599965 0.072 rs12442343 0.061 rs7402254 0.085 
  19,074,202-19,094,178 NA rs12594870 0.080 rs12442343 0.060 rs7402254 0.102 
  19,806,304-19,928,954 NA rs4983927 0.104 rs3848222 0.109 rs7402254 0.089 
  19,885,002-20,097,493 0.37 rs10220883 0.062 rs28651669 0.072 rs1303908 0.069 
  19,982,358-20,068,233 NA rs10220883 0.077 rs11259870 0.086 rs1303908 0.069 
  20,047,790-20,070,506 0.095 rs4983995 0.030 rs1303908 0.031 rs1303908 0.031 
  20,047,790-20,097,493 0.046 rs4983995 0.016 rs28651669 0.012 rs2664997 0.019 
15q13.3 32,489,309-32,494,710 NA rs7403222 0.300 rs4924045 0.511 rs16959239 0.540 
16p11.2-
11.1 34,317,021-34,615,251 0.100 rs4581708 0.377 rs11861828 0.651 rs1019991 0.667 
17q12 36,675,163-36,685,731 0.265 rs9898810 1 rs2191377 1 rs8064493 1 
17q21.31 41,521,114-42,139,954 0.203 rs17651507 0.467 rs17651507 0.467 rs8079215 0.463 





Copy-number variants are an important 
source of variability in the genome17. Thus, 
it is possible that this type of 
polymorphisms, as happens with SNPs, 
play a part in the determination of 
susceptibility to complex diseases, such as 
CRC. We have performed a GWAS on 881 
Spanish CRC cases and 667 matching 
controls to evaluate the relationship 
between structural variation and CRC risk. 
Given the lack of consensus on the 
standardisation of analytic criteria to be 
followed when performing CNV analyses, 
we chose to use two different calling 
algorithms: Birdsuite´s Birdseye12 and 
QuantiSNP v213 to strengthen the validity 
of the associations found, as well as 
decrease the chances of false positive 
findings18. 
 
The comparison between algorithms 
showed no great differences in the overall 
performance of the calling procedures. 
Other studies have proved QuantiSNP to 
outrank other CNV detection methods19. 
Moreover, the improvement of this 
algorithm to allow for its use with of 
Affymetrix arrays (v2 of the software) 
clearly shows a good implementation for 
this type of data. Nevertheless, our data 
seem to indicate that given the current 
thresholds in quality control criteria, 
Birdseye seems to offer a greater sensitivity 
of CNV detection compared to QuantiSNP, 
since the number of CNPs detected was 
higher. In fact, almost all CNPs detected in 
QuantiSNP were also present in Birdseye. 
The consistency in CNP sizes in the 
segments that were shared amongst 
algorithms evidenced that this difference in 
detection did not correspond to a lower 
specificity for CNV detection over intensity 
noise and higher false positive rates. 
Similar results stating the better 
performance of array-matched software 
against other algorithms have also been 
described20, although we consider that in 
our case, behaviour of both methods was 
overall analogous. 
 
Concerning the general behaviour of the 
CNVs detected in our cohort, we found no 
significant difference in the detection rates 
of loss and gain events although there was a 
slight shift in Birdseye when the analysis 
was restricted only to CNVR polymorphic 
regions. This bias has been mentioned in 
the literature, and may appear as a 
consequence of the methodologies used to 
describe CNV maps being classically 
biased against segmental duplications21, or 
as an intrinsic property of the calling 
algorithms themselves deriving in a 
decreased sensitivity to accurately detect 
copy-number gains. Nevertheless, results 
like our own have also reported in other 
studies22, and thus it is likely that the 
differences in the detection rates are a 
consequence of analytic limitations.  
 
We found that a significant number of the 
CNPs detected were shared between 
algorithms. Surprisingly, even when 
locations seemed to match, there were 
many discrepancies in CN status between 
Birdseye and QuantiSNP calls. Although 
this could be due to differences in the 
sensitivities of both algorithms, we find that 
such disagreements are not an exception, 
since a noticeable amount of the CN 
variable regions present in the databases are 
described as both gains and losses (indels) 
(http://projects.tcag.ca/variation/). The fact 
that even databases are so diverse in 
assignment of CN states could also be due 
to the distinct methodologies that have been 
used for CNV discovery and mapping, 
although it has also been described that the 
mechanisms generating losses of genomic 
material generate a complementary gain 
event23. It is likely that progressive fine 
structure analysis of these locations will 
provide better estimations of the CN 
changes underlying these loci. 
 
The evaluation of the association of CNPs 
with CRC susceptibility showed copy-
number states and association measures to 
be consistent for eleven of these CNPs in 
ten different loci, although p-values were 
sometimes very modest. The association 
signals were further evaluated by double-
checking for correspondence in the other 
two subcohorts (GAL and VAS). The 
results were diverse, with some CNVs not 
attaining significance, whereas for others 
no evidences of such CN changes were 
found. These discrepancies are probably 
due to the smaller sample sizes of the 
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subsets, which could directly affect the 
power to detect the association signals. 
Likewise, the quality threshold for both the 
Lod Scores/Bayes Factors and the 
inaccurate estimation of CNV frequency in 
controls could as well explain the absence 
of CN change detection. The divergence in 
these results also provides with a plausible 
explanation for the substratification effect. 
Poorer quality of the callings leading to 
higher noise in intensities could explain the 
separate-cloud effect detected in quality 
control procedures. 
 
None of these 11 associated CNPs seemed 
to affect particularly relevant genes in the 
CRC neoplasic process, although there was 
an interesting candidate at the 4p16.1 
region (SLC2A9 glucose transporter). 
Generally, there seemed to be an 
overrepresentation of CNPs lying in defined 
QTL regions for other diseases, such as 
osteoarthritis or chronic obstructive 
pulmonary disease (COPD). This could 
reflect both a shared component in the 
heritability of these treats or, most likely, an 
overrepresentation of samples suffering 
from these features in either our case or 
control groups. Interestingly, the CNP at 
2p22.3 had also been investigated in our 
pharmacogenomic study (see chapter 5), 
although the association of this locus with 
susceptibility to 5-FU-induced nausea and 
vomiting could not be replicated in second-
stage analysis. 
 
Tagging of CNPs by SNPs has extensively 
been studied10,24,25. It is believed that most 
structural variation has somehow been 
indirectly assayed by GWAS performed on 
SNPs. This does not appear to be the case 
for these ten loci. Most of them are poorly 
tagged by either the SNP counterpart of our 
array, other genotyping arrays used in CRC 
GWA studies (mainly Illumina chips), or 
even HapMap26. This reinforces the idea 
that CNV variation must be inspected on its 
own to evaluate its implication in 
susceptibility to developing CRC, and 
possibly other disorders. 
 
By performing a GWAS on CNV 
polymorphisms, we have successfully 
identified 11 CNPs in 10 different loci as 
potential candidates for CRC susceptibility 
loci. Notwithstanding, we consider that 
even when the detection by two different 
algorithms gives an extra reliability to the 
results found, the association between these 
11 loci and CRC must be carefully 
interpreted. Replication is the most 
important experimental tool for assessing 
the validity of observed associations27. 
Besides, the assignment of CN status 
constitutes a problem in itself. It is 
recommended that confirmation of the 
copy-number changes in these regions is 
validated by independent methods, such as 
MLPA or qPCR, and that the resultant 
genotypes be in high concordance with 
those in our study before any additional 
replication in other cohorts is made. 
 
Additionally, although the initial sample 
size of the study was close to the widely 
used 1000 cases and 1000 controls in first-
stage association studies, the presence of 
population substratification results 
troublesome. Although it does not seem to 
increase the false-positive rate of the 
findings28, it does decrease the effective 
sample size on which to perform the 
association analysis. If we were to assume 
that common CN variation behaves in the 
same way as the susceptibility SNPs 
described so far3,4, then our study would be 
clearly underpowered to detect even the 
greatest of the described effects. Thus, it is 
likely that much larger and homogeneous 
cohorts are needed to detect the effects of 
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Supplementary Figure 1. CNV frequency in controls vs CNV size (bp). Larger CN rearrangements 















Supplementary Figure 2: CNV size versus copy-number for Birdseye and QuantiSNP. Sizes of the 
detected variants seem to be overall consistent for each of the algorithms between copy-number states. 
Left: Birdseye; right: QuantiSNP. 
 
 
Supplementary Figure 3. Quality control scores by copy-number. Quality scores appear higher for 
gains/losses involving a single copy in Birdseye, whereas the distribution is homogeneous for 









Supplementary Figure 4. Correlation between number of probes and quality score. Both quality 
scores seem to be dependent on number of probes. X represents number of probes and Y Lod Score 





Supplementary Figure 5. Relationship between CNV size and quality. There seems to be a tendency 
of greater scores for larger CNVs in the case of Birdseye CN-1 variants. X represents number of probes 











Supplementary Figure 6. Distribution of CNVRs by chromosome. Frequencies for each CNVR are 
shown comparing Birdseye (green) and QuantiSNP (blue) locations in the REST control dataset; CNVRs 





















Supplementary Table 1. Shared CNPs between Birdseye and QuantiSNP findings in the REST 
population. Features for the 56 CNPs that are shared between algorithms. In blue and bold, CNPs with 
consistent association results for both Birdseye and QuantiSNP. In pink, CNPs that have inconsistent 
copy number status between both algorithms. 
 
 BIRDSEYE QUANTISNP 
CHR START END FREQ CTRLS CN P-VALUE CN-P 
FREQ 
CTRLS CN P-VALUE CN-P 
1 25,465,702 25,519,573 0.07-0.36 0,1 0.029 0 0.07 1 NS - 
1 72,528,701 72,583,736 0.12-0.44 0,1 0.0071 0 0.29-0.52 4 2.7E-08 1 
1 150,821,799 150,853,218 0.34-0.44 0,1 NS - 0.07-0.2 0,1 4.5E-12 0 
1 151,028,534 151,035,324 0.11-0.41 0,1 NS - 0.10-.012 0,1 6.1E-06 1 
1 194,994,460 195,076,539 0.05-0.28 0,1 0,0021 1 0.06 1 NS - 
2 34,552,818 34,590,667 0.15-0.5 0,1 1.20E-05 1 0.10-0.17 0,1 9.1E-11 1 
2 52,607,959 52,635,046 0.09-0.37 0,1 0.0062 1 0.08 0 NS - 
2 88,914,226 91,281,977 0.07 0,1 NS - / 1,3,4 2.5E-09 4 
2 146,580,861 146,583,404 0.21-0.41 0,1 NS - 0.17 1 0.0025 1 
2 242,564,139 242,683,359 0.08 1 NS - 0.07 1 NS - 
3 46,776,808 46,824,593 0.07 1 NS - 0.06 1 NS - 
3 131,245,549 131,288,926 0.29-0.40 1 0.037 1 0.11-0.17 1 NS - 
3 163,995,338 164,109,297 0.08-0.35 0,1 0.006 1 0.08-0.27 1,3,4 2.4E-06 4 
3 194,360,583 194,365,597 0.10-0.44 0,1 0.0027 0 0.16 4 7.2E-05 4 
4 9,823,257 9,844,353 0.17-0.34 0,1 0.012 1 0.05-0.28 0,1,4 4.4E-07 0 
4 10,001,452 10,009,766 0.05-0.26 0,1 0.01 1 0.0532995 0 0.008 0 
4 34,455,242 34,501,120 0.08-0.34 0,1 NS - 0.05-0.25 0,1 0.00039 1 
4 69,043,070 69,203,991 0.10-0.38 0,1 0.007 0 0.05-0.38 1,3 3.3E-14 3 
4 115,394,759 116,395,574 0.13-0.19 1 NS - 0.15 1 NS - 
5 57,361,771 57,369,290 0.3-0.6 0,1 NS - 0.30 4 NS - 
5 180,311,303 180,350,709 0.12-0.25 0,1 NS - 0.08-0.11 0,1 6.1E-06 1 
6 74,648,952 74,658,138 0.106218 0 NS - 0.13 0 NS - 
6 77,496,586 77,509,523 0.08-0.34 0,1 0.05 0 0.09 0 0.038 0 
6 79,025,771 79,091,904 0.08-0.34 0,1 NS - 0.06-0.14 0,1 3.4E-10 1 
6 103,844,656 103,868,754 0.17-0.42 0,1 NS - 0.12-0.20 1,3 0.014 1 
7 133,435,704 133,449,386 0.10-0.34 0,1 0.0034 1 0.08 0 NS - 
7 141,416,112 141,715,788 0.28-0.40 0,1 NS 1 0.11-0.16 1,3 3.7E-07 3 
7 142,156,281 142,167,486 0.14-0.44 0,1 NS - 0.10 0,1 NS - 
8 25,030,360 25,040,250 0.11-0.46 0,1 0.022 1 0.12 0,1 NS - 
8 39,349,340 39,506,122 0.22-0.47 0,1 NS - 0.11-0.20 0,1 0.014 1 
8 137,757,067 137,931,617 0.05 1 NS - 0.05 1 NS - 
9 44,667,842 44,795,733 0.10-0.21 1 0.0012 1 0.06-0.16 1 NS - 
10 46,401,426 47,174,643 0.05 3 NS - 0.05-0.41 1,3 1.1E-06 1 
10 58,186,368 58,196,843 0.08 1 NS - 0.07 1 NS - 
10 66,977,929 66,984,452 0.11-0.38 0,1 NS - 0.05-0.11 0 NS - 
11 4,924,226 4,933,658 0.11-0.38 0,1 0.00019 1 0.06-0.1 0,1 NS - 
11 5,743,981 5,768,936 0.05-0.41 0,1 NS - 0.06 0 NS - 
11 55,130,595 55,210,152 0.08-0.41 0,1 0.0026 1 0.05 0,1 0.043 1 









Supplementary Table 1. (Continuation). 
 
 BIRDSEYE QUANTISNP 
CHR START END FREQ CTRLS CN P-VALUE CN-P 
FREQ 
CTRLS CN P-VALUE CN-P 
12 9,521,810 9,626,952 0.08-0.40 0,1 NS - 0.05-0.31 0,1 1.6E-11 1 
12 31,171,857 31,293,957 0.06 3 NS - 0.07 3 NS - 
12 33,191,058 33,198,641 0.10-0.33 0,1 NS - 0.06 0 NS - 
13 36,970,023 36,982,757 0.11-0.25 0,1 NS - 0.10 0 NS - 
14 18,801,397 19,493,212 0.06-0.25 3,4 0.00034 3 0.05-0.17 3 NS - 
15 18,652,835 19,566,875 0.05-0.12 1,3 NS - 
0.05-0.28* 3* 0.0017*  3* 
15 19,818,876 20,089,383 0.06 3,4 3.2E-06 3 
15 32,487,975 32,618,236 0.06-0.15 0,1,3 0.049 0 0.11 1 0.0047 1 
15 74,678,283 74,682,830 0.24-0.31 0,1 0.011 1 0.28 0 NS - 
16 34,324,072 34,614,572 0.13-0.20 3 0.013 3 0.07-0.16 3 0.044 3 
16 76,929,941 76,942,266 0.06-0.23 0,1 NS - 0.20 0 NS - 
17 18,296,117 18,415,358 0.05-0.15 0,1,4 NS - 0.06-0.17 0,1 0.032 1 
17 31,464,091 31,509,204 0.07-0.16 3,4 0,022 4 0.05 3 NS - 
17 36,671,885 36,684,057 0.15 0 2.5E-07 0 0.05-0.29 1 0.017 1 
17 41,521,621 42,120,174 0.05-0.3 1,3,4 0.0029 4 0.07 3 0.044 3 
18 36,514,405 36,519,387 0.09-0.17 0,1 0.048 1 0.08 1 0.0023 1 
20 1,505,190 1,541,893 0.17-0.45 0,1 0.046 0 0.05-0.31 4 0.0066 4 
20 52,081,215 52,092,058 0.11 1 NS - 0.07 1 NS - 
CHR: Chromosome; FREQ CTRLS: CNV frequency in control population; CN-P: copy-number state of best p-value. 
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The development of genotyping technologies has allowed for wider-coverage screenings of 
the hidden heritability underlying the observed variation in drug administration outcome. 
We have performed a Genome-Wide Association Study (GWAS) on 221 colorectal cancer 
(CRC) patients that had been treated with the anticancer chemotherapy agents 5-
fluorouracil (5-FU) alone or in combination with oxaliplatin (FOLFOX). After evaluating 
a set of 1M markers of each SNPs and copy-number variants (CNVs) in a two-stage 
procedure, we found that none of the CNVs but eleven of the SNPs (rs10158985 at 
1q42.12, rs4128317 at 2p22.3, rs17626122 at 2q33.3, rs839533 at 2q34, rs16857540 at 
3q26.31, rs10106310 at 8q21.3, rs2465403 at 8q24.12, rs10876844 at 12q13.2, rs10784749 
at 12q15, rs11080058 at 17q11.2 and rs670454 at 18p11.22) showed evidences of 
association with adverse drug reaction (ADR) phenotypes. Ours is the first study to 
explore the genetic basis underlying inter-individual variation in toxicity responses to the 
administration of 5-FU or FOLFOX in CRC patients in a genome-wide scale. We 
encourage future efforts in the pharmacogenomic field, since the characterisation of such 
variants would help on the optimisation of the chemotherapy protocols, thereby reducing 
health-care costs. 
 




It has been known for many decades now, that 
there is an important inter-individual variation in 
an individuaĺ s response to drug administration1. 
This variation may be represented by differences 
in the delivery of the drug molecule, or by factors 
that affect drug targeting. This divergence usually 
results in either the lack of the desired therapeutic 
effect, or the occurrence of adverse drug 
reactions (ADRs) with any factors such as age, 
sex, intake of other drugs and inheritance 
influencing this outcome2.  
CRC is the third most frequent form of 
neoplasm, and an important cause of morbidity 
in the developed world3. There has been 
increasing evidence from clinical trials that 
chemotherapy treatment greatly improves the 
chances of healing and survival in CRC patients 
with stages III or greater4. Five-fluorouracil has 
been the cornerstone for first-line CRC 
systematic chemotherapy treatment for many 
years5, and its combination with oxaliplatin 
(FOLFOX) has also become a very popular 
treatment of choice for CRC patients6. However, 
the toxicities associated with the administration 
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of these drugs have sometimes overshadowed the 
benefits they deliver. Patients treated with 5-FU, 
or its oral prodrug capecitabine commonly 
present gastrointestinal and haematopoietic 
toxicities, whereas FOLFOX-treated patients are 
exposed to developing sensory neuropathy, 
which may endure even long after chemotherapy 
cessation7. All these side effects are thought to be 
mostly due to the narrow therapeutic indexes of 
most anticancer drugs. 
Until recently, the investigation of the inheritance 
factors underlying the diverse response to CRC 
chemotherapy agents had mainly focused on 
candidate-gene studies, in which variants in 
genes coding for proteins involved in specific 
pathways, such as drug absorption, metabolism 
or target molecules, were screened for evidences 
of their association with therapy outcome. For 
instance, variants in candidate genes such as 
DPYD8, TYMS9 or UGT1A110 have already been 
linked to the development of ADRs in CRC 
patients treated with chemotherapy. However, 
these large-effect phenotypes might not apply to 
the majority of drugs. It is expected that for 
common pharmacogenetic treats, same as for 
most diseases, the inheritance patterns behind 
these responses are complex, with an additive 
interplay of multiple variants in the determination 
of the final outcome11. In this sense, the 
simultaneous study of higher numbers of variants 
has become increasingly necessary in order to 
evaluate the full contribution of inheritance to 
drug response. GWAS may therefore be an 
important tool for this purpose. The main 
advantage of this type of studies against gene-
based strategies, is that they may be able to 
identify variants in genes or pathways that have, 
up-to-now, not been implicated in mediating 
drug response12. Nonetheless, there have still 
been no reports of GWAS in relation to 
colorectal cancer chemotherapy, neither for drug 
response, nor for ADRs. The discovery of the 
genetic factors underlying these expected 
heritability may be fundamental for the 
adjustment of therapies and/or dosage in order to 
achieve a better outcome. 
Thus, we decided to perform an unprecedented 
GWAS on a cohort of samples that had either 
been treated with 5-FU/capecitabine or 
FOLFOX, with the aim to shed a light on the 
genetic variation behind a series of 
gastrointestinal (diarrhoea, mucositis, 
nausea/vomiting), haematological (anemia, 
neutropenia, leukopenia, thrombocytopenia), and 
neurological (oxaliplatin-related neuropathy) 
ADRs. 
 
Materials and Methods 
Study populations. Samples from phase I were 
221 colorectal cancer patients collected through 
the EPICOLON II Project13, a multicentric 
epidemiology overview of the prevalence and 
attributes of colorectal cancer in the Spanish 
population. All patients had received adjuvant 
or palliative chemotherapy, in the case of colon 
cancers, whereas rectal cancer patients had 
undergone neoadjuvant treatments. Clinical and 
toxicity-related information was obtained from 
each of these individuals using a standardarised 
form. Ninety-three of these patients had been 
dosed with 5-FU/capecitabine in monotherapy 
as first-line treatment, and the remaining 133 
had been administered with FOLFOX. Median 
age for 5-FU patients was 72 with a range of 
(26-86), whereas average was 70.59 (68,46-
72,72); age median for FOLFOX patients was 
69 (range 42-85) with an average 65,85 (64,18-
67,53). Gender proportions were 57,47/42,53% 
(male/female) for 5-FU and 67,83/32,17% for 
FOLFOX individuals. 
Samples from phase II were 821 colorectal 
cancer patients collected at four different 
centers: Hospital Sant Pau (Barcelona), Catalan 
Institute of Oncology (ICO, Barcelona), 
Hospital Gregorio Marañón (Madrid) and 
Complexo Hospitalario Universitario de 
Santiago (Santiago de Compostela), that had 
undergone chemotherapeutical treatment after a 
colorectal cancer diagnosis. Of these, 491 had 
received first-line treatment with 5-
FU/capecitabine and 330 with FOLFOX. Age 
features and sex proportions were 62,29 (60,44-
64,15) average, 62 (21-83) median and 
58,67/41,33% (male/female) for 5-FU, and 
60,80 (58,46-63,14) average, 62 (26-75) median 
and a 65,93/34,07% male/female ratio for 
FOLFOX patients. 
All samples were of Caucasian European origin 
and from Spain. DNA was obtained from 
peripheral blood by standard extraction 
methods. 
 
Ethics statement. The study was approved by 
both each of the institutional review boards of 
the hospitals where samples were collected and 
the “Comité Ético de Investigación Clínica de 
Galicia”. All samples were obtained with 
written informed consent reviewed by the 
ethical board of the corresponding hospital, in 
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Table 1. Sample count for each of the phenotypes. 
Summary of sample sizes for 5-FU and FOLFOX 











Diarrhoea 25 63 40 75 
Mucositis 9 79 13 102 
Nausea/ 
Vomiting 
8 80 23 92 
Haematologic 14 74 50 65 




published SNPs or their closest proxies on our 
array. The selection of the markers was 
performed with the help of the PharmGKB 
database (http://www.pharmgkb.org/), and was 
restricted to only those variants with MAF>5%. 
 
Statistical analysis. SNP association analyses 
were performed by logistic regression in 
PLINK16. Covariate adjustment was also used to 
correct for gender and severity of the toxicities 
(grades 1-2 vs 3-4) during the testing. Hospital 
of origin of the sample was also adjusted for in 
phase II analyses. Odds ratios (ORs) and 95% 
confidence intervals (CIs) were calculated for 
each marker. Plots were created using 
Haploview18 and R. 
 
CNV calling and analysis. CNV probes on the 
array were used to screen for structural 
variation. Copy-number status was estimated by 
two different methods: the Birdseye algorithm, 
another part of Birdsuite´s framework15, and 
QuantiSNP version 219, which includes a 
modification that implements the use of the CN-
probe information on Affymetrix arrays. Once 
the calling was made, CN variants were filtered 
according to their MAFs (>5%) and the 
probability score associated with each calling 
algorithm. QC thresholds were set at Lod-scores 
>10 for Birdseye CNVs and a Bayes Factor >30 
for QuantiSNP results. Association analyses 
were then performed with the help of 
CNVAssoc, a home-made tool that allows for 
the comparison of CNV event frequencies 
among cases and controls. Briefly, the program 
considers the presence of a number of different 
copy-number states: homozygous deletion (0), 
single deletion (1), three, four or five copies 
(3,4,5), any loss (0+1), any gain (3+4+5), and 
any CNV (0+1+3+4+5). Then, for each, it 
counts the incidence of every one of these copy-
number states against the absence of the same, 
creating two-by-two contingency tables that can 
be used to calculate Fisher´s exact test for 
association. It also implements a copy-number 
polymorphism test approach, in which each 
CNV is considered to behave as a common 
variant. By these means, the inheritance of such 
variation should follow a 3-state Mendelian 
pattern and the alleles should be in HWE. If the 
counts do not fit this equilibrium, then the 




The results for the SNP analysis for stage I 
on the 88 5-FU and 115 FOLFOX patients 
showed very modest association p-values, 
with none reaching the established genome-
wide significance level. This could be 
mostly due to the lack of power derived 
from the low case numbers that were 
available for each of the phenotypes. The 
quantile-quantile plots showing the 
distribution of the association p-values 
clearly reflect this effect (Supplementary 
Figures 2 and 3). Considering the fact that 
this would imply an increase in type II error 
(false negative rate), we decided to further 
genotype in a second stage the top 5 
association hits for each of the treatment-
phenotype pairs, with the exception of 
neuropathy, for which the top 10 loci were 
selected because of the specificity of this 
adverse reaction with the intake of 
FOLFOX (Table 2). 
As for CNVs, association p-value results 
after Fisher´s exact test were also moderate, 
both for Birdseye and QuantiSNP 
(Supplementary Figure 4). However, there 
were some outstanding regions at 2p22.3 
for 5-FU-nausea/vomiting, 11p11.12 and 
20p13 for 5-FU-haematologic, and 11p15.4 
for FOLFOX-diarrhoea. Another CNV at 
5q35.3 seemed to share susceptibility to 5-
FU induced haematological effects and 
FOLFOX-related mucositis (Table 3). 
These proved interesting enough for a 
second-stage follow-up. All of them were 
already documented copy-number variation 





Table 2. Loci selected for replication on stage two and their associated markers. Principal features 
and phase I association values for the 50 SNPs selected for phase II replication are shown. Five loci were 
selected for each phenotype, with the exception of FOLFOX-neuropathy, for which the top 10 hits were 
chosen. 
CHR SNP LOCATION MINOR ALLELE OR (95%CI) P-VALUE TREATMENT-ADR 
2 rs6713755 223746679 G 8.321 (3.067-22.580) 3.170E-05 5-FU-diarrhoea 
10 rs887339 29545130 G 11.260 (3.831-33.110) 1.076E-05 5-FU-diarrhoea 
12 rs10876844 54336973 T 7.295 (2.799-19.010) 4.784E-05 5-FU-diarrhoea 
12 rs10784749 67708296 C 0.133 (0.047-0.371) 1.174E-04 5-FU-diarrhoea 
20 rs4813881 8916642 A 0.153 (0.060-0.389) 7.854E-05 5-FU-diarrhoea 
3 rs9861291 180274372 G 0.060 (0.015-0.241) 7.473E-05 5-FU-haematologic 
5 rs10055794 171054516 C 11.790 (3.431-40.490) 8.932E-05 5-FU-haematologic 
16 rs7184580 77418447 C 7.104 (2.624-19.230) 1.138E-04 5-FU-haematologic 
18 rs1943423 55641304 C 5.881 (2.278-15.180) 2.507E-04 5-FU-haematologic 
19 rs4805974 39248137 A 8.477 (2.828-25.410) 1.358E-04 5-FU-haematologic 
2 rs2627043 179290782 T 8.276 (2.476-27.660) 5.973E-04 5-FU-mucositis 
3 rs16857540 175383269 C 7.404 (2.393-22.910) 5.130E-04 5-FU-mucositis 
8 rs2465403 120160008 G 14.140 (3.332-59.98) 3.282E-04 5-FU-mucositis 
13 rs927553 23706704 G 22.550 (4.157-122.400) 3.049E-04 5-FU-mucositis 
18 rs670454 8682920 C 8.577 (2.476-29.720) 6.997E-04 5-FU-mucositis 
2 rs10182133 75710000 G 13.730 (3.099-60.810) 5.612E-04 5-FU-nausea/vomiting 
4 rs2060645 183344417 T 15.020 (3.246-69.48) 5.268E-04 5-FU-nausea/vomiting 
4 rs6815391 189161973 A 11.050 (2.751-44.380) 7.086E-04 5-FU-nausea/vomiting 
10 rs7094179 14912433 T 17.960 (3.662-88.050) 3.709E-04 5-FU-nausea/vomiting 
13 rs9300811 102834312 G 13.950 (3.162-61.550) 5.014E-04 5-FU-nausea/vomiting 
2 rs4971347 933636 A 0.151 (0.063-0.366) 2.701E-05 FOLFOX-diarrhoea 
2 rs250944 234661957 C 0.242 (0-126-0-466) 2.182E-05 FOLFOX-diarrhoea 
11 rs1865282 4787228 C 4.377 (2.244-8.538) 1.489E-05 FOLFOX-diarrhoea 
12 rs1347851 89091109 C 5.410 (2.411-12.140) 4.227E-05 FOLFOX-diarrhoea 
21 rs2282469 34151289 C 3.968 (2.059-7.647) 3.820E-05 FOLFOX-diarrhoea 
2 rs17626122 206182257 G 3.638 (1.937-6.834) 5.950E-05 FOLFOX-haematologic 
8 rs10106310 91245050 C 3.901 (2.010-7.569) 5.702E-05 FOLFOX-haematologic 
13 rs7325568 39716284 C 3.716 (1.950-7.083) 6.608E-05 FOLFOX-haematologic 
14 rs2798389 82120903 G 4.109 (2.023-8.347) 9.292E-05 FOLFOX-haematologic 
15 rs4243761 23833884 G 0.279 (0.150-0.517) 5.127E-05 FOLFOX-haematologic 
1 rs520227 188835935 C 11.550 (3.410-39.100) 8.459E-05 FOLFOX-mucositis 
2 rs4128317 29513358 C 9.681 (3.125-29.740) 7.346E-05 FOLFOX-mucositis 
2 rs839533 212516352 T 8.247 (2.760-24.640) 1.585E-04 FOLFOX-mucositis 
14 rs17098912 99174082 A 7.716 (2.587-23.020) 2.480E-04 FOLFOX-mucositis 
19 rs7255865 21596808 C 7.856 (2.674-23.080) 1.778E-04 FOLFOX-mucositis 
1 rs2389972 85963254 G 5.234 (2.266-12.090) 1.069E-04 FOLFOX-nausea/vomiting 
1 rs10158985 224117232 A 4.100 (1.986-8.466) 1.365E-04 FOLFOX-nausea/vomiting 
6 rs851974 152013380 C 5.068 (2.245-11.440) 9.367E-05 FOLFOX-nausea/vomiting 
8 rs2739171 134167847 T 0.182 0.077-0.431) 1.043E-04 FOLFOX-nausea/vomiting 
9 rs724975 120828533 A 5.688 (2.330-13.890) 1.349E-04 FOLFOX-nausea/vomiting 
1 rs1555070 175039581 A 3.461 (1.783-6.717) 2.437E-04 FOLFOX-neuropathy 
2 rs1097701 129863806 A 0.287 (0.149-0.553) 1.881E-04 FOLFOX-neuropathy 
3 rs447978 121973776 C 3.776 (1.908-7.577) 1.354E-04 FOLFOX-neuropathy 
5 rs9312960 257082 T 3.772 (1.878-7.577) 1.910E-04 FOLFOX-neuropathy 
5 rs4957020 367346 A 0.279 (0.143-0.546) 1.909E-04 FOLFOX-neuropathy 
5 rs12188653 101411702 C 0.155 (0.059-0.404) 1.425E-04 FOLFOX-neuropathy 
5 rs6863960 115023680 G 3.294 (1.748-6.208) 2.269E-04 FOLFOX-neuropathy 
11 rs17718902 17741283 G 3.007 (1.691-5.349) 1.790E-04 FOLFOX-neuropathy 
11 rs1944118 110857242 A 0.243 (0.129-0.458) 1.268E-05 FOLFOX-neuropathy 




Table 3. CNV hits chosen for stage II replication. Main features of every CNV and association values 
in stage I are shown. Tagger SNPs for all CNVs and their pairwise r2 measures were extracted from the 
data made available by the Wellcome Trust Case Control Consortium20. 



































Deletion Birdsuite 0.231 2.6E-04 rs10838648 1 FOLFOX-diarrhoea 
 
 
Replication values of the top 50 hits for 
SNPs and the 4 CNV-associated SNP 
taggers from phase I and pooled analysis of 
both phases may be seen on Supplementary 
Table 1. Three of these association signals 
were proven to be consistent throughout 
stages: rs10876844 at 12q13.2 with 
diarrhoea in patients dosed with 5-FU 
(pooled p =0.010; OR= 6.502 (1.552-
27.23)), and rs10106310 at 8q21.3 
(p=1.193x10-4; OR=1.967 (1.393-2.776)) 
and rs17626122 at 2q33.3 (p=4.851x10-4; 
OR=1.720 (1.268-2.332) with haematologic 
side effects after FOLFOX exposure. 
Nevertheless, there were another 8 SNPs 
that, although not significant in the 
replication stage, did show significant 
association values in the pooled analysis of 
the two stages. These were rs10158985, 
rs4128317, rs10784749, rs839533, 
rs16857540, rs2465403, rs11080058 and 
rs670454. The features for each of these 11 
associated loci on each stage are shown on 
Table 4. 
We also evaluated the association signals 
for a series of SNP variants that had been 
linked to either 5-FU or FOLFOX-related 
toxicity in the literature. None of the 




It has been long observed that there is large 
variation in both the effectiveness and 
toxicity outcomes of drug treatment, and at 
least part of it has been proven to be due to 
inheritance24. The definition of these 
genetic factors has been the purpose of 
pharmacogenetic studies for almost 60 
years now. For most of this time, 
pharmacogenetics has focused on 
candidate-gene approaches investigating 
drug-metabolising enzymes, drug 
transporters or drug targets. The recent 
advances on genome knowledge, as well as 
the development of new genotyping 
technologies during the -omics era have 
however made possible the expansion of 
these studies to genome-wide levels25.  
With these expectations, we followed a 
GWA study with the purpose of detecting 
new variants that could help predict the 
toxic effects of the administration of two of 
the most common chemotherapeutical 
drugs in colorectal cancer patients: 5-
fluorouracil and FOLFOX. As major 
toxicity remains the main limitation to 
adequate dosing, the ability to predict 
toxicity before the administration of 
chemotherapy could help provide 
individualised treatment that would likely 
result in an improved outcome, both for the 





Table 4. Summary of association results for the 11 associated loci. P-values for each stages and 























12q15 rs10784749 1.174E-04 0.621 0.017 
0.164   
(0.037-0.726) 
5-FU-diarrhoea 
































The only consistent association signal for 5-
FU and the ADRs considered throughout 
the stages was that of rs10876844 with 
diarrhoea. This SNP lies in the long arm of 
chromosome twelve, 24kb and 26kb 
upstream of the METTL7B (methyl-
transferase like 7B precursor) and ITGA7 
(integrin alpha 7 isoform 1 precursor) 
genes, respectively. Although analysis of 
the LD pattern in this region seemed to 
show that rs10876844 and the gene blocks 
were not well correlated (Supplementary 
Figure 5), this however does not rule out 
the possibility that rs10876844 may be 
capturing part of the known, or even yet 
unknown variation in any of these genes. In 
this sense, METTL7B could be of particular 
relevance, since this very gene, as well as 
other family members, have been proven to 
interact with other drugs, namely 
tamoxifen, both in mice and humans27. 
The rs10106310 SNP, which was 
associated in our cohort with haematologic 
toxicity outcomes in patients treated with 
FOLFOX, is located 80kb upstream from 
the Calbindin 1 (CALB1) gene, in a high 
LD block in the 8q21.3 cytoband 
(Supplementary Figure 6). The presence of 
the calbindin gene in the nearby region 
could provide with a feasible explanation to 
the relationship between this variant and the 
haematologic toxicity observed. Changes of 
calbindin expression levels have been 
proven to influence the apoptotic pathway 
in lymphocytes28; thus, it is reasonable to 
believe that variations in the cellular 
availability of this protein could lead to 
enhanced leukocyte cell death.  
The last of the association signals 
corresponds to rs17626122, a SNP located 
in the intronic region of the PARD3B 
(partitioning defective 3 homolog B) gene 
(Supplementary Figure 7). Although 
initially described in homology with Par 
genes, which are the major effectors of cell 
polarity in the mouse29, the PARD3B 
protein has been shown to act with 
SMAD3, one of the members of the TGF-ß 
signalling pathway. Mutations in SMAD3 
have already been linked to colorectal 
adenocarcinoma development in mice30 and 
wound healing capabilities31, whereas the 
TGF-ß pathway in itself is a very important 
route in cancer development32. 
Even when phase II association values were 
not significant, there were some other 8 
SNPs that held significance in the pooled  
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Table 5. Association results for a revision of markers that had been linked to toxicity outcomes 
after 5-FU or FOLFOX treatments. Markers were selected from previous bibliography whenever 
described MAFs were <5%. 
CHR SNP GENE MAF PROXY R2 P-VALUE OR (95% CI) TREATMENT-ADR REF
1 rs1801159 DPYD 0.167 rs17116806 0.882 0.483 1.374 (0.566-3.338) 5-FU-haematologic 21 
       0.276 0.398 (0.037-2.567) 5-FU-nausea/vomiting 21 
  rs1801265 DPYD 0.150 rs4970722 1 0.216 2.313 (0.613-8.735) 5-FU-nausea/vomiting 21 
3 rs1801019 UMPS 0.167 rs10049380 0.838 0.737 0.822 (0.261-2.588) 5-FU-haematologic 9 
       0.081 0.322 (0.0903-1.152) 5-FU-diarrhoea 9 
18 rs34743033 TYMS 0.337 NA - - - 5-FU-any toxicity 9 
  rs34489327 TYMS 0.470 NA - - - 5-FU-any toxicity 9 
11 rs1695 GSTP1 0.375 rs7952081 0.764 0.366 0.661 (0.270-1.620) 5-FU/FOLFOX-haematologic 23 
            0.360 1.295 (9.745-2.252) FOLFOX-neuropathy 23 
analysis of the two stages. It has been 
suggested that joint analysis of phases may 
be more powerful in detecting true 
association signals than stage-based designs 
particularly in studies with low sample 
sizes33. This may be so because the pooling 
analysis allows for an improvement in 
power in the overall study compared to 
each of the stages independently. Thus, we 
consider these 8 variants as interesting 
locations and do not fully discard them as 
potential susceptibility loci for adverse 
reactions after 5-FU and FOLFOX 
administration. 
Of these other four 5-FU-related SNPs, 
rs16857540 and rs2465403 fall within the 
intronic regions of the neuroligin1 
(NLGN1) and the Collectin subfamily 
member 10 (COLEC10) genes, whereas 
rs10784749 and rs670454 lie in intergenic 
locations. FOLFOX-associated variants 
rs10158985, rs4128317 and rs839533 also 
reside within genes (TMEM63A, ALK and 
ERBB4, respectively), while rs11080058 
appears in a genic dessert as well. 
We must also bear in mind that, for some of 
these SNPs (particularly for 5-FU SNPs 
rs2465403, rs10876844 and rs670454), OR 
ranges were exceptionally wide, thus 
possibly reflecting a type I error or the 
inability of the study to precisely estimate 
the risk associated with that variant due to 
sample size restrictions. ORs for FOLFOX 
variants seem to have more consistent 
ranges, thus confirming the importance of 
sample size in the evaluation of the risk 
conferred by these variants. Hence, we 
believe further follow-up studies in larger 
cohorts necessary to fully ascertain the 
relationship between these variants and 
ADR susceptibility. 
On the other hand, we did not succeed in 
the replication of any of the association 
signals described at other loci in previous 
literature. It must however be highlighted 
that there is a bias that results from none of 
them being directly genotyped in our 
dataset, and the fact that r-squared values 
were sometimes small. Hence, we would 
recommend these to be additionally 
evaluated in other cohorts. 
Scientists have largely speculated on the 
idea that variants contributing to 
pharmacogenetic traits have escaped the 
effects of human selection, for humans have 
spent most of their evolutionary history 
unexposed to drugs. This would have likely 
resulted in the frequencies of these variants 
rising in the populations through genetic 
drift, and the effect sizes of the variants 
being higher than the discovered for GWAS 
of disease susceptibility34. Our study 
however, does not confirm this hypothesis, 
and even when the predicted odds ratios for 
the associated variants we find are 
somewhat higher than the obtained for the 
majority of the GWAS and susceptibility to 
disease signals, the prediction of the effects 
of these variants is moderate. This may be 
yet-another reason to support the idea that 
pharmacogenetic traits behave just as any 
other complex one, and therefore the 
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genetic heritability behind it may mostly lie 
in the form of moderately penetrant 
common variants12. This would reinforce 
GWAS screenings in large sample sets as 
the ideal strategy to resolve the genetic 
variation behind individual differences in 
the response to drug administration. 
In this study, we present the results of the 
first GWAS studying of the toxicity 
outcome of chemotherapeutical 5-
fluorouracil and FOLFOX administration in 
colorectal cancer patients. We have 
successfully identified 11 new variants 
related to 5-FU-induced and FOLFOX-
related side effects. Even when copy-
number alterations account for a high 
percentage of the total variation in the 
genome35, we did not succeed in identifying 
any signals of association regarding CNVs 
and the ADRs in our study. We have also 
proposed feasible biological mechanisms 
by which these association signals may 
modulate the toxicity responses observed. 
Of course, as happens with many of the 
GWAS-related association hits, the real 
biological mechanisms underlying these 
associations are still unknown. This 
however, does not rule out the relevance of 
the discoveries and we encourage further 
efforts be made in this direction. The 
verification of the association signals 
reported in this study with their 
presumptive ADRs would ultimately need 
to be ascertained by replication in larger 
datasets. Functional essays will eventually 
also be required in order to clarify the 
potential biological mechanisms underlying 
these association signals. 
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Supplementary Figure 1. PCA analysis comparing case and control groups for each of the ADR 
phenotypes with 5-FU and FOLFOX patients. First and second eigenvectors are shown for each 
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Supplementary Table 1. Association values for each stage and the pooled analysis for the top 5/10 
loci selected for replication on stage II. Both SNP and CNV markers are depicted. 
 










2 rs6713755 223746679 G 3.170E-05 0.028 0.052 5-FU-diarrhoea 
10 rs887339 29545130 G 1.076E-05 0.638 0.614 5-FU-diarrhoea 
12 rs10876844 54336973 T 4.784E-05 0.023 0.010 5-FU-diarrhoea 
12 rs10784749 67708296 C 1.174E-04 0.621 0.017 5-FU-diarrhoea 
20 rs4813881 8916642 A 7.854E-05 0.525 0.374 5-FU-diarrhoea 
3 rs9861291 180274372 G 7.473E-05 0.233 0.688 5-FU-haematologic 
5 rs10055794 171054516 C 8.932E-05 0.380 0.955 5-FU-haematologic 
16 rs7184580 77418447 C 1.138E-04 0.983 0.551 5-FU-haematologic 
18 rs1943423 55641304 C 2.507E-04 0.684 0.259 5-FU-haematologic 
19 rs4805974 39248137 A 1.358E-04 0.679 0.995 5-FU-haematologic 
2 rs2627043 179290782 T 5.973E-04 NA NA 5-FU-mucositis 
3 rs16857540 175383269 C 5.130E-04 0.102 0.020 5-FU-mucositis 
8 rs2465403 120160008 G 3.282E-04 0.853 9.426E-03 5-FU-mucositis 
13 rs927553 23706704 G 3.049E-04 0.209 0.957 5-FU-mucositis 
18 rs670454 8682920 C 6.997E-04 0.605 5.084E-03 5-FU-mucositis 
2 rs10182133 75710000 G 5.612E-04 0.463 0.058 5-FU-nausea/vomiting 
4 rs2060645 183344417 T 5.268E-04 0.139 0.014 5-FU-nausea/vomiting 
4 rs6815391 189161973 A 7.086E-04 0.523 0.079 5-FU-nausea/vomiting 
10 rs7094179 14912433 T 3.709E-04 0.781 0.391 5-FU-nausea/vomiting 
13 rs9300811 102834312 G 5.014E-04 0.934 0.112 5-FU-nausea/vomiting 
2 CNV-rs10179790 34594505 T 6.300E-04 0.351 NA* 5-FU-nausea/vomiting 
5 CNV-rs2387715 180293872 A 5.100E-04 NA NA 5-FU-haematologic 
11 CNV-rs4466833 49590126 T 2.800E-04 0.475 0.265 5-FU-haematologic 
20 CNV-rs2209313 1547142 T 3.300E-05 0.754 0.754 5-FU-haematologic 
2 rs4971347 933636 A 2.701E-05 0.364 0.394 FOLFOX-diarrhoea 
2 rs250944 234661957 C 2.182E-05 0.967 0.866 FOLFOX-diarrhoea 
11 rs1865282 4787228 C 1.489E-05 0.256 0.333 FOLFOX-diarrhoea 
12 rs1347851 89091109 C 4.227E-05 0.257 0.205 FOLFOX-diarrhoea 
21 rs2282469 34151289 C 3.820E-05 0.333 0.245 FOLFOX-diarrhoea 
2 rs17626122 206182257 G 5.950E-05 0.037 4.851E-04 FOLFOX-haematologic 
8 rs10106310 91245050 C 5.702E-05 0.057 1.193E-04 FOLFOX-haematologic 
13 rs7325568 39716284 C 6.608E-05 0.660 0.067 FOLFOX-haematologic 
14 rs2798389 82120903 G 9.292E-05 0.930 0.183 FOLFOX-haematologic 
15 rs4243761 23833884 G 5.127E-05 0.471 0.223 FOLFOX-haematologic 
1 rs520227 188835935 C 8.459E-05 0.476 0.386 FOLFOX-mucositis 
2 rs4128317 29513358 C 7.346E-05 0.252 5.410E-03 FOLFOX-mucositis 
2 rs839533 212516352 T 1.585E-04 0.096 4.426E-03 FOLFOX-mucositis 
14 rs17098912 99174082 A 2.480E-04 0.580 0.357 FOLFOX-mucositis 
19 rs7255865 21596808 C 1.778E-04 0.543 0.552 FOLFOX-mucositis 
1 rs2389972 85963254 G 1.069E-04 0.970 0.171 FOLFOX-nausea/vomiting
1 rs10158985 224117232 A 1.365E-04 0.140 6.863E-03 FOLFOX-nausea/vomiting
6 rs851974 152013380 C 0.00009367 0.741 0.0714 FOLFOX-nausea/vomiting
8 rs2739171 134167847 T 1.043E-04 0.992 0.156 FOLFOX-nausea/vomiting
9 rs724975 120828533 A 1.349E-04 0.304 0.609 FOLFOX-nausea/vomiting
1 rs1555070 175039581 A 2.437E-04 0.976 0.130 FOLFOX-neuropathy 
2 rs1097701 129863806 A 1.881E-04 0.623 0.157 FOLFOX-neuropathy 
3 rs447978 121973776 C 1.354E-04 0.494 0.348 FOLFOX-neuropathy 
5 rs9312960 257082 T 1.910E-04 0.044 0.506 FOLFOX-neuropathy 
5 rs4957020 367346 A 1.909E-04 0.875 0.114 FOLFOX-neuropathy 
5 rs12188653 101411702 C 1.425E-04 0.468 0.028 FOLFOX-neuropathy 
5 rs6863960 115023680 G 2.269E-04 0.971 0.271 FOLFOX-neuropathy 
11 rs17718902 17741283 G 1.790E-04 0.090 0.771 FOLFOX-neuropathy 
11 rs1944118 110857242 A 1.268E-05 0.351 0.438 FOLFOX-neuropathy 
17 rs11080058 23766187 T 2.220E-04 0.322 3.589E-03 FOLFOX-neuropathy 
5 CNV-rs2387715 180293872 A 2.300E-04 NA NA FOLFOX-mucositis 
11 CNV-rs10838648 5772861 G 2.600E-04 0.219 0.219 FOLFOX-diarrhoea 
NA: not available for genotyping design reasons; NA*: rs10179790 was not included in the Affymetrix 6.0 array, and 







Supplementary Figure 5. LD and rs10876844. LD structure for the block containing rs10876844; the 





Supplementary Figure 6. LD plot for the region surrounding rs10106310. LD structure for the block 









Supplementary Figure 7. LD block at rs17626122. LD structure for the block containing rs17626122; 




























































Discussion and future perspectives 
 135 
Colorectal cancer is one of the most important forms of neoplasia nowadays, and an 
important health issue worldwide1. Considered a complex disease, the development of 
CRC is determined by an interplay of both genetic and environmental factors. The 
genetic component in CRC has been estimated to be around 35% by twin studies2. 
However, only a small proportion of this genetic susceptibility has been identified. 
Rare, high-penetrance mutations, causing the so-called hereditary CRC syndromes, 
explain only 5% of the disease cases, whereas moderately penetrant common risk 
variants are though to account for around 7% of the rest, with the remaining 
susceptibility variation yet to be discovered. 
Thus, one of the aims of this thesis has been the identification of other, yet unidentified, 
moderate/low-penetrance alleles that may account for at least part of the remaining 
genetic risk attributed to CRC. In this framework, case-control association studies 
(CCAS) have been the most widely used implementation to search for such variants. 
CCAS may be approached in two ways: candidate-gene analyses, screening 
polymorphisms in genes that are related to carcinogenetic events, and Genome-Wide 
Association Studies (GWAS), offering a hypothesis free approach to explore the overall 
variability of the genome3. 
 
Candidate-gene studies. 
The study of model animals, and particularly mice, has been very important in the 
unravelling of the physiological and genetic processes that occur during CRC tumour 
development4. As a matter of fact, studies in rodent were able to satisfyingly identify 15 
QTL loci conferring susceptibility to developing CRC (Scc or Susceptibility to 
Colorectal Cancer)5-7. Hence, we decided to investigate the human-mouse syntenic 
regions of the 15 Scc QTLs, searching for relevant genes that could be functionally 
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related to carcinogenetic processes. PTPRJ, the gene responsible for the Scc1 QTL 
signal, had already been linked to CRC in humans, and an association study had already 
been carried out with ambiguous results8. 
Selection of candidate genes was approached by inspection of enriched expression in 
primary affected tissues in humans9. Once the gene list was obtained, we screened a 
number of SNP markers for evidences of any new potential association signals. By 
these means, we were able to identify a region defined by rs954353, located in the 
5´UTR region of the CYR61 gene. In silico analysis of this locus identified the presence 
of transcription factor binding sites (TFBSs) at either sides of rs954353. Even when 
direct sequencing of these two did not succeed in detecting any variants within the 
TFBSs themselves, we did discover a 6bp expansion polymorphism (3-4 repeats) that 
was highly correlated with rs954353. Despite confirmation of this association signal 
being ineffective in a second-stage follow-up, we believe the reduced sample size from 
our study may have been a key factor in the unproductive replication, and therefore 
larger cohorts may be needed to fully ascertain the relationship between this 
polymorphism and CRC. Unluckily, neither rs954353, nor the initial rs12086058 SNP 
were well-tagged in the Affymetrix 6.0 array (best proxy SNP rs12072027; r2=0.288); 
thus, we could not obtain any new information regarding the potential implication of 
these variants with CRC susceptibility. 
Furthermore, we also examined part of the variability in the genes belonging to two 
important signalling pathways in CRC development: Wnt and BMP. Both of these have 
been proven essential in the colorectal neoplasic sequence: Wnt is one of the principal 
CRC tumorigenesis pathways, and contains genes that have been long known to cause 
CRC syndromes (APC, for instance)10, whereas BMP genes have proto-oncogenic roles 
in the pathogenesis of CRC and other cancers11. Although we were unable to identify 
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any new risk variants within our study, the importance of some of these genes in CRC 
susceptiliby, is undeniable. Three different genes in either pathway (BMP4, BMP2 and 
GREM1) have been specifically described in GWA studies as relevant in CRC 
susceptibility12 (Carvajal-Carmona et al., PloS Genet in press). We consider our 
inability to detect these effects a limitation due to sample size restrictions. Additionally, 
our variant selection criteria included only missense and regulatory changes within 
genic regions, and thus they do not offer a whatsoever comprehensively coverage of the 
selected genic regions.  
 
GWAS 
Although candidate-gene approaches have been extensively performed, the conclusions 
they have provided on the genetic nature of complex diseases have been scarce. 
Unsuitable sample sizes, liberal p-values for association calling, lack of appropriate 
quality control measures (such as multiple-testing corrections) and the restrictions of a 
functional hypothesis have mostly resulted in a notable impossibility to replicate 
positive findings13. A change of direction was eminently experimented when CCAS 
switched into the performance of GWAS. This assumption-free approach has indeed 
been proven to be very advantageous, and it has constituted a meaningful milestone in 
the unravelling of the genetic basis of common diseases, with 14 new susceptibility loci 
identified for CRC12,14. 
In this context, we carried out a GWAS analysis on 881 cases and 667 controls in a 
Spanish cohort. Our study favourably identified a new susceptibility variant at 8p12 
(rs11987193). The importance of this finding may be coupled with the fact that this also 
is the first work to describe a CRC GWAS analysis in a Southern-European population. 
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During the association analysis, we were able to detect 64 variants at 24 genomic loci 
that were associated with CRC susceptibility in the first stage of the analysis after 
extensive quality control measures. Nevertheless, replication of these signals could not 
be directly achieved by search for association signals in the nearby regions of all 24 loci 
in the British CORGI population. Although at first this lack of replication would seem 
like the signals could correspond to type I errors of the analysis, we found reasonable 
evidences that some of the SNPs behaved differently in the EPICOLON and CORGI 
populations. Consequently, we decided to genotype the 10 divergent SNPs in a second 
cohort of Spanish samples. 
One of the markers, rs11987193 at 8p12, was positively replicated in this second stage. 
Although p values in the replication stage were not exceedingly good (p=0.039; 
OR=0.847 (0.724-0.991)), pooled analysis of both phases was consistent with the 
assumption of the T allele of this SNP having a protective effect on CRC risk 
((p=2.061x10-5; OR=0.788 (0.706-0.879)). The SNP lies 128kb downstream the DUSP4 
gene, which encodes for a MAP kinase phosphatase that has been implicated in 
carcinogenetic processes15. Members of this phosphatase family of proteins are 
responsible for MAPK inactivation, thus preventing cell division and differentiation, 
and trigging TGFß-induced apoptosis15, thus making them exceptional candidates to 
harbour susceptibility variants for CRC and other types of solid neoplasia. 
We find that the special qualities of this association signal, particularly the divergence 
in MAFs between EPICOLON and CORGI, could be a reflection of variation in the 
local LD patterns of this locus leading to differences in the ability of the tagger to 
capture the real causative variant. This could be a way to explain the inability to detect 
the association signal in the CORGI cohort, even when SNP features (both MAF and 
OR) are similar to those of the loci that have already been identified in these British 
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samples. Even though the European population is presumed to be quite homogeneous, 
we cannot however discard the possibility that the effect of this variant may have a 
higher prevalence or even be specific to one of the populations. Although this would 
indeed be less likely, since most specific variants with these features have been 
described in considerably divergent populations, similar events have been described in 
CRC and other diseases16,17. If we consider the possibility that these local differences 
may indeed be happening at other locations in the genome, the screening of other 
Southern European populations could be a helpful tool for the discovery of new 
susceptibility variants for CRC and other complex diseases. 
 
Besides the newly-identified variant at 8p12, we notably replicated the association 
signals for 6 of the 14 already-described loci (8q24, 10p14, 11q23, 12q13, 15q13 and 
18q21). No evidences were found for the other 8 loci whatsoever, but ORs were 
consistent with the bibliography12,14. Although this lack of replication could well be due 
to sample size restrictions, it could also be the case that, same as with our marker at the 
8p12 locus, population frequency differences constitute a limitation in our ability to 
detect these association signals. Surely further analyses in larger cohorts will be 
decisive in the determination of the specificities of these variants and CRC risk in 
Southern European populations. 
 
CNVs 
Even when SNPs are the most frequent form of genetic polymorphisms, genomic 
variability exists in very different forms, ranging from single base changes to large 
chromosomal rearrangements18. If this is so, then it is sensible to believe that other 
kinds of common variation may also be influencing an individual´s susceptibility to 
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common diseases. In the recent years, the discovery of the presence and abundance of 
copy-number variants (CNVs) shifted the attention of CCAS towards these forms of 
genetic markers. 
The study of CNVs does not come straightforward however. Copy-number assignment 
is often a complicated mathematical procedure, and several methodologies have been 
proposed for analysis, with no agreement on overall standard analytic procedures19. 
Besides, association studies of CNVs suffered a major drawback when some authors 
proposed that the CNV variability had already been indirectly captured through SNP 
GWAS20,21. This statement was based on the fact that pairwise LD measures for 
common SNP and CNV markers seemed to be very good, and so, SNPs could be used 
as taggers in the screening of CNV variation. 
Although this relationship may be overall true, there are a couple of factors that should 
be considered. Firstly, CNV regions are often underrepresented in HapMap because 
they are experimentally difficult regions to sequence, and thus mostly correspond to the 
heterochromatic portion that is missing from reference sequences (and thereby are 
barely covered in commercial arrays). Secondly, when present, SNPs in these regions 
are often compromised during standard quality control procedures, and so in most of the 
cases, fail to make it through the association analyses unless they are specifically 
considered22. For these reasons, we believed that an assessment of the CNV common 
variability was necessary in itself and we performed a GWAS study on CN variation at 
1M locations. CNV probes were not directed against specific described regions, but 
designed to cover the whole of the genome physically. This pattern was optimal for our 
study, since we wanted to avoid the previous ascertainment biases, and also allowed for 
new CNV discovery. 
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To reduce the chances of false positive findings, we implemented the use of two 
different calling algorithms: Birdsuite´s Birdseye23 and QuantiSNP v224. By these 
means, an association signal present in both analyses would have smaller chances of 
being spurious25. Accordingly to the physical design of the array, we found that only a 
small proportion of the sites were copy-number variable, and an even smaller proportion 
polymorphic (at a frequency of >5% in the population). However, the overlap between 
common CNV regions between both algorithms was quite remarkable, thus supporting 
the accuracy of the calling procedure. Indeed, most of the shared regions had already 
been described in preceding studies and were included in genomic variation databases26. 
Eleven of the polymorphic CNVs (CNPs) at ten different loci showed considerable 
evidences of association with the CRC phenotype. These were at 2p22.3, 4p16.1, 
6q14.1, 11q11, 15p11.1-q11.1, 15q13.3, 16p11.2-p11.1, 17q12, 17q21.31 and 18q12.2. 
As has happened many times with SNP GWAS, the analysis of these locations does not 
directly lead to a biological explanation on how these CNVs affect CRC risk. In fact, 
most of the genes described within these regions are putative predictions based on 
ORFs, and even some of the loci are located in gene desserts. The only exception would 
be 4p16.1, which is linked to the SLC2A9 glucose transporter. Glycolytic processes 
have been already linked in the literature with cancer evolution; although this 
relationship seems to be somatic, the presence of a germline factor that would constitute 
a growth advantage for transformed tumoural cells could be of relevance in the 
development of the disease27. 
It is also worth mentioning that for 7 of these loci, the coverage from the SNP part of 
the array was very low (r2<0.8). Moreover, for 4 of these locations, there is no 
appropriate SNP tagger even in HapMap, which enhances the demonstration that not all 
common CNVs are well-tagged by SNP markers. 
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Even when the finding of these locations has been consistent both between algorithms 
and the three subpopulations within EPICOLON II, we must stress that the p-values for 
most have been very modest, and would not have, for once, resisted multiple testing 
corrections. Thus, we believe it important that both the presence of these CNPs and 
copy-number status is double-checked by alternative methodologies, such as MLPA or 
qPCR, and that association results are replicated in independent sample sets. We also 
note the fact that, if we expect CNVs to behave similarly to susceptibility SNPs, larger 
cohorts will be required to detect the subtle effects they may impose on CRC risk. 
 
The stratification problem 
Throughout our GWAS studies, both for SNPs and CNVs, we have been faced with a 
stratification issue. Albeit case and control populations being analogous, the inspection 
of other variables revealed considerable heterogeneity derived from the hospital of 
origin of the samples. This effect divided the population into three subgroups: samples 
from the Meixoeiro hospital (GAL samples; n=366), samples from the Donostia 
hospital (VAS samples; n=167) and all other samples (REST subpopulation; n=944 
samples). 
This resulted in the continuous need to adapt analytic procedures to our scenario. For 
SNP analyses, the problem was mostly overcome by performing a meta-analysis with 
the results from the three separate populations28. This strategy proved successful, since 
we were able to effectively replicate the association signals at 6 of the 14 described loci. 
In the case of CNVs, the road was more problematic, with the REST population taking 
a predominant role and the other two serving as "replicates" of the findings. We found 
that although associations could not always be replicated in the three groups (probably 
due to GAL and VAS having such small sample sizes), results were in general 
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concordant among the three subgroups. Also, the predominant effect of the REST 
population over the others was very clear, with all association signals driven by results 
found in this subgroup. Of course, this relationship derives from size effect, since GAL 
and VAS numbers are considerably smaller than those in REST. Notwithstanding, the 
subdivision also allows for considerable false positive detection, since only findings that 
were consistent in the GAL and VAS groups as well were considered as true positives. 
Despite the fact that these hospitals were the only collection centres from Galicia (NW 
Spain) and the Basque Country (N Spain), we do not believe that this effect was due to 
real genetic differences within the Spanish population. Indeed, there were samples from 
these hospitals that were not of Galician or Basque origin (as stated by geographical 
origin of 4 grandparents of the proband) and yet clustered away from the main cloud in 
the PCA analysis, and some other individuals of Galician or Basque origin that had 
been collected in other hospitals and still belonged to the main cloud. Thus, this effect 
clearly corresponds to bias within the collection centre and not to genetic heterogeneity 
within the Spanish population. 
We believe these differences may be the result of differential outcome during the DNA 
extraction procedure leading to decreased sample qualities or a bias within the sample 
collection procedure in itself that are reflected on the intensity signals in the array. This 
would explain the variability observed at the selected quality thresholds for some of the 
CNPs in our GWAS study, and thereby the lack of concordance between the subgroups 
in association measures. 
Our experience has proven that even when case and control populations seem matching, 
there are other sources of bias that could lead to increased false positive rates in 
association findings. The assessment of proper cohort homogeneity is thus of 
noteworthy importance in the performance of association studies. 
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Pharmacogenomics 
It is a fact that response to drug administration is highly variable. Given any medical 
treatment, there is a considerable percentage of individuals that is expected not to 
respond, and a similar fraction that will develop adverse drug reactions (ADRs)29. The 
distribution of this variation has been seen to approach normality, which is highly 
suggestive of the underlying genetic causes following a polygenic model analogous to 
the one applied to complex diseases30. Considering this, it would be thus most certainly 
appropriate to believe that common genetic variants may play a relevant role in the 
determination of the outcome. Knowledge on such factors driving response would 
enable individualisation of the treatments by optimisation of drug dosages and 
minimisation of toxic effects.  
The identification of these genetic markers has been the purpose of pharmacogenetic 
studies for many years now. Up to very recently, these have relied on candidate-gene 
approaches investigating the relationship between genetic polymorphisms in drug 
detoxification enzymes or membrane transporters with toxicity responses for several 
pharmaceuticals. Nevertheless, the development in high-throughput genotyping 
technologies and the recent accomplishements in GWAS studies in complex diseases 
have encouraged pharmacogenetic studies to step aside these hypothesis-based 
strategies and go genomic31. 
In this context, we performed a GWAS on 221 CRC patients that had received 
chemotherapy treatment with two of the most commonly administered agents: 5-
fluorouracil (5-FU) and the combined forms of oxaliplatin (FOLFOX). By investigating 
both SNP and CNV variation, we have been able to identify 11 variants (rs16857540, 
rs2465403, rs10876844, rs10784749, rs670454, rs10158985, rs4128317, rs17626122, 
rs839533, rs10106310 and rs11080058) that show considerable evidences of association 
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with a series of ADRs in a two-stage association study. Of these all, again some appear 
to be located nearby promising genes (such as rs10876844 and METTL7B, rs10106310 
and CALB1 and rs17626122 and PARD3B), whereas for others their biological 
implications remain unclear. Granting that significant findings in GWAS do often not 
directly provide for a biological on the changes resulting in response variability, they do 
provide for quantitative measures on how the variants affect outcome results. Thus, the 
description of markers modifying an individual´s risk to developing ADRs or its ability 
to respond to a certain treatment could be an essential factor to take into account before 
treatment decision. 
It had been proposed by some authors that, unlike heritability to common diseases, 
variants underlying pharmacogenetic traits would most probably have large ORs32. This 
assumption was based on the belief that, since drug administration is a recent 
proceeding on human populations, selection would not have had time to act upon such 
variants. Our study proves however, that at least for the genetics of 5-FU and FOLFOX 
toxic reactions, this does not appear to be so. Although detected ORs for these 11 
variants are slightly higher than most of the described for disease susceptibility, risk 
distribution in our study clearly supports a more moderate effect of the genetic markers 
on toxic outcome. Moreover, the fact that drug administration is contemporary does not 
necessarily exclude the possibility that selection has been acting on those genomic 
locations for some other reasons. 
Considering this, we would expect that the features of the yet unidentified associated 
variants resemble those that have been described for disease susceptibility. In this 
context, we are aware that sample size is a considerable limitation of our own study. 
The number of samples used in stage I is clearly not large enough to detect even 
moderately penetrant variants, as is clearly reflected in the quantile-quantile plots. 
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Hence, it is likely that even when we have been able to successfully identify 11 variants, 
many may have been missed. It is therefore of great importance that further 
pharmacogenomic studies are performed on appropriately powered cohorts. 
The power restriction consequence appears to have been particularly important in CNV 
analysis, where only very few markers produced significant association values in stage I 
of the analysis. Additionally, SNP tagging of CNV variants is not always possible, and 
there were other interesting CNV loci that could regretfully not be assessed in the 
second stage by classical SNP genotyping. Replication may therefore have to be 
accomplished by other molecular methods, such as the previously mentioned MLPA 
and qPCR. Since, pharmacogenetic traits have been described to be susceptible to allele 
dosage changes33,34, we believe that some of these unreplicated CNVs may still be good 
candidates for strong association signals, and thus further efforts will be made to 
ascertain the relationship between these and 5-FU/FOLFOX-related ADRs. 
It is interesting to note that, although not significant after the replication analysis, one of 
the CNV locations identified as potentially associated in first stage analysis for 5-FU 
and nausea/vomiting (2p22.3) has also come up as a result in the overall CRC 
susceptibility analysis. A proper biological explanation for a single variant conferring 
risk to more than one phenotype would most likely be difficult to support, although 
there have been other reports of such happenings35. Notwithstanding, it would also be 
sensible to believe that this event happening twice could be the result of some unknown 
variable being more prevalent in the one of the nausea/vomiting and general groups, 
thus yielding a false positive signal (which would be in fact supported by the lack of 
replication in the pharmacogenomic study). 
 
The dark matter: missing heritability 
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The percentage of overall heritability explained by the already described loci does still 
only explain a small fraction of the expected risk for which genetic factors are thought 
to be responsible, both in CRC susceptibility and in pharmacogenetic studies. 
It has been proposed that part of this missing heritability could be explained by the 
imperfect tagging relationship of the markers identified and the real causative variants, 
which would have resulted in an underestimation of the overall risks behind these 
association signals36.     
However, it is also probably realistic to believe that other forms of genetic variation, not 
only common alleles, may be as well playing an important role in CRC susceptibility. 
The hypothesis that multiple rare variants are also important in common diseases had 
already been proposed some years ago37 and there has been increasing evidence lately 
that this may be so (rare CNV reports on schizophrenia, for instance). In this context, 
CCAS present little power and alternative study methodologies will have to be used for 
the identification of such variables. Surely the advances of new sequencing technologies 
will represent a most helpful tool in this matter, and will hopefully identify new 
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The conclusions that may be extracted from this work are as follows: 
 
1. Although we could not successfully find enough evidences of new CRC risk variants 
through candidate-gene strategies, SNP rs954353, upstream the CYR61 gene, stands out 
as a potential candidate that, in our consideration, should not be directly discarded. We 
believe that sample size restrictions may have been considerably limiting in our study 
and thus further assessment of the relationship between this variant and CRC 
susceptibility may be needed. 
 
2. Our GWAS study has successfully identified a new low-penetrance CRC variant, 
rs11987193, at 8p12. The T allele of this SNP shows a protective effect against CRC 
risk. This locus harbours the DUSP4 gene, which had been previously related to 
carcinogenetic processes. Given the MAF discrepancies between the EPICOLON and 
CORGI cohorts about the association signal, it is likely that there are differences in the 
ability to tag the causative variant at this locus between Northern and Southern 
European populations. 
 
3. We have favourably identified eleven CNPs that present substantial evidences of 
association with CRC. Despite this association signals being highly reliable, further 
concordant estimations of copy-number status and replication in larger, independent 
cohorts will be necessary to fully ascertain their relationship with CRC risk. 
 
4. Even when previous studies have described that common copy-number variation is 
well tagged by SNPs, our findings suggest that this assumption may have been biased 
by the incomplete coverage of previous array designs. Thus, we encourage CNV 
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association studies to be performed in order to completely determine the extent to which 
this type of variants may be responsible for CRC phenotypes. 
 
5. Our GWAS study on the genetic susceptibility to several ADRs and treatment with 5-
fluorouracil and the combined forms of oxaliplatin (FOLFOX) has conveniently 
described 11 new variants that harbour evidences of association with toxicity 
phenotypes. We consider that GWAS studies constitute a good implementation for the 
detection of pharmacogenetic variants, and thus praise future works in this direction be 




























Heritability in colorectal cancer (CRC) predisposition has been estimated to be around 
35% by twin studies. Although ! 5% of this proportion may be explained by high-
penetrance mutations and an additional 7% is thought to be due to the presence of a 
combination of some of the already-described 16 susceptibility SNPs, there is still a 
significant fraction of CRC susceptibility that remains unexplained. 
On the other hand, there is also considerable variation in the way CRC patients respond 
to chemotherapy. Besides, the fact that most drugs used in CRC treatment have narrow 
therapeutic ranges results in the frequent development of adverse drug reactions 
(ADRs). Hence, the identification of the genetic variation modulating this outcome 
would be most helpful in both the individualisation of the treatment and the reduction of 
health costs. 
In this context, we have intended to search for new variants that could explain at least a 
part of the missing heritability in CRC. For this purpose, we have chosen to investigate 
the most common sources of variability in the genome: SNPs and CNVs. 
In the SNP part of the study, we have followed two different approaches: a candidate-
gene strategy evaluating the polymorphic variation in genes with a potential functional 
implication in CRC carcinogenesis and a genome-wide association study. For the 
former, we have assayed in separate studies the genes present in the human syntenic 
regions of the 15 Scc (susceptibility to colorectal cancer) mouse loci, and those 
belonging to two pathways that have been consistently linked to CRC development: 
Wnt and BMP. For the latter, we have carried out a GWAS in a Spanish cohort. The 
advantage of this strategy against the candidate-gene one is that there is no a priori 
hypothesis on where the susceptibility loci may be located. 
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Regarding the CNV study, we have also performed a GWAS scan of the genomic 
structural variation and its potential implication in CRC neoplasia, using two different 
copy-number calling algorithms: Birdsuite´s Birdseye and QuantiSNP v2. 
 
In the second part of the study, our purpose has been to analyse the relationship between 
common genetic variation and the development of ADRs after chemotherapy. For this, 
we evaluated the correlation between two of the most common administered drugs in 
CRC treatment: 5-fluorouracil and oxaliplatin (FOLFOX) and the presence of ADRs by 
screening both SNP and CNV markers at a genome-wide level. 
 
The conclusions that may be extracted from this work are as follows: 
1. Although we could not successfully find enough evidences of new CRC risk variants 
through candidate-gene strategies, rs954353 stands out as a potential candidate that, in 
our consideration, should not be directly discarded. We believe that sample size 
restrictions may have been considerably limiting in our study and thus further 
assessment of the relationship between this variant and CRC susceptibility may be 
needed. 
2. Our GWAS study has successfully identified a new low-penetrance variant at 8p12 
conferring risk to CRC. This locus harbours the DUSP4 gene, which had been 
previously related to carcinogenetic processes. Given the MAF discrepancies between 
the EPICOLON and CORGI cohorts about the association signal, it is likely that there 
are differences in the ability to tag the causative variant at this locus between Northern 
and Southern European populations. 
3. We have favourably identified ten common CNV loci that present substantial 
evidences of association with CRC. Despite this association signals being highly 
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reliable, further concordant estimations of copy-number status and replication in larger, 
independent cohorts will be necessary to fully ascertain their relationship with CRC 
risk. 
4. Even when previous studies have described that common copy-number variation is 
well tagged by SNPs, our findings suggest that this assumption may have been biased 
by the incomplete coverage of previous array designs. Thus, we encourage CNV 
association studies to be performed in order to completely determine the extent to which 
this type of variants may be responsible for CRC phenotypes. 
5. Our GWAS study on the genetic susceptibility to several ADRs and treatment with 5-
fluorouracil and the combined forms of oxaliplatin (FOLFOX) has conveniently 
described 11 new variants that harbour consistent evidences of association with toxicity 
phenotypes. We consider that GWAS studies constitute a good implementation for the 
detection of pharmacogenetic variants, and thus praise future works in this direction be 












































El cáncer colorrectal (CCR) es una de las neoplasias más frecuentes, siendo el tercer 
tipo de cáncer más común en ambos sexos, después del cáncer de mama en mujeres y el 
de pulmón en hombres. La tasa global de prevalencia del CCR es del 11.5%, aunque la 
distribución global no es homogénea, con más del 60% de los casos registrados en 
países desarrollados. Es una enfermedad especialmente prevalente entre los hombres 
(ratio 1.4:1), con una edad media de diagnóstico bastante alta (72 años). De hecho, casi 
el 90% de los casos de CCR se detectan a edades superiores a los 50 años, y un 70% de 
ellos serán mayores de 56 años. 
Se considera que, etiológicamente, el CCR, al igual que otras enfermedades comunes, 
es una enfermedad compleja. Esto implica que la enfermedad surge como resultado de 
la interacción entre diversos factores ambientales y genéticos. Estudios en gemelos 
estimaron en la década de los 90 que la contribución hereditaria al CCR es de 
aproximadamente un 35%. Esta heredabilidad está representada tanto por mutaciones 
raras de alta penetrancia, como por un número de variantes comunes en la población 
que confieren un pequeño efecto sobre el riesgo de desarrollar la enfermedad. Las 
mutaciones de alta penetrancia, responsables de los síndromes hereditarios de cáncer 
colorrectal (principalmente la Poliposis Adenomatosa Familiar y el Síndrome de 
Lynch),  sólo son capaces de explicar alrededor de un 5% de los casos de CCR. Es por 
esto que el estudio de las variantes de baja/moderada penetrancia ha adquirido gran 
importancia en estos últimos años, ya que se espera que sean las responsables de los 
casos hasta ahora genéticamente inexplicables de CCR. 
La estrategia más optimizada y utilizada para la detección de estas variantes de baja 
penetrancia son los estudios de asociación. En ellos se compara la frecuencia de una 
determinada variable entre una población de individuos afectos, o casos, y una de sanos, 
o controles. Diferencias en la prevalencia de una de estas variantes podrían ser 
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indicativas de que el cambio esté relacionado con la aparición de la enfermedad. El uso 
de este tipo de estrategias ha sido impulsado en estos últimos años gracias a la 
compleción del Proyecto Genoma Humano y al desarrollo de las plataformas de 
genotipado masivo de estos marcadores. Gracias a esto también, se descubrió que una 
gran parte del genoma humano era variable y que gran parte de esta variación genética 
se debía a cambios en una única base: los denominados Single Nucleotide 
Polymorphisms o SNPs. 
Inicialmente, los estudios de asociación se centraron en la inspección de SNPs 
existentes en genes cuya función podría estar relacionada con procesos carcinogénicos. 
Estos estudios de genes candidatos tenían como ventaja la fácil interpretación biológica 
de los resultados positivos de asociación y fueron usados extensamente en el estudio del 
CCR y otras enfermedades complejas. Sin embargo, la mayoría de los hallazgos 
resultaron infructuosos, ya que los resultados obtenidos no podían ser replicados en 
estudios posteriores. En este marco, el desarrollo del proyecto HapMap y el 
descubrimiento de la herencia en bloques del genoma permitieron que los estudios de 
asociación se pasasen a realizar a escala genómica con los denominados estudios de 
asociación pangenómicos, o GWAS (del inglés Genome-Wide Association Studies). 
Estos permitían el estudio, libre de hipótesis previas, de una gran cantidad de 
marcadores repartidos a lo largo de todo el genoma. La comercialización de los arrays 
de GWAS supuso un boom en el mundo de la genómica, posibilitando la identificación 
de un gran número de loci de susceptibilidad en un gran número de enfermedades. En 
CCR en particular, los GWAS han identificado 16 nuevas variantes de susceptibilidad 
en 14 loci distintos: rs6983267 en el locus 8q24, rs4939827 en 18q21.1, rs4779584 en 
15q13.3, rs3802842 en 11q23.1, rs16892766 en 8q23.3, rs10795668 en 10p14, 
rs4444235 en 14q22.2, rs9929218 en 16q22.1, rs10411210 en 19q13, rs961253 en 
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20p12.3, rs6691170 y rs6687758 en 1q41, rs10936599 en 3q26.2, rs11169552 y 
rs7136702 en 12q13.13 y rs4925386 en 20q13.33. Como era esperable, todas estas 
variantes tienen efectos muy modestos sobre el riesgo a desarrollar CCR, con odds 
ratios típicamente por debajo de 1,5. Aún cuando los GWAS han tenido bastante éxito 
en cuanto al descubrimiento de nuevas variantes de riesgo, los 16 SNPs identificados 
son sólo capaces de explicar un 7% de la heredabilidad atribuida CCR. Este hecho 
resalta la importancia de la realización de nuevos estudios con mayores números de 
muestra o incluso en otras poblaciones, que puedan descubrir nuevas variantes que 
expliquen la proporción restante de heredabilidad genética. 
 
Por otro lado, se conoce desde hace varias décadas que existe una alta variabilidad 
interindividual en la respuesta a la administración de fármacos. Estas diferencias se 
pueden deber a múltiples factores, como la edad, el sexo, el estado de salud del paciente 
o factores genéticos. El estudio de las variantes genéticas que determinan la distinta 
respuesta a fármacos es el campo de la farmacogenética. Esta ciencia intenta entender 
las bases genéticas de la variabilidad observada en el resultado terapéutico con el fin de 
individualizar los tratamientos para mejorar la respuesta del individuo y minimizar los 
efectos adversos tóxicos. En el caso del cáncer, la gran mayoría de los medicamentos 
usados en quimioterapia presentan rangos terapéuticos reducidos. Esto implica que la 
diferencia entre las dosis efectivas del fármaco y aquellas que causan respuestas tóxicas 
es muy pequeña. Por ello, la individualización de los protocolos de administración de 
fármacos para cada paciente es de especial relevancia en este ámbito. 
Inicialmente, los trabajos en farmacogenética se centraban en el estudio de variantes 
raras con efectos mendelianos. A pesar de que se han identificado un gran número de 
variantes con este tipo de herencia, el patrón normal de distribución de la respuesta 
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poblacional a fármacos sugiere que al igual que sus homólogos patológicos, el resultado 
de la administración de medicamentos depende de una herencia poligénica. De este 
modo, los estudios de asociación pasaron a ser también una metodología importante 
para la detección de nuevos loci. Al igual que en el caso de los estudios de asociación 
para la identificación de variantes de riesgo a enfermedades, hasta hace muy poco los 
estudios de asociación en farmacogenética analizaban mayoritariamente variantes en un 
número muy reducido de genes candidatos. Los genes codificantes de proteínas 
transportadoras de moléculas o enzimas metabolizadoras son ejemplos de gran parte de 
los estudios realizados. En los últimos años, la revolución de los GWAS ha llegado 
también al campo de la farmacogenética, y ya se han empezado a publicar los primeros 
resultados de este tipo para algunos fármacos concretos. Se espera que el éxito de esta 
estrategia sea al menos similar al que han tenido los GWAS en enfermedades. 
 
Objetivos 
Con estos antecedentes, el trabajo realizado en esta tesis de doctorado tiene dos 
objetivos principales:  
1. La búsqueda de variantes nuevas de susceptibilidad al CCR. 
2. 2. El análisis de la variabilidad genética en relación a las diferentes respuestas 
tóxicas en pacientes de CCR tratados con quimioterapia. 
Para la consecución del primer objetivo, hemos interrogado los dos tipos de 
polimorfismos genéticos más frecuentes en el genoma, los SNPs y los CNVs. En el 
primer caso, hemos adoptado además dos estrategias diferentes: una de genes 
candidatos, evaluando la presencia de SNPs en genes con una potencial implicación 
funcional en la carcinogénesis colorrectal, y un GWAS. En la parte del estudio de genes 
candidatos, se investigaron en dos estudios independientes los marcadores presentes en 
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las regiones sinténicas humanas de los 15 loci de susceptibilidad (Scc) identificados en 
ratones (Capítulo 1), y también los pertenecientes a dos de las rutas más importantes en 
el desarrollo de neoplasias colorrectales: la ruta Wnt y la BMP (Capítulo 2). Para la 
parte del GWAS, el análisis se realizó en una cohorte de muestras españolas (Capítulo 
3). La ventaja de esta estrategia frente a la primera es que no existen hipótesis a priori 
sobre la localización de los loci de susceptibilidad. 
En cuanto al estudio de CNVs, hemos realizado también un GWAS en la variabilidad 
genómica estructural con el fin de evaluar su posible implicación en la neoplasia 
colorrectal mediante el uso de dos algoritmos diferentes de identificación de CNVs: 
Birdseye y QuantiSNP (Capítulo 4). 
 
La segunda parte de la tesis está dirigida al análisis de la relación entre los 
polimorfismos genéticos comunes y el desarrollo de respuestas adversas a fármacos tras 
un tratamiento quimioterapéutico. Para ello, evaluamos la correlación entre dos de los 
medicamentos más usados en la quimioterapia del CCR: el 5-FU y el FOLFOX, y la 
presencia de respuestas tóxicas mediante el estudio de ambos SNPs y CNVs a nivel 
genómico (Capítulo 5). 
 
Resultados y discusión. 
El estudio de modelos animales, particularmente de ratones, ha sido de gran importancia 
para el descubrimiento de los procesos, tanto fisiológicos como genéticos, que ocurren 
durante la transformación tumoral celular. Por ello, la investigación de las regiones 
sinténicas en humanos de los 15 QTLs de susceptibilidad al CCR suponía una buena 
estrategia para la búsqueda de nuevas variantes de susceptibilidad. La selección de los 
genes candidatos se realizó mediante la inspección de tránscritos que presentaban una 
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expresión enriquecida en tejidos primarios afectados en humanos. Una vez que se 
obtuvo esta lista de genes, se seleccionaron una serie de marcadores para buscar 
potenciales señales de asociación. De este modo, identificamos una región definida por 
el SNP rs954342, localizado en la región 5´UTR del gen CYR61, como candidata a 
modificar el riesgo de padecer CCR. Los análisis in silico de este locus identificaron la 
presencia de dos lugares de unión a factores de transcripción (TFBS, del inglés 
Transcription Factor Binding Sites), uno a cada lado del SNP. La secuenciación directa 
de esta región no consiguió identificar ninguna variación dentro de las propias 
secuencias consenso TFBS. Sin embargo, sí detectamos la presencia de un 
polimorfismo de expansión de 6 pares de bases, con dos alelos predominantes (3 o 4 
repeticiones) y que presentaba un alto grado de correlación con rs954353. A pesar de 
que la señal de asociación no pudo ser confirmada en una segunda fase, creemos que el 
reducido número muestral del estudio puede haber sido un factor decisivo en la 
improductividad de la réplica, y por lo tanto se necesitarán estudios en cohortes 
mayores para determinar con certeza la relación entre este polimorfismo y el CCR.  
Además, examinamos en otro estudio independiente la variabilidad en los genes de las 
rutas Wnt y BMP. Ambas rutas son esenciales en la secuencia neoplásica colorrectal. 
Wnt es una de las principales vías tumorogénicas, y contiene genes, como por ejemplo 
APC, que han sido relacionados con la aparición de síndromes hereditarios. Los genes 
de la ruta BMP son predominantemente proto-oncogenes que se han visto involucrados 
en la patogénesis de CCR y otros tipos de cánceres. A pesar de que no pudimos 
identificar ninguna variante nueva de riesgo a través de nuestro estudio, la importancia 
de algunos de estos genes en la susceptibilidad a desarrollar CCR es innegable. Tres 
genes pertenecientes a estas rutas (BMP4, BMP2 and GREM1) han sido específicamente 
vinculados por GWAS al CCR. Consideramos que nuestra incapacidad de detectar estos 
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efectos es debida a la limitación impuesta por el número muestral de nuestro estudio. 
Adicionalmente, nuestra selección de variantes únicamente incluía variantes missense y 
cambios reguladores en las regiones 5´y 3´no transcritas, por lo que no ofrecen una 
cobertura óptima de las regiones seleccionadas. 
Aunque las aproximaciones mediante estudios de genes candidatos han sido 
extensamente utilizadas, las conclusiones que se han podido extraer de estos estudios 
sobre la base genética de las enfermedades complejas son escasas. Tamaños muestrales 
inadecuados, p valores liberales, falta de medidas de control de calidad adecuadas 
(como por ejemplo correcciones por tests múltiples) y las restricciones de la hipótesis 
funcional han resultado en una notable imposibilidad para replicar resultados positivos. 
Los estudios de asociación caso-control experimentaron un cambio radical cuando 
aparecieron los primeros arrays para el estudio del genoma completo. Este tipo de 
protocolos no basados en hipótesis previas han resultado muy ventajosos, identificando 
14 nuevos loci de susceptibilidad al CCR. 
En este contexto, realizamos un estudio GWAS en 881 casos y 667 controles de 
población española. Nuestro estudio ha conseguido identificar una nueva variante de 
susceptibilidad localizada en el brazo corto del cromosoma 8 (8p12, SNP rs11987193). 
La importancia de este hallazgo está además acompañada por el hecho de que éste es 
también el primer GWAS en CCR que se realiza en una población del sur de Europa. 
Durante el análisis de asociación, detectamos 64 variantes en 24 loci genómicos que 
presentaban evidencias de asociación tras el control de calidad y los análisis en la 
primera fase. Ninguna de estas variantes pudo ser replicada mediante inspección directa 
de las regiones adyacentes en la cohorte británica CORGI. A pesar de que en un 
principio esta falta de replicación podría parecer resultado de errores de tipo I durante 
los análisis estadísticos, encontramos evidencias considerables de que al menos algunos 
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de estos loci se comportan de forma diferente en EPICOLON y CORGI. 
Consecuentemente, decidimos genotipar los 10 SNPs divergentes en una segunda 
cohorte de muestras españolas. 
Uno de los marcadores, rs11987193 en 8p12, resultó asociado en esta segunda fase. 
Aunque los p valores de la réplica no eran extremadamente buenos (p=0.039; OR=0.847 
(0.724-0.991)), el análisis en conjunto de las muestras de ambas fases era consistente 
con la asunción de que el alelo T de este SNP presenta un efecto protector frente al 
riesgo de desarrollar CCR (p=2.061x10-5; OR=0.788 (0.706-0.879)). El SNP se localiza 
128kb downstream del gen DUSP4, que codifica para una fosfatasa de MAP kinasas 
que ha sido implicada en procesos carcinogénicos. Los miembros de esta familia de 
proteinas son los responsables de la inactivación de MAPK, previniendo la division 
cellular y activando los mecanismos de apoptosis inducida por TFGß. 
Las particulares cualidades de esta señal de asociación, particularmente la divergencia 
de MAFs entre EPICOLON y CORGI, podrían ser el reflejo de la variación en los 
patrones locales de LD del locus que resulta en diferencias en la habilidad de estas 
poblaciones de capturar la señal de la verdadera variante causal. Esto podría explicar la 
falta de réplica en la cohorte CORGI, aún cuando las características del SNP (tanto 
MAF como OR) son similares a las identificadas en el grupo de muestras británicas. Si 
consideramos esta posibilidad, entonces el estudio de otras poblaciones del sur de 
Europa podría constituir una herramienta fundamental para el descubrimiento de nuevas 
variantes de CCR en enfermedades comunes. Además de la nueva variante identificada, 
es de resaltar que nuestro estudio ha replicado las señales en 6 de los 14 loci descritos 
hasta ahora (8q24, 10p14, 11q23, 12q13, 15q13 y 18q21). Además, los ORs para el 
resto de loci eran concordantes con la bibliografía.  
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Aunque los SNPs son las formas más frecuentes de polimorfismos genéticos, la 
variabilidad genómica existe en un gran número de formas, desde cambios en una única 
base hasta grandes reorganizaciones cromosómicas. Por esto, es sensato pensar que 
además de los SNPs, otras formas de variación también puedan estar implicadas en la 
modulación de la susceptibilidad genética al CCR. En los últimos años, el 
descubrimiento de la presencia y abundancia de los CNVs ha acaparado la atención de 
los estudios de asociación hacia esta forma de marcadores genéticos. A pesar de que 
varios estudios han descrito que la mayoría de CNVs comunes están intrínsecamente 
relacionados con los SNPs, existen evidencias de que esta afirmación puede estar 
sesgada. Por ello, es recomendable que los estudios de asociación analicen directamente 
los CNVs.  
Para minimizar el riesgo de falsos positivos en nuestro análisis, la asignación de los 
números de copia en cada locus se hizo a través de dos algoritmos diferentes: Birdseye 
y QuantiSNP. De este modo, los eventos CNV detectados mediante las dos 
metodologías tendrían menos probabilidades de ser espurios. El grado de solapamiento 
entre los dos algoritmos para CNVs polimórficos (aquellos con una frecuencia superior 
al 5% en la población de controles, también denominados CNPs), resultó ser muy 
elevado. Once de estos CNPs (2p22.3, 4p16.1, 6q14.1, 11q11, 15p11.1-q11.1, 15q13.3, 
16p11.2-p11.1, 17q12, 17q21.31 y 18q12.2) además aparecieron como asociados tras 
los tests de asociación. Es destacable el hecho de que para muchos de estos CNVs, no 
existen buenos SNP taggers descritos en los arrays comerciales disponibles o incluso en 
HapMap. Esto apoya nuestra teoría de que la variabilidad en CNVs debe ser 
inspeccionada por sí misma, y no indirectamente a través de SNPs. Aunque las 
evidencias de asociación son sólidas para estos 11 CNPs, los p valores para la mayoría 
son moderados. Por ello, es importante que tanto la presencia de estos CNPs como el 
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estatus de número de copia sean confirmados por metodologías alternativas, como el 
MLPA o la qPCR. También resaltamos el hecho de que si esperamos que los CNPs se 
comporten de igual forma que los SNPs descritos hasta ahora, probablemente se 
necesiten cohortes con mayores números muestrales para detectar tan sutiles efectos. 
 
En cuanto al segundo objetivo sobre farmacogenética en CCR, se sabe desde hace años 
que existe una gran variabilidad en la respuesta a fármacos. Tras la administración de 
cualquier tratamiento se espera que un porcentaje de los individuos no respondan, 
mientras que otra fracción desarrollará respuestas tóxicas (ADRs, del inglés Adverse 
Drug Reactions). Considerando que la distribución de esta variabilidad se aproxima a la 
normalidad, es apropiado pensar que las variantes genéticas comunes puedan ser 
relevantes en la determinación de estos fenotipos. El conocimiento de estos factores 
permitiría la individualización de los tratamientos mediante la optimización de las dosis 
farmacológicas y la minimización de los efectos tóxicos. En este contexto, realizamos 
un GWAS en 221 pacientes de CCR que habían recibido los agentes quimioterapéuticos 
5-FU y FOLFOX. A través del análisis de la variación en forma tanto de SNPs como de 
CNVs conseguimos identificar 11 variantes (rs16857540, rs2465403, rs10876844, 
rs10784749, rs670454, rs10158985, rs4128317, rs17626122, rs839533, rs10106310 y 
rs11080058) que muestran evidencias considerables de asociación con una serie de 
ADRs en un estudio en dos fases. A pesar de que en la mayoría de las ocasiones los 
resultados positivos en GWAS no proveen con explicaciones biológicas directas sobre 
los mecanismos de acción de estas variantes, sí que son capaces de proporcionar un 
medida quantitativa de cómo estos polimorfismos afectan el riesgo individual de sufrir 
ADRs, por lo que prodrían constituir un factor de decisión esencial a la hora de 





Las conclusiones que se pueden extraer de este trabajo son las siguientes: 
1. A pesar de que no hemos conseguido encontrar evidencias suficientes de la presencia 
de nuevas variantes de riesgo a través de la estrategia de genes candidatos, el SNP 
rs954353, en la región upstream del gen CYR61 es un potencial candidato que, a nuestro 
parecer, no debería ser descartado. Creemos que las restricciones en el número muestral 
pueden haber sido limitantes en nuestro estudio, y por lo tanto la realización de más 
análisis es necesaria para concretar la relación entre esta variante y la susceptibilidad al 
CCR.  
 
2. Nuestro GWAS de SNPs ha identificado exitosamente una nueva variante de baja 
penetrancia, rs11987193, en 8p12. El alelo T de este SNP presenta un efecto protector 
contra el riesgo de desarrollar CCR. Este locus contiene al gen DUSP4, que ha sido 
relacionado con procesos carcinogenéticos. Dadas las discrepancias en MAFs entre 
EPICOLON y CORGI, es probable que ambas poblaciones difieran en su habilidad de 
capturar la señal de la variante real. 
 
3. Hemos identificado 11 CNPs que presentan evidencias sustanciales de asociación con 
CCR. A pesar de esto, será necesaria la replicación del estatus de número de copia por 
otras técnicas moleculares, y la replicación en cohortes independientes para determinar 
por completo la relación de estos CNPs con el riesgo de CCR. 
 
4. Aún cuando estudios previos han descrito que la variabilidad en los CNVs comunes 
puede ser bien capturada a través de los SNPs, nuestros resultados sugieren que esta 
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aserción puede estar sesgada por la cobertura incompleta en los diseños de arrays 
previos. Por ello, recomendamos que los estudios de asociación de CNVs se realicen de 
una forma directa, con el fin de determinar la extensión de la implicación de este tipo de 
variantes en la modulación del riesgo a CCR. 
 
5. El GWAS para estudiar la susceptibilidad genética a varios ADRs tras tratamientos 
con 5-FU y FOLFOX ha identificado 11 nuevas variantes que presentan señales de 
asociación con fenotipos tóxicos. Consideramos pues que los GWAS son una estrategia 
válida para la detección de variantes farmacogenéticas, e invitamos a la realización de 





























List of publications: 
 Pharmacogenomics in Colorectal Cancer: A Genome-Wide Association Study to 
predict toxicity after 5-Fluorouracil or FOLFOX administration. Fernandez-Rozadilla C, 
Cazier JB, Crous M, Guinó E, Moreno V, Durán G, Lamas MJ, Paré L, Baiget M, Páez D, 
López JL, Cortejoso L, García MI, Bujanda L, González D, Gonzalo V, Rodrigo L, Reñé JM, 
Jover R, Brea-Fernández A, Andreu M, Bessa X, Llor X, Palles C, Tomlinson I, Castells A, 
Castellví-Bel, Carracedo A, Ruiz-Ponte C for the EPICOLON consortium. Submitted to the 
Pharmacogenomics Journal. 
 A Two-Phase Case-Control Study for Colorectal Cancer Genetic Susceptibility: 
Candidate Genes from Chromosomal Regions 9q22 and 3q22. Anna Abulí, Ceres 
Fernández-Rozadilla, María Dolores Giráldez, Jenifer Muñoz, Victoria Gonzalo, Xavier Bessa, 
Luisa de Castro, Luis Bujanda, Josep M. Reñé, Angel Lanas, Ana M. García, Joan Saló, Lídia 
Argüello, Àngels Vilella, Ramiro Carreño, Rodrigo Jover, Xavier Llor, Luis Carvajal-Carmona, 
Ian PM. Tomlinson, David J. Kerr, Richard S. Houlston, Josep M. Piqué, Angel Carracedo, 
Antoni Castells, Montserrat Andreu, Clara Ruiz-Ponte, and Sergi Castellví-Bel, for the 
Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. Submitted to 
Cancer Epidemiology Biomarkers and Prevention. 
 A two-phase case-control study for Colorectal Cancer genetic susceptibility: 
historical variants and mucins. Anna Abulí, Ceres Fernández-Rozadilla, Virginia Alonso, 
María Dolores Giráldez, Jenifer Muñoz, Xavier Bessa2 Rodrigo Jover, Xavier Llor5, Luis 
Carvajal-Carmona, Victor Moreno, Angel Carracedo, Antoni Castells, Montserrat Andreu, 
Clara Ruiz-Ponte, Sergi Castellví-Bel, for the Gastrointestinal Oncology Group of the Spanish 
Gastroenterological Association. Submitted to BMC Cancer. 
 An Update of In Silico Tools for the Prediction of Pathogenesis in Missense 
Variants. Brea-Fernández AJ, Ferro M, Fernández-Rozadilla C, Blanco A, Fachal L, 
Santamariña M, Vega A, Pazos A, Carracedo A and Ruiz-Ponte C. Current Bioinformatics. In 
press. 
 The GREM1, BMP4 and BMP2 loci harbor multiple common susceptibility 
variants for colorectal cancer. Luis G Carvajal-Carmona, Sara E Dobbins, Albert Tenesa, 
Angela M Jones, Kimberley Howarth, Claire Palles, Peter Broderick, Emma EM Jaeger, Susan 
Farrington, Annabelle Lewis, James GD Prendergast, Alan M Pittman, Evi Theodoratou, Bianca 
Olver, Rebecca A Barnetson, Steven Penegar, Ella Barclay, Nicola Whiffin, Lynn Martin, Amy 
Lloyd, Maggie Gorman, The COGENT Consortium, The CORGI collaborators, Clara Ruiz-
Ponte, Ceres Fernandez-Rozadilla, Antoni Castells, Angel Carracedo, Sergi Castellvi-Bel, 
David Duggan, David Conti, Jean-Baptiste Cazier, David J Kerr, Harry Campbell, Oliver 
Sieber, Lara Lipton, Peter Gibbs, Grant Montgomery, Joanne Young, Paul Baird, Brent Zanke, 
Steven Gallinger, Polly Newcomb, John Hopper, Mark A Jenkins, Lauri A Aaltonen, Jeremy 
Cheadle, Paul Pharoah, Graham Casey, Malcolm G Dunlop, Ian PM Tomlinson, Richard S 
Houlston. PLOS Genetics. In press. 
 Single nucleotide polymorphisms in the Wnt and BMP pathways and colorectal 
cancer risk in a Spanish cohort. Ceres Fernández-Rozadilla, Juan Clofent, Luisa de Castro, 
Alejandro Brea-Fernández, Xavier Bessa, Anna Abulí, Montserrat Andreu, Rodrigo Jover, 
Xavier Llor, Antoni Castells, Sergi Castellví-Bel, Angel Carracedo, Clara Ruiz-Ponte* for the 
Gastrointestinal Oncology Group of the Spanish Gastroenterological Association. PLoS One. 
Sep 2010. 
 Nuevos métodos de diagnóstico molecular: genómica. Clara Ruíz-Ponte, Ceres 




 Colorectal cancer susceptibility QTLs in mice as a novel approach to detect low-
penetrance variants in humans: a two-stage case-control study. Ceres Fernández-Rozadilla, 
Rosa Tarrío, Juan Clofent, Luisa de Castro, Alejandro Brea-Fernández, Xavier Bessa, Anna 
Abulí, Montserrat Andreu, Rodrigo Jover, Rosa Xicola, Xavier Llor, Antoni Castells, Sergi 
Castellví-Bel, Angel Carracedo, Clara Ruiz-Ponte* for the Gastrointestinal Oncology Group of 
the Spanish Gastroenterological Association. Cancer Epidemiology Biomarkers and Prevention. 
Feb 2010. 
 Molecular analysis of the APC and MYH genes in Galician and Catalonian FAP 
families: a different spectrum of mutations? Nuria Gómez-Fernández, Sergi Castellví-Bel, 
Ceres Fernández-Rozadilla, Francesc Balaguer, Jenifer Muñoz, Irene Madrigal, Montserrat 
Milà, Begoña Graña, Ana Vega, Antoni Castells, Angel Carracedo, Clara Ruiz-Ponte§BMC 
Medical Genetics. Jun 2009. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
